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Abstract: Background   : In A Randomized trial of Unruptured Brain Arteriovenous malformations
(ARUBA), randomisation was halted by recommendation of the National Institute of
Neurological Disorders and Stroke appointed data and safety monitoring board at a
mean follow-up of 33·3 months after a pre-specified interim analysis demonstrated that
medical management alone was superior to the combination of medical management
and interventional therapy in preventing symptomatic stroke or death.  We aimed to
study whether these differences persist in the longer-term of 5 years follow-up.
 
Methods  : ARUBA was an open, randomised (1:1), parallel group trial of adult patients
diagnosed with an unruptured brain arteriovenous malformation, who had never
undergone interventional therapy, and were considered by participating clinical centres
suitable for intervention to eradicate the lesion. The trial compared medical
management alone with medical management and interventional therapy
(neurosurgery, embolisation, or stereotactic radiotherapy, alone or in any combination,
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
sequence or number). Patients were randomised at 39 international clinical centres
with randomisation stratified by clinical centre using a random permuted block design
generated by a trial statistician and implemented via a central web based data
collection system. The primary outcome was time to death or symptomatic stroke
confirmed by imaging, assessed by a neurologist at each centre not involved in the
management of participants’ care, and monitored independently using an adaptive
approach with interim analyses. Enrolment began on April 4  th  , 2007 and was halted
on April 15  th  , 2013, after which follow-up continued until July 15  th  , 2015. All
analyses were by intention-to-treat. The trial is registered with ClinicalTrials.gov,
number NCT00389181.
 
Findings  : 226 patients were randomly allocated, 110 to medical management alone
and 116 to medical management plus interventional therapy. During a mean duration
of follow-up of 50·4 ±22·9 months, the incidence of death or symptomatic stroke was
lower with medical management alone (15/110, 3·39 per 100 patient-years) compared
to medical management with interventional therapy (41/116, 12·32 per 100 patient-
years; HR 0·31, 95% CI 0·17-0·56). Two patients in the medical management group
and four patients in the interventional therapy group died during follow-up (two
attributed to intervention). Adverse events were observed less often (283 vs 369; 58·97
vs 78·73 per 100 patient-years; risk difference -19·76 ((95% confidence interval, -30·33
to -9·1)) in patients allocated to medical management compared with interventional
therapy.
 
Interpretation:   After extended follow-up, medical management alone remained
superior to interventional therapy for the prevention of death or symptomatic stroke in
patients randomised to ARUBA with unruptured brain arteriovenous malformations.
These data should affect standard specialist practice and the information presented to
patients. The longer-term risks and difference between the two therapeutic approaches
are uncertain.
 
Funding  :
National Institute of Neurological Disorders and Stroke (NINDS) U01NS051483 &
U01NS051566 (2007-2013). Vital Projects Fund, private gift to Columbia University
(2014-2015)
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ABSTRACT 56 
 57 
Background: In A Randomized trial of Unruptured Brain Arteriovenous malformations 58 
(ARUBA), randomisation was halted by recommendation of the National Institute of 59 
Neurological Disorders and Stroke appointed data and safety monitoring board at a mean follow-60 
up of 33·3 months after a pre-specified interim analysis demonstrated that medical management 61 
alone was superior to the combination of medical management and interventional therapy in 62 
preventing symptomatic stroke or death.  We aimed to study whether these differences persist in 63 
the longer-term of 5 years follow-up.  64 
 65 
Methods: ARUBA was an open, randomised (1:1), parallel group trial of adult patients 66 
diagnosed with an unruptured brain arteriovenous malformation, who had never undergone 67 
interventional therapy, and were considered by participating clinical centres suitable for 68 
intervention to eradicate the lesion. The trial compared medical management alone with medical 69 
management and interventional therapy (neurosurgery, embolisation, or stereotactic 70 
radiotherapy, alone or in any combination, sequence or number). Patients were randomised at 39 71 
international clinical centres with randomisation stratified by clinical centre using a random 72 
permuted block design generated by a trial statistician and implemented via a central web based 73 
data collection system. The primary outcome was time to death or symptomatic stroke confirmed 74 
by imaging, assessed by a neurologist at each centre not involved in the management of 75 
participants’ care, and monitored independently using an adaptive approach with interim 76 
analyses. Enrolment began on April 4th, 2007 and was halted on April 15th, 2013, after which 77 
follow-up continued until July 15th, 2015. All analyses were by intention-to-treat. The trial is 78 
registered with ClinicalTrials.gov, number NCT00389181. 79 
  80 
Findings: 226 patients were randomly allocated, 110 to medical management alone and 116 to 81 
medical management plus interventional therapy. During a mean duration of follow-up of 50·4 82 
±22·9 months, the incidence of death or symptomatic stroke was lower with medical 83 
management alone (15/110, 3·39 per 100 patient-years) compared to medical management with 84 
interventional therapy (41/116, 12·32 per 100 patient-years; HR 0·31, 95% CI 0·17-0·56). Two 85 
patients in the medical management group and four patients in the interventional therapy group 86 
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died during follow-up (two attributed to intervention). Adverse events were observed less often 87 
(283 vs 369; 58·97 vs 78·73 per 100 patient-years; risk difference -19·76 ((95% confidence 88 
interval, -30·33 to -9·1)) in patients allocated to medical management compared with 89 
interventional therapy. 90 
 91 
Interpretation: 92 
After extended follow-up, medical management alone remained superior to interventional 93 
therapy for the prevention of death or symptomatic stroke in patients randomised to ARUBA. 94 
These data should affect standard specialist practice and the information presented to patients. 95 
The longer-term risks and difference between the two therapeutic approaches are uncertain. 96 
 97 
Funding:  98 
National Institute of Neurological Disorders and Stroke (NINDS) U01NS051483 & 99 
U01NS051566 (2007-2013). Vital Projects Fund, private gift to Columbia University (2014-100 
2015). 101 
102 
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INTRODUCTION  103 
 104 
A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) addressed the 105 
longstanding uncertainty whether medical management alone or with interventional therapy is 106 
superior for those with a brain arteriovenous malformation that has never bled.1–7  The two-fold 107 
primary aim of the study was, first, to determine whether medical management was superior to 108 
interventional therapy for preventing the composite outcome of death from any cause or stroke 109 
(symptomatic and confirmed by imaging). Failure to declare superiority would not necessarily 110 
imply that the two treatments were equivalent; therefore, if medical management was not 111 
superior to interventional therapy, the second and subsequent aim of the study was to determine 112 
whether medical management was not inferior to interventional therapy.  113 
 114 
The first patient was randomised on April 4th 2007. On April 15th 2013, randomisation in the trial 115 
was terminated prematurely following the recommendation of its independent data and safety 116 
monitoring board. Their decision was based on the results of a planned interim analysis 117 
demonstrating a log-rank Z value (4·10) exceeding the pre-specified stopping boundary value 118 
(2·87), early and consistent separation of survival curves in two arms, and strong magnitude of 119 
effect. After a mean follow-up of 33 months, medical management alone was found to be 120 
superior to medical management with interventional therapy for the prevention of death or stroke 121 
(hazard ratio (HR) 0·27, 95% CI 0·14-0·54).8 Further analyses showed that medical management 122 
was also superior to medical management with interventional therapy for the prevention of fatal 123 
or disabling stroke (defined as a mRS score ≥2).9 124 
 125 
In response to the recommendation by the data and safety monitoring board, but without 126 
continued funding by the National Institute of Neurological Disorders and Stroke, follow-up 127 
continued in order to evaluate treatment effects at five years. Centre participation continued until 128 
July 15th 2015. The present report describes outcomes observed over the initial randomisation 129 
phase and during continued follow-up to assess whether medical management alone remained 130 
superior to medical management plus interventional therapy. 131 
 132 
 133 
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METHODS 134 
 135 
Study design 136 
 137 
ARUBA was an open, parallel group, trial in which participants were randomly allocated 1:1 to 138 
medical management alone (i.e., pharmacological therapy for neurological symptoms as needed) 139 
or medical management with interventional therapy (i.e., neurosurgery, embolisation, or 140 
stereotactic radiotherapy, alone or in any combination or sequence).1 Patients were randomised 141 
in nine countries at 39 clinical centres (Supplemental Table 1). Protocol and consent forms were 142 
approved by the relevant institutional review boards or equivalent ethics committees at all 143 
institutions. 144 
 145 
Participants  146 
 147 
Patients eligible for randomisation were adults (age ≥18 years) whose brain arteriovenous 148 
malformation had never bled, and who were considered suitable for attempted AVM eradication 149 
by the local centres. Each patient provided written informed consent. No control in case selection 150 
was exerted by the clinical coordinating centres (ARUBA-WEST: Columbia University Medical 151 
Center; ARUBA-EAST: Hôpital Lariboisière). A full list of eligibility criteria can be found in 152 
the study protocol available in the Supplement).  153 
 154 
Randomisation and masking 155 
 156 
Randomisation was stratified by clinical centre using a random permuted block design with 157 
block sizes of 2, 4, and 6. The randomisation sequence was generated by a trial statistician at the 158 
data coordinating centre (the International Center for Health Outcomes and Innovation Research 159 
at the Icahn School of Medicine at Mount Sinai) and assignment was controlled via a central 160 
web-based data collection system, which did not reveal treatment allocation until all baseline 161 
data had been submitted.  Site coordinators randomised participants after verifying eligibility and 162 
obtaining patient consent. All individual clinical centres were aware of the treatment assignment 163 
for their own patients but were not informed of the outcomes from other clinical centres in the 164 
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trial. Outcomes at each clinical centre were assessed by a senior study neurologist who did not 165 
perform interventional procedures. 166 
 167 
Participants and study leaders, including those at the clinical coordinating center, remained 168 
blinded as to the overall randomisation assignments and outcomes until April 15th 2013 when the 169 
results of a planned interim analysis were provided to the trial executive committee at a meeting 170 
with the data and safety monitoring board.  171 
 172 
Procedures 173 
 174 
Interventional therapy options comprised endovascular embolisation, neurosurgical resection, or 175 
stereotactic radiotherapy, as single or multiple therapies, in any order, sequence or number. No 176 
published guidelines for selection or sequence of choice(s) of intervention existed during the 177 
trial.10 Centres implemented the approaches considered standard practice in their specialist centre 178 
and country. 179 
 180 
During the blinded phase of the trial, patient data were collected at six-month intervals for the 181 
first two years of follow-up, thereafter annually, with the goal of final status report at year 5, the 182 
planned end of the trial by the original protocol. Follow-up was expected to continue also for 183 
those experiencing a primary outcome event. Although clinical centres were free to undertake 184 
whatever management they deemed appropriate after the primary outcome event, reports of 185 
outcomes depended on the willingness of those affected to continue in follow-up. After the end 186 
of the randomisation phase, supported by Vital Projects Fund, New York, NY and without 187 
funding by the National Institute of Neurological Disorders and Stroke, clinical centres 188 
continued efforts at follow-up and reported the status of their patients until July 15th 2015 when 189 
the database was closed, eight years and two months from the start of accrual of randomisations. 190 
Due to lack of continued funding, further follow-up was not feasible. Supplemental Figure 1 191 
provides the number of last follow-up reports by year. 192 
 193 
Outcomes 194 
 195 
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The primary outcome was time to the composite event of death from any cause or symptomatic 196 
stroke (haemorrhage or infarction), documented by imaging (CT or MR scan). Until the end of 197 
the randomisation phase in 2013, all primary outcome events were adjudicated by a four-member 198 
committee comprised of internationally-renowned experts in stroke neurology, endovascular 199 
therapy, radiosurgery, or vascular neurosurgery. All primary outcomes reported after the end of 200 
the randomisation phase were adjudicated by a single member of the original adjudication 201 
committee (Prof Marie-Germaine Bousser, Hôpital Lariboisière, Paris, France). 202 
 203 
The secondary outcome was death or neurological disability at five years after randomisation.   204 
Neurological disability was defined as a score ≥ 2 on the modified Rankin scale (mRS), which 205 
ranges from 0 to 6, with higher scores indicating more severe disability with 6 indicating death.11  206 
Additional secondary outcomes included the incidence of adverse events which were collected 207 
systematically and adjudicated by the event adjudication committee.  Definitions of adverse 208 
events are available in the protocol included in the supplement.  More information on study 209 
conduct, data collection, and outcome assessments are also available in the primary publication.1 210 
 211 
Statistical analysis  212 
 213 
The intial protocol, submitted and approved by two National Institute of Neurological Disorders 214 
after two separate Stroke Study Section reviews, had a sample size of 800 patients which would 215 
have an estimated 87·5% power to detect a 40% reduction in the hazard for death or 216 
symptomatic stroke over 5 years based on an assumed 5-year event rate of 22% in the medical 217 
management and  interventional therapy arm. The study was overseen by a National Institute of 218 
Neurological Disorders and Stroke-appointed data and safety monitoring board.   219 
 220 
During the study start-up period, the anticipated number of participating clinical centres was not 221 
realized, resulting in a lower than expected recruitment rate. Eighteen months after the first 222 
randomisation, given the opportunity for longer follow-up to achieve the outcome event rates 223 
within the period of National Institute of Neurological Disorders and Stroke funding, the data 224 
and safety monitoring board reviewed the emerging data by treatment group in private, keeping 225 
clinical investigators blinded. The board accepted a revised sample size of 400 patients presented 226 
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by the study statisticians, which would have an estimated 80% power to detect a 46% reduction 227 
in the hazard of death or symptomatic stroke, equivalant to a hazard ratio of 0.54. This hazard 228 
ratio corresponded to an absolute decrease in 5-year event rates of 9.5% for medical management 229 
alone, from an assumed 5-year event rate of 22% for medical management with interventional 230 
therapy. ARUBA had an adaptive design involving pre-specified interim analyses. Two interim 231 
analyses were pre-specified in the protocol with early stopping boundaries defined by an O’Brien 232 
Fleming-type spending function using a Lan-DeMets approach.  There were no interim 233 
assessments for futility since the study was set up to assess superiority and non-inferioirty. 234 
 235 
The statistical analysis was carried out by the data coordinating center. For the primary outcome, 236 
cumulative event–free survival curves for each group were estimated using the Kaplan–Meier 237 
method. The incidence rate of primary outcome events is the number of patients who had an 238 
event divided by the number of event-free patient years observed. A Cox proportional–hazards 239 
model was used to estimate the hazard ratio and corresponding 95% confidence interval. To 240 
account for potential clustering effects by clinical centre, a Cox model including a frailty term 241 
for clinical centre was also explored.   242 
 243 
Risk of death or clinical impairment at five years after randomisation was summarised using the 244 
proportion of patients with mRS ≥2 at five years and compared between groups by computing 245 
the relative risk and corresponding 95% confidence interval. Five-year mRS scores were based 246 
on mRS assessments documented between 54 and 66 months from randomisation for participants 247 
whose date of randomisation made them eligible for assessment before closure of the trial 248 
database. For patients who had multiple assessments in this window, the assessment closest to 249 
the expected 60-month (five years) follow-up visit date was selected as the patient’s five-year 250 
mRS. Patients who died before month 66 were assigned a mRS score of 6, irrespective of the 251 
cause of death.  252 
 253 
Frequencies of adverse events including all strokes, focal deficits, seizures, and headaches were 254 
computed by allocated treatment group, as well as the rate difference between the groups and the 255 
corresponding 95% confidence interval.  Duration of follow-up in months was calculated using 256 
the last date of contact with each patient. Exploratory subgroup analyses of the primary outcome 257 
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were conducted using Cox proportional hazards models and tested for heterogeneity of treatment 258 
effect using interaction terms. 259 
 260 
All analyses were conducted by the intention-to-treat principle using SAS version 9.4 (Cary, 261 
NC). Due to the descriptive nature of the study there is no bias adjustment due to the adaptive 262 
design.  Additional information on the timing and results of the two pre-specified interim 263 
analyses are given in supplemental figure 2. The trial is registered with ClinicalTrials.gov, 264 
number NCT00389181. 265 
 266 
Role of the Funding Source 267 
National Institute of Neurological Disorders and Stroke officers participated in study design, data 268 
interpretation, and writing of the report, but had no role in data collection or data analysis. The 269 
Vital Projects Fund, New York, New York, had no role in study design, data collection, data 270 
analysis, data interpretation, or writing of the report. The corresponding author had full access to 271 
all the data in the study after the end of the randomisation phase and had final responsibility for 272 
the decision to submit for publication.  273 
 274 
RESULTS 275 
 276 
Of 1740 patients screened, 1014 (58·3%) were ineligible and 726 were eligible, of whom 323 277 
(44·5%) refused participation and 177 (24·4%) decided their management outside the trial 278 
(figure 1); outcomes were not collected for eligible patients who were not randomised. Thirty-279 
nine international centres randomised a total of 226 participants at a rate of 3.2 patients per 280 
month from April 4th 2007 to April 15th 2013 (Supplemental Figure 3). Of the 226 patients 281 
randomised, 110 were allocated to medical management alone and 116 to medical management 282 
plus interventional therapy. Three patients randomised in the interval between data lock for the 283 
final report presented to the Data and Safety Monitoring Board on April 15th 2013 and the end of 284 
enrolment were not included in the primary publication1, but are included in the current report.  285 
All randomised patients were included in the time-to-event analysis of the primary outcome. 286 
 287 
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At final data lock on July 15th 2015, patients randomised had a mean length of follow-up of 50·4 288 
months (SD±22·9; median 48·0, IQR 35·9-71·1). The average follow-up for patients allocated to 289 
medical management patients was 52·4 months (SD±23·7; median 49·1, IQR 36·1-71·8), and for 290 
patients allocated to interventional therapy it was 48·5 months (SD±22·0; median 45·5, IQR 291 
34·7-62·1). The distribution of dates of the last patient contact is shown in Supplemental figure 292 
1. 293 
 294 
Baseline characteristics and mRS scores were similar between groups (Table 1), apart from focal 295 
neurological deficits at presentation, small AVM nidus size and Spetzler Martin grade.  296 
 297 
In total, there were 15 primary outcome events in patients randomised to medical management 298 
(incidence rate: 3·39 per 100 patient-years) versus 41 in patients randomised to interventional 299 
therapy (incidence rate: 12·32 per 100 patient-years; Table 2), resulting in a hazard ratio of 0·31 300 
(95% CI 0·17-0·56; Figure 2). These results remained consistent after accounting for the 301 
potential clustering effect of clinical centre (adjusted HR 0.31, 95% CI 0.16-0.61). Of the 56 302 
primary outcomes, 10 were new events reported between April 15th 2013 and July 15th 2015. 303 
Four of these 10 occurred in the medical management arm and six in those randomised to 304 
medical management plus interventional therapy. In total, two patients allocated to medical 305 
management alone and four patients allocated to medical management plus interventional 306 
therapy died during follow-up. In the latter group two of the four deaths were attributed to the 307 
intervention (Table 2). 308 
 309 
The risk of the secondary outcome of death or neurological disability at five years after 310 
randomisation, available for 96 patients, was lower for those allocated to medical management 311 
alone (Table 2). Supplemental Figure 4 illustrates the distribution of mRS scores by study arm 312 
for those with data available at 5years.  313 
 314 
Patients allocated to interventional therapy experienced more adverse events compared to those 315 
allocated to medical management (Table 3) 316 
 317 
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Subgroup analyses of the primary outcome were consistently in favour of medical management 318 
over medical management plus interventional therapy, except for venous drainage (superficial 319 
only versus any deep), arteriovenous malformation maximum nidus size (<3 cm versus ≥3 cm), 320 
and Spetzler-Martin grade, where there was heterogeneity of the treatment effects (Figure 3). 321 
The effect of medical management in patients with Spetzler-Martin Grade I AVMs appeared to 322 
differ from Spetzler-Martin Grade II-V AVMs, although the effect in the Spetzler-Martin Grade 323 
1 group was not significant (HR 1·82, 95% CI 0·46-7·28). 324 
 325 
Eight patients who were randomised to medical management alone received medical 326 
management plus interventional therapy. Of the 116 randomised to interventional therapy, three 327 
experienced an outcome before interventional therapy began and 15 never received 328 
interventional therapy. Ultimately 106 patients received interventional therapy. The median time 329 
from randomisation to first intervention in this group was 76 days (IQR 42-136). For the 43 330 
patients who reached a primary outcome following the initiation of interventional therapy, the 331 
median time since the last intervention was one day (IQR 0-43). Sixty-eight of the 106 patients 332 
who received interventional therapy (64·2%) were treated by a single modality, while for 38/106 333 
(35·8%) the therapy was multimodal. At the time of final data lock, 47/106 (44·3%) of those 334 
receiving medical management plus interventional therapy had angiographic evidence of brain 335 
arteriovenous malformation eradication, 43/106 (40·6%) had evidence of a brain arteriovenous 336 
malformation remnant on last follow-up imaging, and in 16/106 (15·1%, all after radiotherapy) 337 
the brain arteriovenous malformation status was unknown due to missing follow-up imaging 338 
(Supplemental Table 2).  339 
 340 
Twenty-two of 106 (20·8%) patients who were treated with medical management and 341 
interventional therapy underwent neurosurgery, either alone or as part of a multimodal 342 
interventional therapy strategy following embolisation. In 21of 22 (95·5%) the brain 343 
arteriovenous malformation had been eradicated based on a post-operative angiogram. Nine of 344 
22 (40·9%) patients who were operated on experienced a primary outcome event (Supplemental 345 
Table 2). Stereotactic radiotherapy was used in the treatment of 57 of 106 (53·8%) patients 346 
treated with medical management and interventional therapy, either alone or as part of a 347 
multimodal strategy with either embolisation alone or with both endovascular and surgical 348 
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therapy (n=1). At the time of the final analysis, 12 of 57 patients (21·1%) had reached 349 
angiographically-documented eradication of the brain arteriovenous malformation, and 21/57 350 
(36·8%) had had a primary outcome event (Supplemental Table 2). Sixty-six of 106 (62·3%) 351 
patients were treated by endovascular embolisation, either alone or as part of a multimodal 352 
treatment strategy with neurosurgery and/or radiotherapy; 34 of 66 (51·5%) demonstrated 353 
eradication of the brain arteriovenous malformation on catheter angiography, and 33 of 66 354 
(50·0%) experienced a primary outcome event (Supplemental Table 2). 355 
 356 
DISCUSSION 357 
 358 
With extended follow-up of 226 participants with unruptured brain  arteriovenous malformations 359 
in ARUBA, the risk of death or stroke remained significantly lower after medical management 360 
alone than after medical management with interventional therapy after a mean follow-up of 50 361 
months. Ninety-six participants followed up for 60 months without intervention also had a 362 
significantly lower risk of death or neurological disability, and fewer adverse events. Although 363 
the persisting difference between the two management options persisted, ideally longer follow-364 
up would be desirable but was not possible due to funding constraints.   365 
 366 
This longer-term follow-up report of ARUBA has limitations. The number of patients included 367 
in the study was much smaller than the 800 patients initially planned, but with 223 patients, whos 368 
disparity in outcomes led to the early suspension of randomisation. In addition, due to limited 369 
resources, the duration of follow-up was shorter than the five years for all participants that had 370 
initially been planned. Although 26 of 226 patients were lost to follow-up at the time of the final 371 
data lock, their numbers were similar in both arms, so that potentially missed outcomes for them 372 
are unlikely to have had a large effect on the reported results. Because of the smaller number of 373 
included patients than initially planned, the estimates of the treatment effect in the subgroup 374 
analyses were less precise than anticipated. 375 
 376 
Strengths of ARUBA are its randomised design and its inclusion of patients at 39 centres, which 377 
enhances the generalisability of its findings. A recent systematic review in the Cochrane 378 
Database (search date January 14th 2019) found ARUBA was the only published randomised trial 379 
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comparing medical management with interventional therapy for unruptured brain arteriovenous 380 
malformations.12 The study also has striking similarities with the literature: ARUBA was 381 
consistent with the outcomes for intervention in a meta-analysis13 from the few cohorts of 382 
untreated unruptured brain AVMs, 14, 15 and a non-randomised cohort study with concurrent 383 
controls with follow-up for up to 12 years.16 The distribution of the Spetzler-Martin grades of 384 
included brain AVMs were bias towards those more safely and easily treated, indicating few 385 
participants were unsuitable for interventional therapy.  386 
 387 
Previous case series have reported differing risks of clinical outcomes and angiographic 388 
obliteration after treatment for brain arteriovenous malformations.13 For unruptured brain  389 
arteriovenous malformations, the risk of treatment has to be weighed against the risk of rupture 390 
with medical management alone, 1.3% per year over a period of 10 years among the largest 391 
reported series of 1389 from four major centers.17 Comparative observational studies with 392 
concurrent controls have also reported worse outcomes associated with interventional therapy for 393 
brain  arteriovenous malformations compared to medical management over up to 12 years.16 394 
 395 
Patients with an unruptured brain arteriovenous malformation should, therefore, be informed 396 
about the absolute and relative risks of both treatment strategies in ARUBA. In addition, the 397 
current report may inform the design of other randomised controlled trials seeking to investigate 398 
the reproducibility of the ARUBA model. An improved design depends on a better 399 
understanding of the natural history of unruptured brain arteriovenous malformations, and in the 400 
context of other settings or approaches to improvements in therapeutic interventional therapies.  401 
 402 
Three other RCTs are currently ongoing in patients with brain arteriovenous malformations; all 403 
three including both patients with ruptured and patients with unruptured brain arteriovenous 404 
malformations. One is testing whether two embolisation approaches are equivalent (endovascular 405 
embolisation with Onyx versus with TRUFILL n-butyl cyanoacrylate n-BCA;NCT00857662); 406 
one whether conservative management or intervention will reduce the risk of death or 407 
debilitating stroke and whether endovascular treatment can improve the safety and efficacy of 408 
surgery or radiosurgery (NCT02098252), and the third is testing whether transvenous 409 
embolisation or trans-arterial embolisation is most effective and safe in achieving angiographic 410 
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obliteration of the  arteriovenous malformation (NCT03691870). The longer-term risks of 411 
interventional therapy compared to medical management than reported here will remain 412 
unknown unless future randomised trials are sufficiently funded to permit an adequate duration 413 
of follow-up. 414 
 415 
How some lesions seem stable for decades or life-time is still unclear. 18,19 The few studies 416 
assessing these risks have documented that haemorrhage risk is related to high intra-nidal 417 
pressure20 and to single-vein drainage.21 Future studies may extend these findings but likely will 418 
depend on further innovations in non-invasive imaging to assess arteriovenous resistivity 419 
patterns. Continued interest in long-term outcomes in patients with unruptured brain 420 
arteriovenous malformations is being pursued in a large, international observational cohort study 421 
funded by National Institute of the Neurological Disorders and Stroke (R01 NS099268) based on 422 
the methods used for the Multicenter Arteriovenous Malformations Study (MARS), with a goal 423 
of identifying predictors of haemorrhage and treatment risks in >2500 patients.22 Also ongoing is 424 
the Treatment Of Brain Arteriovenous malformations Study (TOBAS) comprising two open-425 
label randomised arms.23 426 
 427 
No formal detailed guidelines on the management of unruptured brain AVM have emerged from 428 
professional associations. Two consensus reports endorsed by the American Heart Association, 429 
the first from 2001 cited that treatment results vary considerably24 and the most recent from 2017 430 
that medical management alone and three often complementary methods of interventional 431 
therapy exist.25   432 
 433 
In summary, after mean length of follow-up 50·4 months (SD±22·9; median 48·0, IQR 35·9-434 
71·1), medical management alone remained superior to medical management with interventional 435 
therapy for the prevention of death or symptomatic stroke in patients with an unruptured brain 436 
arteriovenous malformation in the ARUBA trial. Evidence of this hazard should have an impact 437 
on standard specialist practice and should be among the materials presented to patients.  The rate 438 
of outcome events and degree of disparity between the two management options beyond four 439 
years remain uncertain. 440 
 441 
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Data Sharing Statement: Trial data collected during the NINDS-funded phase are archived by 444 
NINDS and available upon request.  Information on how to request the data is available here: 445 
https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-446 
Research/Archived-Clinical-Research-Datasets (last accessed 29/03/2020).   447 
The trial has been funded internationally by the US National Institutes of Health / National  448 
Institute of Neurological Disorders and Stroke (NIH/NINDS) via cooperative agreements  449 
U01NS051483 (J.P.Mohr, PI Clinical Coordinating Center) and U01 NS051566 (A.J. 450 
Moskowitz, PI Data Coordinating Center).  451 
The post-NIH funding period was supported by a gift from the Vital Projects Fund, Inc. 452 
(J.P.Mohr, PI Clinical Coordinating Center).   453 
ARUBA has been officially adopted by the UK Stroke Research Network and endorsed by the 454 
Société Française Neurovasculaire (SFNV). No commercial funding sources have been involved.  455 
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PANEL: RESEARCH IN CONTEXT 521 
 522 
Evidence before this study:    523 
Case series have reported different risks of clinical outcomes and angiographic obliteration for 524 
brain arteriovenous malformations, which are unreliable for comparison with the best available 525 
data indicating a 1% annual risk of haemorrhage from un-treated unruptured brain arteriovenous 526 
malformations. Comparative observational studies with concurrent controls have reported worse 527 
outcome associated with interventional therapy for brain arteriovenous malformations compared 528 
to medical management over up to 12 years. A recent systematic review in the Cochrane 529 
Database (search date January 14th 2019) found one published randomised trial comparing 530 
medical management with interventional therapy for unruptured brain arteriovenous 531 
malformations. The ARUBA trial terminated recruitment when its data monitoring committee 532 
concluded that medical management was superior to interventional therapy for the prevention of 533 
stroke or death on the basis of the first 223 recruited participants after a mean follow-up of 33 534 
months (HR 0·27, 95% CI 0·14-0·54). The data monitoring committee concluded that there was, 535 
“a compelling need for additional long-term data.” 536 
 537 
Added value of this study:  538 
The current report includes longer term outcomes than in the initial publication of the 539 
randomised phase of the ARUBA trial, now including all 226 participants recruited at 39 540 
international hospitals with mean follow-up extended from 33 months to 50 months. The final 541 
results of ARUBA show that medical management remained superior to interventional therapy 542 
(HR 0·31, 95% CI 0·17-0·56). 543 
 544 
Implications of all the available evidence:   545 
The final results of ARUBA demonstrate harm from interventional therapy compared to medical 546 
management over an average duration of follow-up of more than four years. Patients with 547 
unruptured brain arteriovenous malformation should be informed about the absolute and relative 548 
risks in ARUBA, which may inform the design of other randomised controlled trials seeking to 549 
investigate the reproducibility of ARUBA in the context of other settings or approaches to 550 
interventional therapy. The long-term risks of interventional therapy compared to medical 551 
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management will remain unknown unless future randomised trials are sufficiently funded to 552 
permit an adequate duration of follow-up. 553 
554 
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Table 1. Baseline Characteristics  
 
 
Interventional 
Therapy 
(N=116) 
Medical 
Management 
(N=110) 
Demographics   
Mean age (±SD) years 44·5 (±12·5) 44·3 (±12·2) 
Female sex (%) 50/116 (43·1) 44/110 (40·0) 
Male sex (%) 66/116 (56.9) 66/110 (60) 
White (%) 100/116 (86·2) 88/110 (80·0) 
Right-handed (%) 109/116 (94·0) 101/110 (91·8) 
Clinical presentation   
Seizure (%) 52/116 (44·8) 45/110 (40·9) 
Headaches (%) 56/116 (48·3) 60/110 (54·5) 
Focal deficit (%)  21/116 (18·1) 10/110 (9·1) 
Other (%) 3/116 (2·6) 8/110 (7·3) 
Asymptomatic (%) 45/116 (38·8) 49/110 (44·5) 
Modified Rankin Scale score at 
randomisation 
  
0 (%) 57/116 (49·1) 51/110 (46·4) 
1 (%) 59/116 (50·9) 59/110 (53·6) 
Spetzler-Martin grade**   
I (%) 32/114 (28·1) 33/110 (30·0) 
II (%) 45/114 (39·5) 27/110 (24·5) 
III (%) 29/114 (25·4) 35/110 (31·8) 
IV (%) 8/114 (7·0) 15/110 (13·6) 
AVM nidus morphology   
Mean maximum diameter (±SD), mm 24.8 (±12·1) 27.6 (±11·1) 
Maximum diameter <3cm (%) 79/116 (68·1) 61/110 (55·5) 
Left-sided (%) 50/116 (43·1) 51/110 (46·4) 
Any lobar location (%) 105/116 (90·5) 100/110 (90·9) 
Infratentorial location (%) 8/116 (6·9) 5/110 (4·5) 
Eloquent location (%)*** 55/116 (47·4) 52/110 (47·3) 
Concurrent arterial intracranial aneurysms   
Associated aneurysm (%)‡ 15/116 (12·9) 21/110 (19·1) 
Unrelated aneurysm (%) 4/116 (3·4) 7/110 (6·4) 
Venous drainage pattern*   
Superficial only  (%) 79/114 (69·3) 69/110 (62·7) 
Any deep (%) 35/114 (30·7) 41/110 (37·3) 
Plus-minus values are means ± SD.  
Categorical variables are the number with the value / number with available data (%). 
*Patients may have more than one presenting symptom. 
** Baseline score unavailable for 2 patients enrolled without angiography in the interventional therapy 
group. 
*** Eloquent (as defined by the Spetzler-Martin scale) is any AVM location involving the 
sensorimotor, language, or visual cortex; the hypothalamus and thalamus; the internal capsule; the 
brainstem; the cerebellar peduncles; or the deep cerebellar nuclei.  
‡ Associated arterial aneurysms are flow-related aneurysms located on a feeding artery or within the 
AVM nidus (“intranidal aneurysms”). 
AVM,arteriovenous malformation; mRS,modified Rankin scale; SD = standard deviation, no. number; 
obs, observations. 
Table
Table 2 Primary and secondary outcomes by randomised assignment to medical management alone vs 
medical management with interventional therapy  
 
 
Interventional Therapy 
(N=116) 
Medical Management 
(N=110) 
Effect of Medical 
management alone vs 
Interventional Therapy 
Primary outcome N 
Incidence 
Rate Per 100 
Patient-Years N 
Incidence 
Rate Per 
100 Patient-
Years 
Hazard Ratio  
(95% CI) 
Symptomatic stroke or death  41 12·32 15 3·39 0·31 (0·17 - 0·56) 
     Symptomatic stroke      
 Any incident stroke 40 11·99 13 2·94 0·27 (0·15 - 0·51) 
      Haemorrhagic 30  9   
      Ischaemic 10  4   
     Death      
      Any* 4 0·85 2 0·42 0·49 (0·09 – 2·67) 
      AVM-related 2  0   
      Not AVM-related 2  1   
      Unknown cause 0  1   
Functional Outcome 
N/N with 
follow-up 
available % 
N/N with 
follow-up 
available % 
Relative Risk   
(95% CI) 
mRS 2-6 at 5 years 
 
17/45 37·8 9/51 17·7 0·47 (0·23 - 0·94) 
* Three patients in the IT arm experienced at least one stroke and eventually died during the course of the trial 
 
AVM, arteriovenous malformation; N, number, mRS, modified Rankin scale; CI = Confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 Adverse events by randomisation assignment to medical management alone vs medical 
management with interventional therapy 
 
Event type 
Interventional  
Therapy  
(n=116) 
Medical  
Management 
(n=110) Risk Difference for 
MM-IT  
(95% CI) 
Number  
of Events 
Rate per 100 
patient-years 
Number  
of Events 
Rate per 100 
patient-years 
Stroke      
All 52 11·09 16 3·33 -7.76 (-11.19, -4.33) 
Haemorrhagic 39 8·32 11 2·29 -6.03 (-8.97, -3.09) 
Ischemic 13 2·77 5 1·04 -1.73 (-3.49, 0.03) 
  Focal deficit, unrelated to stroke      
All 20 4·27 3 0·63 -3.64 (-5.64, -1.64) 
Persistent 7 1·49 1 0·21 -1.29 (-2.46, -0.11) 
Reversible 13 2·77 2 0·42 -2.36 (-3.97, -0.74) 
Seizure      
All 95 20·27 68 14·17 -6.1 (-11.39, -0.81) 
Simple focal 38 8·11 17 3·54 -4.57 (-7.64, -1.49) 
Partial complex 19 4·05 7 1·46 -2.6 (-4.71, -0.48) 
Generalized 34 7·25 34 7·08 -0.17 (-3.58, 3.24) 
Not classified 4 0·85 10 2·08 1.23 (-0.31, 2.77) 
  Headache, unrelated to stroke      
All 116 24·75 111 23·13 -1.62 (-7.85, 4.61) 
Migraine (with or without aura) 23 4·91 57 11·88 6.97 (3.29, 10.65) 
Tension-type (episodic, chronic) 55 11·73 39 8·13 -3.61 (-7.62, 0.41) 
Unclassified, other 38 8·11 15 3·13 -4.98 (-8.01, -1.96) 
Other AVM related:      
Contrast reaction 1 0·21 0 0·00 -0.21 (-0.63, 0.2) 
Catheter adherence 1 0·21 0 0·00 -0.21 (-0.63, 0.2) 
Systemic embolisation 1 0·21 0 0·00 -0.21 (-0.63, 0.2) 
Infection after interventional 2 0·43 0 0·00 -0.43 (-1.02, 0.16) 
Procedural vascular injury 2 0·43 0 0·00 -0.43 (-1.02, 0.16) 
MM, medical management; IT, interventional therapy; AVM, arteriovenous malformation; CI, confidence 
interval  
 
 
Figure 1 Trial profile 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Risk of the primary outcome by randomised assignment to medical management 
alone vs medical management with interventional therapy. Crosses depict censored patients. 
Numbers below the x-axis indicate the numbers at risk at the start of each follow-up interval. 
 
 
 
MM, medical management; IT, interventional therapy; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Effects of medical management alone vs medical management with interventional 
therapy on the primary outcome in sub-groups 
 
 
 
MM, medical management; IT, interventional therapy; 
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ABSTRACT 
 
Background: The clinical benefit of preventive eradication of unruptured brain arteriovenous 
malformations (AVMs) remains controversial. A Randomised trial of Unruptured Brain 
Arteriovenous malformations (ARUBA) showed that medical management alone was superior to 
the combination of medical and interventional therapy over a mean follow-up of 33 months. 
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However, whether these differences persist in the longer-term is unknown. : In A Randomized 
trial of Unruptured Brain Arteriovenous malformations (ARUBA), randomisation was 
halted by recommendation of the National Institute of Neurological Disorders and Stroke 
appointed data and safety monitoring board at a mean follow-up of 33·3 months after a 
pre-specified interim analysis demonstrated that medical management alone was 
superior to the combination of medical management and interventional therapy in 
preventing symptomatic stroke or death.  We aimed to study whether these differences 
persist in the longer-term of 5 years follow-up. 
 
Methods: ARUBA was an open-label, randomised (1:1), parallel group trial of adult patients 
diagnosed with an unruptured brain AVM, who had never undergone interventional 
therapy, and were considered by participating clinical centres suitable for intervention to 
eradicate the lesion. The trial compareding medical management alone with standard 
interventional therapy versus medical management  alone. (neurosurgery, embolisation, or 
stereotactic radiotherapy, alone or in any combination, sequence or number. Patients 
were randomised at 39 international clinical centres with randomisation stratified by 
clinical centre using a random permuted block design generated by a trial statistician 
and implemented via a central web based data collection system.  The primary outcome 
was death or symptomatic stroke  stroke confirmed by imaging, assessed by a neurologist 
at each centre not involved in the management of participants’ care, and monitored 
independently using an adaptive approach with interim analyses..  
After recruitment was halted in April 2013, follow-up continued until July 2015. Here we extend 
the analysis of the primary outcome until final follow-up 29 months after the blind was broken 
and assess the risk of death or disability (measured as modified Rankin Scale score ≥2) for those 
eligible for status report at five years after randomisation. Enrolment began on April 4th, 2007 
and was halted on April 15th, 2013, after which follow-up continued until July 15th, 2015. 
All analyses were by intention-to-treat. The trial is registered with ClinicalTrials.gov, 
number NCT00389181. 
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Findings: Among the 226 patients were randomily allocatedsed, 110 to medical management 
alone and 116 to medical management plus interventional therapy. During a mean 
duration of follow-up of  was 50·4 ±22·9 months. Medical management alone remained superior 
to interventional therapy , the incidence of death or symptomatic stroke was lower with 
medical management alone (15/110, 3·39 per 100 patient-years) compared to medical 
management with interventional therapy (41/116, 12·32 per 100 patient-years; (Hazard 
Ratio=0·31, 95% CI 0·17-0·56, p<0·0001) .with 15 primary outcome events in the 110 patients 
randomised to medical management (incidence rate: 3·39 per 100 patient-years) compared to 41 
in the 116 patients randomised to interventional therapy (incidence rate: 12·32 per 100 patient-
years). Two patients in the medical management group and four patients in the 
interventional therapy group died during follow-up (two attributed to intervention).The risk 
of death or disability at 5 years was also lower after medical management (n=9/51, 17·6%) 
compared to interventional therapy (n=17/45, 37·8%; Relative Risk: 0·47, 95% CI 0·23-0·94). 
Interventional therapy led to significantly more adverse events, including epileptic seizures and 
neurological deficits. Adverse events were observed less often (283 vs 369; 58·97 vs 
78·73 per 100 patient-years; risk difference -19·76 ((95% confidence interval, -30·33 to -
9·1)) in patients allocated to medical management compared with interventional 
therapy. 
 
 
Interpretation: After extended follow-up, Mmedical management alone remained was superior 
to interventional therapy for the prevention of death or symptomatic stroke in patients 
randomised to ARUBA., and death or disability, over five years in patients with an unruptured 
brain AVM. The rate of outcome events in the even longer term remains unknown. These data 
should affect standard specialist practice and the information presented to patients. The 
longer-term risks and difference between the two therapeutic approaches are uncertain 
 
Funding:  
National Institute of Neurological Disorders and Stroke (NINDS) U01NS051483 & 
U01NS051566 (2007-2013)  
Vital Projects Fund, private gift to Columbia University (2014-2015) 
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INTRODUCTION  
A Randomised trial of Unruptured Brain Arteriovenous malformations (ARUBA) addressed the 
longstanding uncertainty about whether medical management with or without interventional 
therapy is superior for those the management of patients with brain arteriovenous malformations 
(AVM) that has who have never bled.1–7  
 
The first patient was randomised in April 4th 2007. At a planned meeting with the investigators 
on April 15th 2013, the randomisation in phase of the trial was terminated prematurely following 
on the recommendation of its independent Ddata and Ssafety Mmonitoring Board (DSMB). 
Their decision was based on the results of a planned interim analysis demonstrating a log-rank Z 
statistic value (4·10) exceeding the pre-specified stopping boundary value (2·87), early and 
consistent separation of survival curves in two arms, and strong magnitude of effect. The initial 
results found that aAfter a mean follow-up of 33 months, medical management alone (MM) was 
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superior to interventional therapy with medical management (IT) for the prevention of death or 
stroke (as-randomised hazard ratio (HR) 0·27, 95% CI 0·14-0·54, p=0·0001; as-treated HR 0·19, 
95% CI 0·09-0·38, p<0·0001).8 Further analyses incorporating modified Rankin Scale (mRS) 
score ≥2 found that showed that medical management was also superior to medical 
management with interventional therapy MM was superior to IT for the prevention of fatal or 
disabling stroke(defined as a mRS score ≥2). .9 
In response to the recommendation by the data and safety monitoring boardDSMB, but 
without continued funding by the National Institute of Neurological Disorders and Stroke 
post-randomisation follow-up efforts continued as originally planned in order to evaluate 
treatment effects at 5-years. Centre participation continued until the database was closed in July 
15, 2015. The initial and combined extended results were presented at the 2016 International 
Stroke Conference10 and comprise the present manuscript. The present report describes 
outcomes observed over the initial randomisation phase and during continued follow-up 
to assess whether medical management alone remained superior to medical 
management plus interventional therapy 
 
METHODS 
Trial design and randomisation 
The study design and randomisation procedures have been describied previously.1 Briefly, 
ARUBA was a an open, parallel group trial in which participants were randomised 1:1 to 
medical management with interventional therapy (IT; ie, neurosurgery, embolisation, or 
stereotactic radiotherapy, alone or in any combination or sequence) or medical management 
alone (MM; ie, pharmacological therapy for neurological symptoms as needed). A sample size of 
400 guaranteed 80% power to detect a 46% reduction in the hazard of death or stroke (due to 
haemorrhage or infarction), equivalant to a hazard ratio of 0.54. This hazard ratio corresponds to 
an absolute decrease in 5-year event rates of 9.5% for medical management, from an assumed 5-
year event rate of 22% for interventional therapy. The original design for ARUBA included a 
total sample size of 800 patients which guaranteed 87·5% power to detect a 40% reduction in the 
hazard for death or symptomatic stroke over 5 years based on assumed 5-year event rate of 22% 
in interventional therapy; however, because of lower than expected accrual rates after 18 months 
of randomisation, and the opportinity for longer follow-up to achieve the outcome event rates, 
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the DSMB accepted the revised design of 400 patients. Patients were randomised in nine 
countries at 39 clinical centres (Supplemental Table 1). Protocol and consent forms 
were approved by the relevant institutional review boards or equivalent ethics 
committees at all institutions. 
 
 
Participants  
Those Patients eligible for randomisation were adults (age ≥18) whose brain arteriovenous 
malformation had never AVM had not bled, and were considered by the local centres suitable 
for attempted  lesion AVM eradication by the local centres. Each patient provided written 
informed consent. . No control in case selection was exerted by the clinical coordinating 
centres (ARUBA-WEST: Columbia University Medical Center; ARUBA-EAST: Hôpital 
Lariboisière). A full list of eligibility criteria can be found in the study protocol.1 
 
Procedures Interventions 
Interventional therapy options comprised endovascular embolisation, neurosurgical resection, or 
stereotactic radiosurgery, as single or multiple therapies, in any order, number, or sequence. No 
published guidelines for selection or sequence of choice(s) of intervention existed during the 
trial.11 Centres implemented the approaches considered standard practice in their specialist centre 
and country. 
Formatted: Font: Arial, English (United Kingdom)
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During the blinded phase of the trial, patient data were collected at six-month intervals 
for the first two years of follow-up, thereafter annually, with the goal of final status report 
at year 5, the planned end of the trial by the original protocol. Follow-up was expected 
to continue also for those experiencing a primary outcome event. Although clinical 
centres were free to undertake whatever management they deemed appropriate after 
the primary outcome event, reports of outcomes depended on the willingness of those 
affected to continue in follow-up. After the end of the randomisation phase, supported 
by Vital Projects Fund, New York, NY and without funding by the National Institute of 
Neurological Disorders and Stroke, clinical centres continued efforts at follow-up and 
reported the status of their patients until July 15th 2015 when the database was closed, 
eight years and two months from the start of accrual of randomisations. Due to lack of 
continued funding, further follow-up was not feasible. Supplemental Figure 1 provides 
the number of last follow-up reports by year. 
 
Outcomes 
The primary outcome was the composite event of death from any cause or symptomatic stroke 
from haemorrhage or infarction, documented by imaging (CT or MR scan). The secondary 
endpoint was death or functional outcome measured at 5 years after randomisation. Poor 
functional outcome was defined as a score ≥ 2 on the modified Rankin scale (mRS), which 
ranges from 0 to 6, with higher scores indicating more severe disability.12 More information on 
study conduct, data collection, and outcome assessments are available in the primary 
publication.1 
Randomisation and masking 
 
Randomisation was stratified by clinical centre using a random permuted block design 
with block sizes of 2, 4, and 6. The randomisation sequence was generated by a trial 
statistician at the data coordinating centre (the International Center for Health Outcomes 
and Innovation Research at the Icahn School of Medicine at Mount Sinai) and 
assignment was controlled via a central web-based data collection system, which did 
not reveal treatment allocation until all baseline data had been submitted.  Site 
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coordinators randomised participants after verifying eligibility and obtaining patient 
consent. 
 
Blinding and Outcome Assessment 
All individual centres were aware of the treatment assignment for their own patients but were not 
informed of the outcomes from other centres in the trial. Assessment of oOutcomes at each 
centre was by a senior study neurologist who did not perform interventional procedures. 
not involved in the individual patient’s care, but qualified to perform the NIH Stroke Scale 
(NIHSS) and the mRS, and who had agreed to the classification of case histories and images 
circulated by study leaders before the start of the trial. Clinical coordinating centre personnel and 
outcome events committees were blinded to treatment assignment.  
 
Participants and study leaders including those at the clinical coordinating center, remained 
blinded as to the overall randomisation assignments and  outcomes until April 15, 2013 when 
the results of a planned interim analysis were provided to the trial executive committee at a 
meeting with the data and safety monitoring board.  
. The first public presentation of the results was during the 22nd European Stroke Conference in 
May 31, 2013. Acting on the DSMB recommended follow-up, ARUBA centres continued to 
report outcomes, albeit no longer blinded to the overall study results, until the database was 
closed in July 15, 2015.\  
Outcomes 
TThe primary outcome was time to the composite event of death from any cause or 
symptomatic stroke (haemorrhage or infarction), documented by imaging (CT or MR 
scan). hrough Until the end of the randomisation phase in 2013 all primary outcome events were 
adjudicated by a four-member committee comprised of internationally-renowned experts in 
stroke neurology, endovascular therapy, radiosurgery, or vascular neurosurgery. All primary 
outcomes reported after the end of the recruitment randomisation phase were adjudicated by a 
single member of the original adjudication committee (Prof Marie-Germaine Bousser, Hôpital 
Lariboisière, Paris, France). 
The secondary outcome was death or neurological disability at five years after 
randomisation.   Neurological disability was defined as a score ≥ 2 on the modified 
Formatted: Font: (Default) Arial
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Rankin scale (mRS), which ranges from 0 to 6, with higher scores indicating more 
severe disability with 6 indicating death.11  Additional secondary outcomes included the 
incidence of adverse events which were collected systematically and adjudicated by the 
event adjudication committee.  Definitions of adverse events are available in the 
protocol included in the supplement.  More information on study conduct, data 
collection, and outcome assessments are also available in the primary publication.1 
 
Follow-up 
During the blinded phase of the trial, patient data were collected at six-month intervals for the 
first two years of follow-up, thereafter annually, with the goal of final status report at year 5, 
which was the planned end of the trial by the original protocol. Follow-up was expected to 
continue even for those experiencing a primary outcome event. Although centres were free to 
undertake whatever management they deemed appropriate after the primary outcome event, 
reports of outcomes depended on the willingness of those affected to continue in follow-up.  
 
After the end of the randomisation phase, centres continued initial efforts to follow-up and 
reported the status of their patients through July 2015. Supplemental figure 1 provides the 
number of last follow-up reports by year.  
 
Statistical analysis  
The intial protocol, submitted and approved by two National Institute of Neurological 
Disorders after two separate Stroke Study Section reviews, had a sample size of 800 
patients which would have an estimated 87·5% power to detect a 40% reduction in the 
hazard for death or symptomatic stroke over 5 years based on an assumed 5-year 
event rate of 22% in the medical management and  interventional therapy arm. The 
study was overseen by a National Institute of Neurological Disorders and Stroke-
appointed data and safety monitoring board.   
During the study start-up period, the anticipated number of participating clinical centres 
was not realized, resulting in a lower than expected recruitment rate. Eighteen months 
after the first randomisation, given the opportunity for longer follow-up to achieve the 
outcome event rates within the period of National Institute of Neurological Disorders and 
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Stroke funding, the data and safety monitoring board reviewed the emerging data by 
treatment group in private, keeping clinical investigators blinded. The board accepted a 
revised sample size of 400 patients presented by the study statisticians, which would 
have an estimated 80% power to detect a 46% reduction in the hazard of death or 
symptomatic stroke, equivalant to a hazard ratio of 0.54. This hazard ratio corresponded 
to an absolute decrease in 5-year event rates of 9.5% for medical management alone, 
from an assumed 5-year event rate of 22% for medical management with interventional 
therapy. ARUBA had an adaptive design involving pre-specified interim analyses. Two 
interim analyses were pre-specified in the protocol with early stopping boundaries 
defined by an O’Brien Fleming-type spending function using a Lan-DeMets approach.  
There were no interim assessments for futility since the study was set up to assess 
superiority and non-inferioirty. 
 
The statistical analysis was carried out by the data coordinating center. For the primary 
outcome, Cumulative event–free survival curves for each group were estimated by the Kaplan–
Meier method. The primary null hypothesis was tested in an intent-to-treat analysis using a 0·05 
level log-rank test. The incidence rate of primary outcome events is the number of 
patients who had an event divided by the number of event-free patient years observed. 
A Cox proportional–hazards regression models wasere used to estimate hazard ratios (HR) and 
corresponding 95% confidence interval.   To account for potential clustering effects by 
clinical centre, a Cox model including a frailty term for clinical centre was also explored.   
Risk of death or clinical impairment at five years after randomisation was summarised 
using poor functional outcome was based on the proportion of patients with mRS ≥2 at 5 years 
and compared between groups using a Chi–square test. Five-year mRS scores were based on 
mRS assessments documented between 54 and 66 months from randomisation for participants 
those whose date of randomisation made them eligible for such assessment before the closure of 
the trial dataset. For patients who had multiple assessments in this window, the assessment 
closest to the expected 60-month (five years) follow-up visit date was selected as the patient’s 
5-year mRS. Patients who died before month 66 were assigned a mRS score of 6, irrespective of 
the cause of death.  
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Frequencies Group differences in the incidence rates of adverse events including all strokes, 
focal deficits, seizures, and headaches were computed by allocated treatment group, as well 
as the rate difference between the groups and the corresponding 95% confidence 
interval compared using Poisson regression. Duration of follow-up in months was calculated 
using the last date of contact with each patient. Exploratory subgroup analyses of the 
primary outcome were conducted using Cox proportional hazards models and tested for 
heterogeneity of treatment effect using interaction terms. 
All analyses were conducted by the intention-to-treat principle using SAS version 9.4 
(Cary, NC). Due to the descriptive nature of the study there is no bias adjustment due to 
the adaptive design.  Additional information on the timing and results of the two pre-
specified interim analyses are given in supplemental figure 2.  
 
Patients who were randomised to MM alone but who changed to IT and subsequently received 
IT were analysed as MM in ‘as-randomised’ analyses but were reported in IT in ‘as treated’ 
analysis if the reason for intervention was other than brain AVM rupture. Patients randomised to 
IT who never received it or who suffered a stroke before the initiation of interventional therapy 
were reported in the IT for the ‘as-randomised’ analysis but reported in MM for the ‘as-treated’ 
analysis. 
 
The trial is registered with ClinicalTrials.gov, number NCT00389181. 
 
Role of the Funding Source 
NINDS participated in study design, data interpretation, and writing of the report, but had no role 
in data collection or data analysis. The Vital Projects Fund had no role in study design, data 
collection, data analysis, data interpretation, or writing of the report. The corresponding author 
had full access to all the data in the study after the end of the randomisation phase and had final 
responsibility for the decision to submit for publication. 
 
RESULTS 
Of 1740 patients screened, 1014 (58·3%) were ineligible and 726 were eligible, of 
whom 323 (44·5%) refused participation and 177 (24·4%) decided their management 
Formatted: Font: (Default) Arial, English (United
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outside the trial (figure 1); outcomes were not collected for eligible patients who were 
not randomised. Thirty-nine international centres randomised a total of 226 participants at a 
steady rate of 3.2 per month from April 4, 2007 to April 15, 2013 (supplemental figure 2). A 
CONSORT diagram of patient retention at key intervals is shown in figure 1. It is based on the 
years of participation and not calendar dates. No outcomes were reported for the 177 eligible 
patients whose treatment choices were made outside the trial, many from centres who enrolled 
no patients. Almost half of the participants were randomised within 3 years (before April 15, 
2010) and finished their 5-year participation before or during 2015; for the other half, recruited 
later, most were not eligible for a formal 5-year report when the database closed, although many 
had their status reported during the final two years of follow-up while the database remained 
open.  
 
Of the 226 patients randomised, 110 were allocated to medical management alone MM and 
116 to medical management plus interventional therapyIT. Three patients randomised in the 
interval between data lock for the final DSMB report and presentation to the data and safety 
monitoring board DSMB in April 2013, were not included in the primary publication.1 but are 
included in the current report.  At final data lock on July 15, 2015, patients randomised, 
regardless of outcome status, had a mean length of follow-up of 50·4 months (SD±22·9; median 
48·0, IQR 35·9-71·1). The average follow-up for patients allocated to medical management 
MM patients was 52·4 months (SD±23·7; median 49·1, IQR 36·1-71·8), and for patients 
allocated to interventional therapy IT patients was 48·5 months (SD±22·0; median 45·5, IQR 
34·7-62·1). The distribution of dates of the last patient contact is shown in supplemental figure 1.  
 
Baseline characteristics and mRS scores were previously reported for the first 223 randomised 
patients and were similar between groups.1 apart from focal neurological deficits at 
presentation, small AVM nidus size and Spetzler Martin grade. An updated baseline table 
including all 226 randomised patients is given in the supplement (Supplemental Table 1). Minor 
imbalances existed towards more focal neurological symptoms at presentation in patients 
allocated to IT. 
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Between April 15, 2013 and July 15, 2015, four new primary outcome events were reported in 
the MM arm and six in the IT arm. Combined with previously reported events, there were a total 
of 15 primary outcome events (incidence rate: 3·39 per 100 patient-years) in patients randomised 
to MM versus 41 (incidence rate: 12·32 per 100 patient-years) in patients randomised to IT 
(Table 1). Compared with the primary publication, the updated analysis of the primary outcome 
continued to favour MM over IT, in both the ‘as-randomised’ (HR 0·31, 95% CI 0·17-0·56, 
p<0·0001) and ‘as-treated’ (HR 0·22, 95% CI 0·12-0·41, p<0·0001) analyses (Figure 2). Based 
on the primary outcome analysis, the number needed to harm by IT at 5 years was 5 (95% CI 3-
13) when analysed by ‘as randomised’ groups and 3 (95% CI 2 to 6) when analysed by ‘as-t In 
total, there were 15 primary outcome events in patients randomised to medical 
management (incidence rate: 3·39 per 100 patient-years) versus 41 in patients 
randomised to interventional therapy (incidence rate: 12·32 per 100 patient-years; Table 
2), resulting in a hazard ratio of 0·31 (95% CI 0·17-0·56; Figure 2). These results 
remained consistent after accounting for the potential clustering effect of clinical centre 
(adjusted HR 0.31, 95% CI 0.16-0.61). Of the 56 primary outcomes, 10 were new 
events reported between April 15th 2013 and July 15th 2015. Four of these 10 occurred 
in the medical management arm and six in those randomised to medical management 
plus interventional therapy. In total, two patients allocated to medical management 
alone and four patients allocated to medical management plus interventional therapy 
died during follow-up. In the latter group two of the four deaths were attributed to the 
intervention (Table 2). 
reated’ groups. 
The risk of the secondary outcome of death or neurological disability at five years after 
randomisation, available for 96 patients, was lower for those allocated to medical 
management alone (Table 2). Supplemental Figure 4 illustrates the distribution of mRS 
scores by study arm for those with data available at 5years.  
 
Subgroup analyses of the primary outcome were consistently in favour of MM over IT, except 
for venous drainage, AVM maximum nidus size, and Spetzler-Martin grade, where there was 
statistically significant heterogeneity of the treatment effects. Figure 3 shows the primary 
outcomes by subgroup in an ‘as randomised ‘analysis. For patients with Spetzler-Martin Grade I 
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the ‘as randomised’ analyses appeared to favour IT (HR 1·82, 95% CI: 0·46, 7·28) but the ‘as 
treated’ analyses appeared to favour MM (HR 0·66, 95% CI: 0·18, 2·44, supplemental figure 3). 
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Figure 4 illustrates the distribution of mRS scores by study arm for those with data available at 5 
years. The risk the secondary outcome of death or neurological disability at five years after 
randomisation, available for 96 patients, poor functional outcome (i.e., mRS score ≥2) was 
lower for those allocated to medical management alone MM (n=9/51, 17·6%) compared to 
those allocated to IT (n=17/45, 37·8%; RR 0·47, 95% CI 0·23-0·94, p=0·03). A similar effect is 
seen in the ‘as treated’ analysis (RR 0·41, 95% CI 0·20-0·83, p=0·009).  
Patients allocated to interventional therapy IT experienced significantly more adverse events 
compared to those allocated to medical managementMM (78·73 versus 58·97 per 100 patient-
years; p<0·001), including more epileptic seizures (20·27 versus 14·17 per 100 patient-years; 
p=0·02), and more focal neurological deficits (4·27 versus 0·62 per 100 patient-years; p<0·001). 
No difference was observed in the rates of documented episodes of headache (Supplemental 
Table 2). 
 
Subgroup analyses of the primary outcome were consistently in favour of medical 
management over medical management plus interventional therapy, except for venous 
drainage (superficial only versus any deep), arteriovenous malformation maximum 
nidus size (<3 cm versus ≥3 cm), and Spetzler-Martin grade, where there was 
heterogeneity of the treatment effects (Figure 3). The effect of medical management in 
patients with Spetzler-Martin Grade I AVMs appeared to differ from Spetzler-Martin 
Grade II-V AVMs, although the effect in the Spetzler-Martin Grade 1 group was not 
significant (HR 1·82, 95% CI 0·46-7·28). 
 
Eight patients who were randomised to medical management alone MM crossed over to received 
medical management plus interventional therapy =IT. Of the 116 randomised to interventional 
therapyIT, three experienced an outcome before interventional therapy began 18 are included in 
the MM group in the as-treated analysis (3 experienced an outcome before IT began and 15 
never received interventional therapyIT). Among the 106 patients who received interventional 
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therapy IT prior to experiencing an outcome, the median time from randomisation to first 
intervention was 76 (IQR 42-136) days. For the 43 patients who reached a primary outcome 
following the initiation of interventional therapyIT, the median delay after the last intervention 
was 1 day (IQR 0-43). Sixty-eight (64·2%) of the 106 patients who received interventional 
therapy (64·2%) were treated by a single modality of IT, while for 38 (35·8%) the therapy was 
multimodal. At the time of final data lock, 47 (44·3%) of those receiving I medical management 
plus interventional therapy T treatment had angiographic evidence of brain arteriovenous 
malformation AVM eradication, 43 (40·6%) had evidence of a brain arteriovenous malformation 
AVM remnant on last follow-up imaging, and in 16 (15·1%, all post radiotherapy) the brain 
arteriovenous malformation AVM status was unknown due to missing follow-up imaging (Table 
2).  
 
Twenty-two of 106 (20·8%) Of the 22 patients who who were treated with medical management 
and interventional underwent neurosurgery, either alone or as part of a multimodal treatment 
strategy following embolisation. In , 21 of 22 (95·5%) were free of evidence of brain AVM 
arteriovenous malformation had been eradicated based on a post-operative angiogram. ,Nine of 
the 22 (40·9%) patients who were operated on experienced a primary outcome event. 
Stereotactic radiotherapy was used in the treatment of 57 of 106 patients, either alone or as part 
of a multimodal strategy with either embolisation alone or with both endovascular and surgical 
therapy (n=1).; Aat the time of the final analysis, 12 of 57 patients (21·1%) had reached 
angiographically-documented absence of the brain arteriovenous malformationAVM, and 21 
(36·8%) had had a primary outcome event. Finally, 66 Sixty-six of 106 (62·3%) patients were 
treated by endovascular embolisation, either alone or as part of a multimodal treatment strategy 
with neurosurgery and/or radiotherapy; 34 of 66 (51·5%) demonstrated absence of the brain 
AVM on catheter angiography, and 33 of 66 (50·0%) experienced a primary outcome event 
(Table 2). 
 
DISCUSSION 
This updated analysis of ARUBA, with mean follow up extended from 33 to 50 months, 
continues to show that for patients with an unruptured bran AVM medical management alone is 
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superior to intervention management (single or multimodality) as prophylaxis for haemorrhage, 
both during the randomisation period of trial and thereafter. 
With extended follow-up of 226 participants with unruptured brain arteriovenous 
malformations in ARUBA, the risk of death or stroke remained significantly lower after 
medical management alone than after medical management with interventional therapy 
after a mean follow-up of 50 months. Ninety-six participants followed up for 60 months 
without intervention also had a significantly lower risk of death or neurological disability, 
and fewer adverse events. Although the persisting difference between the two 
management options persisted, ideally longer follow-up would be desirable but was not 
possible due to funding constraints.   
 
ARUBA remains the only randomised trial comparing MM with or without IT for patients with 
an unruptured brain AVM.1,13 The rationale for the trial and its design have been reviewed 
elsewhere.14 The 37 academic and two private clinical centres who enrolled patients in ARUBA 
had ample prior published experience with interventional treatment of brain AVMs: 630 
publications in PubMed as of July 2019. The 226 patients randomised in the ARUBA trial 
represent 31% of the 726 screened patients deemed eligible for enrolment. Of the remainder of 
the screened eligible patients, 323 refused participation in the trial and 177 were treated 
according to the wishes of their own clinician, outside of the trial. These screening data include 
information from 23 centres who contributed screening and eligibility data but enrolled no 
patients, all such issues a hindrance to success for neurosurgical trials.15  
This longer-term follow-up report of ARUBA has limitations. The number of patients 
included in the study was much smaller than the 800 patients initially planned, but with 
223 patients, whos disparity in outcomes led to the early suspension of randomisation. 
In addition, due to limited resources, the duration of follow-up was shorter than the five 
years for all participants that had initially been planned. Although 26 of 226 patients 
were lost to follow-up at the time of the final data lock, their numbers were similar in 
both arms, so that potentially missed outcomes for them are unlikely to have had a large 
effect on the reported results. Because of the smaller number of included patients than 
initially planned, the estimates of the treatment effect in the subgroup analyses were 
less precise than anticipated. 
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Strengths of ARUBA are its randomised design and its inclusion of patients at 39 
centres, which enhances the generalisability of its findings. A recent systematic review 
in the Cochrane Database (search date January 14th 2019) found ARUBA was the only 
published randomised trial comparing medical management with interventional therapy 
for unruptured brain arteriovenous malformations.12 
Although generalizability of ARUBA’s results has been questioned16, baseline characteristics of 
the trial population, observed event rates, and the direction as well as the magnitude of the 
effects of interventional therapy were remarkably similar to those seen in a contemporary 
prospective population-based study, in which the association between interventional therapy and 
the risk of stroke persisted for up to 12 years.17 Patient characteristics, outcome rates, and mRS 
values observed in the ARUBA trial are also comparable to those seen in other populations who 
presented without haemorrhage and who did not receive interventional therapy, which were 
published in two single-centre reports.18,19 These measures were also similar to a meta-analysis 
of published reports of treated patients aggregated regardless of haemorrhage status.20 
Strengths of ARUBA are its randomised design and its inclusion of patients at 39 
centres, which enhances the generalisability of its findings. A recent systematic review 
in the Cochrane Database (search date January 14th 2019) found ARUBA was the only 
published randomised trial comparing medical management with interventional therapy 
for unruptured brain arteriovenous malformations.12 The study also has striking 
similarities with the literature: ARUBA was consistent with the outcomes for intervention 
in a meta-analysis13 from the few cohorts of untreated unruptured brain AVMs, 14, 15 and 
a non-randomised cohort study with concurrent controls with follow-up for up to 12 
years.16 The distribution of the Spetzler-Martin grades of included brain AVMs were bias 
towards those more safely and easily treated, indicating few participants were 
unsuitable for interventional therapy.  
Previous case series have reported differing risks of clinical outcomes and angiographic 
obliteration after treatment for brain arteriovenous malformations.13 For unruptured brain  
arteriovenous malformations, the risk of treatment has to be weighed against the risk of 
rupture with medical management alone, 1.3% per year over a period of 10 years 
among the largest reported series of 1389 from four major centers.17 Comparative 
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observational studies with concurrent controls have also reported worse outcomes 
associated with interventional therapy for brain  arteriovenous malformations compared 
to medical management over up to 12 years.16 
 
Patients with an unruptured brain arteriovenous malformation should, therefore, be 
informed about the absolute and relative risks of both treatment strategies in ARUBA. In 
addition, the current report may inform the design of other randomised controlled trials 
seeking to investigate the reproducibility of the ARUBA model. An improved design 
depends on a better understanding of the natural history of unruptured brain 
arteriovenous malformations, and in the context of other settings or approaches to 
improvements in therapeutic interventional therapies.  
 
Three other RCTs are currently ongoing in patients with brain arteriovenous 
malformations; all three including both patients with ruptured and patients with 
unruptured brain arteriovenous malformations. One is testing whether two embolisation 
approaches are equivalent (endovascular embolisation with Onyx versus with TRUFILL 
n-butyl cyanoacrylate n-BCA;NCT00857662); one whether conservative management 
or intervention will reduce the risk of death or debilitating stroke and whether 
endovascular treatment can improve the safety and efficacy of surgery or radiosurgery 
(NCT02098252), and the third is testing whether transvenous embolisation or trans-
arterial embolisation is most effective and safe in achieving angiographic obliteration of 
the  arteriovenous malformation (NCT03691870). The longer-term risks of interventional 
therapy compared to medical management than reported here will remain unknown 
unless future randomised trials are sufficiently funded to permit an adequate duration of 
follow-up. 
Efforts to delineate which patients with unruptured AVMs will bleed and the degree of syndrome 
severity they will experience has been a long-term priority.21,22 ARUBA study statisticians had 
estimated that 12 to 30 years would be needed for the events experienced by MM patients to 
meet those already experienced by IT patients.23 This analysis had an impact on the decision by 
NINDS Study section reviewers who reviewed our proposed 5-year extension of follow-up. 
Further, although outcomes in the medical arm were infrequent, and few patients with Spetzler-
20 
 
Martin Grade III to IV AVMs were randomised in ARUBA, a recent analysis of the original 
ARUBA data failed to show an association between haemorrhage rate and lesion size among 
patients in the medical management arm.24 The declining slope of haemorrhage events in the 
Kaplan-Meier curves over the 10-year follow-up for those presenting without haemorrhage in the 
observational Multicentre Arteriovenous malformation Research Study (MARS) also suggests 
that the risk of rupture in unbled patients may subside over time.25 
How some lesions seem stable for decades or life-time is still unclear. 18,19 The few 
studies assessing these risks have documented that haemorrhage risk is related to high 
intra-nidal pressure20 and to single-vein drainage.21 Future studies may extend these 
findings but likely will depend on further innovations in non-invasive imaging to assess 
arteriovenous resistivity patterns. Continued interest in long-term outcomes in patients 
with unruptured brain arteriovenous malformations is being pursued in a large, 
international observational cohort study funded by National Institute of the Neurological 
Disorders and Stroke (R01 NS099268) based on the methods used for the Multicenter 
Arteriovenous Malformations Study (MARS), with a goal of identifying predictors of 
haemorrhage and treatment risks in >2500 patients.22 Also ongoing is the Treatment Of 
Brain Arteriovenous malformations Study (TOBAS) comprising two open-label 
randomised arms.23 
 
For the participants in ARUBA, we cannot exclude the possibility that patients not appearing at 
the local centre for follow-up visits in the planned 5-year period had experienced outcome 
events. However, overall, missing visit numbers are comparable between MM and IT and the 
low event rate in all reporting centres argues against a significant undetected morbidity or 
mortality. 
 
No formal guidelines on the management of unruptured brain AVM have emerged from 
professional associations. Two consensus reports endorsed by the American Heart 
Association, the first from 2001 cited that treatment results vary considerably24 and the 
most recent from 2017 that medical management alone and three often complementary 
methods of interventional therapy exist.25   
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since the initial publication of the results of the ARUBA trial, although an AHA scientific 
statement recently endorsed the trial’s findings.26 The results of ARUBA demonstrate clinically 
and statistically significant excess hazard from interventional therapy. Evidence of this hazard 
should have an impact on standard specialist practice in many countries in several continents, 
and should be among the materials presented to patients. Continued interest in long-term 
outcomes in patients with unruptured brain AVMs is being pursued in a large, international 
observational cohort study funded by NINDS (R01 NS099268) based on the methods used for 
MARS, with a goal of identifying predictors of haemorrhage and treatment risks in >2500 
patients.27 Also ongoing is a study (TOBAS) comprising two open-label randomised arms.28 
 
In summary, after mean length of follow-up 50·4 months (SD±22·9; median 48·0, IQR 
35·9-71·1), medical management alone remained superior to medical management with 
interventional therapy for the prevention of death or symptomatic stroke in patients with 
an unruptured brain arteriovenous malformation in the ARUBA trial. Evidence of this 
hazard should have an impact on standard specialist practice and should be among the 
materials presented to patients.  The rate of outcome events and degree of disparity 
between the two management options beyond four years remain uncertain. 
 
 
 
 
 
 
 
 
 
 
 
Data Sharing Statement: Trial data collected during the NINDS-funded phase are archived by 
NINDS and available upon request.  Information on how to request the data is available here: 
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https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Clinical-
Research/Archived-Clinical-Research-Datasets.   
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RESEARCH IN CONTEXT 
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Evidence before this study:    
Despite a literature on management options dating back to the 1930’s, no randomised clinical 
trial had been mounted, nor formal professional, societal, or national guidelines existed prior to 
ARUBA. The literature had conflicting reports concerning both the natural history of those 
whose brain AVM was discovered not having bled and outcomes from single and multiple 
therapies. These uncertainties prompted the support of an international, randomised clinical trial 
funded by the NINDS 
. Case series have reported different risks of clinical outcomes and angiographic 
obliteration for brain arteriovenous malformations, which are unreliable for comparison 
with the best available data indicating a 1% annual risk of haemorrhage from un-treated 
unruptured brain arteriovenous malformations. Comparative observational studies with 
concurrent controls have reported worse outcome associated with interventional therapy 
for brain arteriovenous malformations compared to medical management over up to 12 
years. A recent systematic review in the Cochrane Database (search date January 14th 
2019) found one published randomised trial comparing medical management with 
interventional therapy for unruptured brain arteriovenous malformations. The ARUBA 
trial terminated recruitment when its data monitoring committee concluded that medical 
management was superior to interventional therapy for the prevention of stroke or death 
on the basis of the first 223 recruited participants after a mean follow-up of 33 months 
(HR 0·27, 95% CI 0·14-0·54). The data monitoring committee concluded that there was, 
“a compelling need for additional long-term data.” 
 
 
Added value of this study:  
The current report includes longer term outcomes than in the initial publication of the 
randomised phase of the ARUBA trial, now including all 226 participants recruited at 39 
international hospitals with mean follow-up extended from 33 months to 50 months . 
The results of ARUBA are comparable to non-randomised reports from individual and 
population-based sources, some extending well beyond the time frame of ARUBA. The 
most recent review is a Cochrane Database Systemic Review published on September 
10, 2019. ARUBA was cited as the only randomised clinical trial. The quality of evidence 
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was deemed moderate and at low risk of bias but high risk of performance bias due to 
participants and treating physicians not being blinded to allocated treatment. (The 
adjudication committee was blinded). A wide range of recommendations were offered 
for the design of future randomised trials. How to achieve the desired blinding for a 
treatment plan that may include many hospital admissions and the participation of a 
large treating team remains a problem. The final results of ARUBA show that medical 
management remained superior to interventional therapy (HR 0·31, 95% CI 0·17-0·56). 
 
 
Implications of all the available evidence:   
The results of ARUBA demonstrate clinically and statistically significant excess hazard harm 
from interventional therapy compared to medical management over an average duration 
of follow-up of more than four yearsfor those 226 participants from 37 academic and 2 private 
international centres originally randomised to medical management alone or with interventional 
therapy whose outcome status was known as late as 5 years from randomisation. Patients with 
unruptured brain arteriovenous malformation should be informed about the absolute and 
relative risks in ARUBA which may inform the design of other randomised controlled 
trials seeking to investigate the reproducibility of ARUBA in the context of other settings 
or approaches to interventional therapy. The long-term risks of interventional therapy 
compared to medical management will remain unknown unless future randomised trials 
are sufficiently funded to permit an adequate duration of follow-up. The disparities in 
primary outcomes for the two arms of the ARUBA trial provide a background for those seeking 
to organize further research based on a randomised clinical trial model. An improved design 
depends on a better understanding of the natural history of unruptured brain AVMs, and 
improvements in therapeutic interventions.  
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Table 1 Primary and secondary endpoints by randomisation assignment and as treated 
 
Outcome per Randomisation 
(intention to treat) 
Interventional Therapy 
(N=116) 
Medical Management 
(N=110) 
Effect of Medical 
management alone 
 
P Value Primary Outcome N 
Incidence 
Rate Per 100 
Pt-Years N 
Incidence 
Rate Per 
100 Pt-
Years 
Hazard Ratio  
(95% CI) 
Symptomatic stroke or death  
(primary outcome) 
41 12·32 15 3·39 0·31 (0·17 - 0·56) <0·0001 
     Symptomatic stroke       
 Any incident stroke 40 11·99 13 2·94 0·27 (0·15 - 0·51) <0·0001 
      Haemorrhagic 30  9    
      Ischemic 10  4    
     Death       
      Any* 4 0·85 2 0·42 0·49 (0·09 – 2·67) 0·49 
      AVM-related 2  0    
      Not AVM-related 2  1    
      Unknown cause 0  1    
 
Functional Outcome 
No./No. 
Obs % 
No./No. 
Obs % 
Relative Risk   
(95% CI) P Value 
mRS 2-6 at 5 years 
(secondary endpoint) 
17/45 37·8 9/51 17·7 0·47 (0·23 - 0·94) 0·03 
 
 
Outcome on Treatment** 
(per protocol) 
Interventional Therapy 
(N=106) 
Medical Management 
(N=120) 
Effect of Medical 
management alone 
 
P Value Primary Outcome N 
Incidence 
Rate Per 100 
Pt-Years N 
Incidence 
Rate Per 
100 Pt-
Years 
Hazard Ratio 
(95% CI) 
Symptomatic stroke or death 
(primary outcome) 
43 14·08 13 2·77 0·22 (0·12, 0·41) <0·0001 
     Symptomatic stroke       
      Any incident stroke 42 13·72 11 2·34 0·19 (0·10, 0·37) <0·0001 
      Haemorrhagic 29  10    
      Ischemic 13  1    
     Death       
      Any* 4 0·92 2 0·39 0·43 (0·08, 2·35) 0·33 
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      AVM-related 2  0    
      Not AVM-related 2  1    
      Unknown cause 0  1    
 
Functional Outcome 
No./No. 
Obs % 
No./No. 
Obs % 
Relative Risk  
(95% CI) P Value 
mRS 2-6 at 5 years 
(secondary endpoint) 
17/42 40·5 9/54 16·7 0·41 (0·20 - 0·83) 0·009 
* Three patients in the IT arm experienced at least one stroke and eventually died during the course of the trial  
**Eight patients randomised to MM crossed over to IT. Among the 116 patients randomised to IT, n=15 never 
received therapy and n=3 suffered a stroke prior to the initiation of IT; all were therefore considered part of the MM 
group in the as-treated analysis. 
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Table 2  Treatment strategy and primary outcome in n=106 patients with unruptured brain AVM 
undergoing interventional therapy (as-treated analysis) 
 
 
*   Primary outcome: Symptomatic stroke or death 
**  Documented AVM obliteration required cerebral angiography by study protocol. For n=16 (15%) 
patients, the AVM obliteration status was unknown due to missing imaging information, n=43 (41%) had 
a documented AVM remnant on last follow-up imaging. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interventional treatment received 
With primary 
outcome* 
With documented 
AVM 
obliteration** 
n (row %) n (row %) 
Monomodal   
Endovascular (n=28) 14 (50·0) 14 (50·0) 
Surgery (n=7) 2 (28·6) 7 (100·0) 
Radiotherapy (n=33) 8 (24·2) 6 (18·2) 
Multimodal   
Endovascular and Surgery (n=14) 6 (42·9) 14 (100·0) 
Endovascular and Radiotherapy (n=23) 12 (52·2) 6 (26·1) 
Endovascular and Surgery and Radiotherapy (n=1) 1 (100·0) 0 (0) 
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Figure 1: CONSORT Diagram of Patient Flow and Follow-up 
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Figure 2: Kaplan-Meier estimated event rates by randomisation assignment (Panel A) and as treated (Panel 
B). Crosses depict censored patients. 
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Figure 3 Primary outcome sub-group analyses ‘as randomised’. Hazard ratios and 95% confidence 
intervals for each sub-group are plotted in the centre. MM=Medical management only and IT=Medical 
management with intervention. ‘As treated’ analyses are shown in the supplemental figure 3. 
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Figure 4: Secondary endpoint analysis: modified Rankin scale scores at 5 years 
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Editorial points to be addressed: 
 
1.      Study title: doesn’t comply with your Lancet style; How about “Long-term outcomes of medical 
management with standard interventional therapy versus medical management alone in patients with 
unruptured brain arteriovenous malformations (ARUBA): a multicentre, open-label, parallel, 
randomised controlled trial”? 
 
Thank you for this suggestion – We’ve changed the title to “Medical management with 
interventional therapy versus medical management alone for unruptured brain arteriovenous 
malformations (ARUBA): final follow-up of a multicentre, open, parallel group, randomised 
controlled trial” which reflects the contents and avoids “long-term” as in the manuscript we 
say that the long-term effects remain uncertain. 
 
2.      Please check spelling, punctuation, spacing etc. and check for cohesion and clarity of each 
sentence. Please avoid repetitions between the individual section, this is currently the case in the 
method section. Please keep in mind that not all readers might be familiar with the original study and/or 
topic (eg, readers might not know why there was uncertainty whether medical management with or 
without interventional therapy is superior or not). 
 
Thank you for this suggestion. We have done this including the use of the spelling ‘center’ in the 
co-author list for those not in the UK, centre for the others, and ‘centre’ throughout the 
manuscript.  
 
3.      Please follow CONSORT guidelines including these for the abstract.  
         
 We’ve modified the abstract (see 5 below) and completed the CONSORT checklist. 
 
4.      Please complete and submit CONSORT checklist. 
 
We have submitted this alongside the manuscript. 
 
5.      Abstract (please format according to CONSORT, we have some leeway with the wordcount to 
comply with CONSORT): 
 
a.      Background: 
i.      not clarify why the “clinical benefit of preventive eradication of unruptured brain 
arteriovenous malformations (AVMs) remains controversial” given the positive results 
of the ARUBA trial. Here might be the place to explain ARUBA. 
 
We have re-stated ARUBA’s statistically significant finding, removed mention of it being 
controversial, and indicated why it is not clinically significant for some because the 
long-term risk/benefit balance is unknown. 
 
ii.     Please add how long the FU of the original trial was as well as the FU of the 
current report to help with the flow. 
 
Reply to Reviewers Comments
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Thank you for these suggestions – We have included the mean follow-up of the original 
report (pg 3, line 61) as suggested and added the mean follow-up of the current report 
to the results section (pg 3, lines 82-83) and think the flow has improved. 
 
b.      Methods: 
i.      Indicate the setting (community, hospital) where participants were recruited (which 
countries, how many centres or hospitals), and the key participant eligibility criteria. 
 
We’ve added the number and international nature of centres who randomised patients 
(pg 3, lines 71-72).  The key inclusion criteria are given in the first sentence: “adult 
patients diagnosed with an unruptured brain arteriovenous malformation, who had 
never undergone interventional therapy” (pg 3, lines 66-68) 
 
ii.     Explain the groups participants were randomly assigned to, and provide 
information about the methods of randomisation, masking, and stratification (eg, block 
size). How were participants allocated to groups and by whom? Were participants, 
investigators, and those assessing outcomes masked to group assignment? 
 
We added more details to the existing sentence that detailed the random permuted block 
design to include how patients were randomised and who generated the sequence (pg 3 
lines 72-74). We also added that primary outcome events were assessed by a neurologist 
at each centre not involved in participants’ treatment (pg 3, lines 75-76). 
 
iii.    Give details of interventions (type, method of delivery, duration). For drugs please 
provide the generic name (rINN), doses, route, and schedule of administration. 
 
We added the definition of interventional therapy to the second sentence (pg 3, lines 70-
71) in parentheses, “The trial compared medical management alone with medical 
management and interventional therapy (neurosurgery, embolisation, or stereotactic 
radiotherapy, alone or in any combination, sequence or number).”  
 
iv.     What was the main outcome of this report and when was it assessed? We do not as 
standard include additional outcomes in the Summary. 
 
We specified, “The primary outcome was time to death or symptomatic stroke confirmed 
by imaging, assessed by a neurologist at each centre not involved in the management of 
participants’ care, and monitored independently using an adaptive approach with 
interim analyses” (pg 3, lines 74-77). 
 
v.      State who was included in primary and safety analyses (eg, intention to treat, per 
protocol, all participants who received one dose of study drug). 
 
Methods includes sentence that states: “All analyses were by intention-to-treat’ (pg 3, 
line 78). 
 
c.      Findings: 
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i.      Provide exact dates (day, month, year) between which participants were recruited 
and the number of participants assigned and analysed in each group, accounting for 
dropouts. 
 
This is included in the methods – we added the day to the previously given month and 
year. 
 
ii.     For the primary outcome give a result for each group (provide actual numbers of 
participants or events and their percentages), and estimated effect size (eg, odds ratio) 
and its precision (eg, 95% CI, p value). Report SDs for mean values and IQRs for 
medians, and give exact p values unless p<0·0001. Use SI units. For risk changes or 
effect sizes, give absolute values rather than relative changes. 
 
Done. 
 
iii.    Please report ONLY the primary endpoint data. Secondary outcomes cannot be 
selectively reported in the abstract, and space restrictions typically prevent all secondary 
outcomes from being included in the abstract. 
 
Done. 
 
iv.     Summarise adverse events (actual numbers and percentages in both groups; 
include treatment-related deaths). 
 
A summary of adverse events is included in the abstract and in Table 3 – rather than 
providing percentages we give the number of events per patient year to account for 
differential follow-up times.  We have also added the overall number of deaths and the 
number attributed to treatment to the abstract (pg 3-4, lines 85-87). 
 
v.      Results stated should agree with what is in the main paper, and all data here should 
also appear in. 
 
Done. 
 
d.      Interpretation: For clarity, please rephrase to something like this “At 5 years, medical 
management alone was superior to medical management with interventional therapy for the 
prevention of death or symptomatic stroke in patients with unruptured brain arteriovenous 
malformations”. This should be followed by the clinical implications/future directions, and or 
the key limitations and strengths of the study. 
 
We reworded the interpretation section of the abstract accordingly, “After extended follow-up, 
medical management alone remained superior to interventional therapy for the prevention of 
death or symptomatic stroke in patients randomised to ARUBA with unruptured brain 
arteriovenous malformations. These data should affect standard specialist practice and the 
information presented to patients. The longer-term risks and difference between the two 
therapeutic approaches are uncertain. 
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6.      Where dates are given, please give the exact dates (if known)—ie, day, month, year throughout 
the manuscript. 
 
Done. 
 
7.      It is Lancet style to give actual numbers (numerator and denominator) together with all 
percentages, throughout the text and in tables etc. Please check. 
 
We revised table 1 to include the numerators and denominators for each entry. We also 
reviewed the results text and added denominators where they were missing. 
 
8.      Please check and confirm that you have provided p values to two significant figures, unless 
p<0.0001 (note number of decimal places). 
 
We have just included p-values in Figure 3 to aid in the interpretation of the exploratory 
analyses of heterogeneity of treatment effects between subgroups.  In the update figure that 
includes these p-values, they are provided to two significant figures.   
 
9.      As mentioned previously, the Methods section should be structured in this order please: Study 
design, Participants, Randomisation and masking, Procedures, Outcomes, Statistical analysis, Role of 
the funding source (see below).  
 
We moved the sections to match the order defined above. 
 
10.     Introduction: Remove the last sentence and instead end with the aim of your study. 
 
Done. 
 
11.     Method (needs to be completely revised to conform with CONSORT): 
 
Done. 
 
12.     Study design: 
a.      Start with the study descriptor (randomised, parallel, cluster, non-inferiority, open-label, 
doubleblind, etc).  
 
Methods state, “ARUBA was an open, randomised (1:1), parallel group trial…” (pg 6, line 
138). 
 
b.      Move the aim of ARUBA from here to the introduction  
 
We have moved the aim up to the first paragraph of the introduction (pg 5, lines 107-113). 
 
c.      Indicate where the study was done (community, hospital), in which countries, and in how 
many centres or hospitals. If too many, please add them to the appendix.  
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We added a sentence about the number of countries and centres that randomised patients (pg 6, 
line 142).  We also added a table to the supplement that includes the country, centre name, and 
number of patients randomised at each centre (Supplemental Table 1). 
 
d.      State the centre where ethics approval was obtained. 
 
We moved the sentence about IRB and ethics approval that was previously under participants to 
the study design section (page 6, lines 142-144). 
 
e.      Provide a link to the study protocol if available online. Please note the weblink must be 
permanent. Alternatively, the protocol can be included in your appendix if you wish – please 
indicate this in your responses. 
 
We will provide the protocol for the appendix.   
 
13.     Participants: 
a.      Describe the planned population, with inclusion and exclusion criteria and how 
participants were recruited. If too many criteria, please add the key one here and refer to 
appendix. These key criteria need to be also added to the abstract 
 
Done. 
 
b.      Add which centre was the Clinical Coordinating Centre 
 
Added in parentheses to the following sentence, “No control in case selection was exerted by 
the Clinical Coordinating Center (ARUBA-WEST: Columbia University Medical Center; 
ARUBA-EAST: Hôpital Lariboisière).” (pg 6, lines 151-152). 
 
14.     Randomisation and masking. 
 
a.      Please start with a description of the actual method of randomisation (ie, the method used 
to generate the sequence with which participants are allocated to comparison groups (eg, 
computer, random-number tables, coin-toss], including details of the methods used to restrict 
the randomisation—eg, block, stratification), and any stratification or minimisation factors. 
Words and phrases such as "randomised", and "randomly assigned" without qualification are 
not acceptable. Please clarify what you mean by “Statistical Coordinating Center by clinical 
center”. Please add which centre this was. 
 
Done (pg 6-7, lines 157-166) 
 
a. Followed by a description of the method used to conceal assignment of a participant 
without knowledge of the next assignment in the sequence. 
 
We believe stating they were assigned by a web-based system clarifies this – but we have 
added, “assignment was controlled via a central web-based data collection system, which 
did not reveal treatment allocation until all baseline data had been submitted.” (pg 6, lines 
161-162) 
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b. Please described who generated the allocation sequence, who enrolled participants, and 
who assigned them to the trial groups, and whether they had any involvement in the rest of 
the trial. 
 
Done (pg 6, line 158-159). 
 
c. Describe how masking (blinding) was achieved (eg, tablets with identical appearance, 
syringe taped up to conceal colour of liquid inside). Please add a description of whether 
participants, those giving the interventions, those assessing outcomes, and those analysing 
the data were masked to group assignment; and how was the success of masking evaluated 
 
Done – investigators and statisticians were not blinded to individuals’ treatment 
assignment.  Details are given in the Randomisation and masking section. 
 
d. Delete “The first public presentation of the results was during the 22nd European Stroke 
Conference on 31 May 2013.” 
 
Done. 
 
15.     Procedures. 
 
1.      Give details of interventions (type, method of delivery, duration). For drugs please 
provide the recommended international non-proprietary name, dose, route, and schedule of 
administration. For all commercial tests or devices, state the name of the manufacturer and 
place of manufacture. 
 
Done (pg 7, lines 175-179). 
 
2.      State the follow-up intervals and assessments done at each visit. 
 
Done – we’ve combined the previous “intervention” and “follow-up” sections into a single 
procedure section as recommended. 
 
16.     Outcomes. If applicable, please ensure the following items are included: 
 
a. State the primary outcome (for multicentre trials, whether this was centrally assessed).  
 
Done (pg 8, lines 196-197). 
 
b. List secondary outcomes (a complete list). 
 
We stipulated that modified Rankin Scale score was the lead secondary outcome, and 
added adverse events as the other secondary outcomes. 
 
c. Describe assessment of safety and adverse events. 
 
Done (pg 8, lines 207-208). 
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d.      Please ensure any post-hoc or exploratory endpoints are clearly described as such. (this is 
not the case yet) 
 
Done – we clarified that the subgroup analyses of the primary endpoint were exploratory 
in the statistical analysis section in the methods (page 9, line 257) 
 
e.      If your paper is a primary trial report, all prespecified primary and secondary outcomes 
specified in the protocol should be listed in the Methods and reported in the Results. If any 
outcomes prespecified in the protocol are not reported in the present paper, this should be stated 
in the Outcomes section with a full justification. 
            
 N/A 
 
17.     Statistical analysis. 
 
a. Correct name: “Statistical Coordinating Center International Center for Health Outcomes 
and Innovation Research”? 
 
Done – we removed the full name of the data coordinating center here as it is already 
referenced in the randomisation and masking section. 
 
b. Indicate how the target sample size was calculated and what power the study had to detect 
a significant difference between treatment groups. 
 
Done – we moved the section on power, previously in the study design section, to the top of 
the statistical analysis section (pgs 8-9, lines 214- 231). 
 
c. Definitions of population assessed for primary and secondary outcomes, and for safety (eg, 
ITT, per protocol, etc). 
 
We added that all analyses were by intention-to-treat (pg 10, line 261). 
 
d. Give details of main comparative analyses, followed by assessment of safety and adverse 
events, and then description of any post-hoc or exploratory endpoints (this is not the case 
yet) 
 
Done – comparison of the primary endpoint is described first, followed by risk of death or 
clinical impairment at 5 years, adverse events, and exploratory subgroup analyses of the 
primary endpoint. 
 
e.      State whether a data monitoring committee oversaw the study. 
 
Added to the first paragraph of the section (pg 8, lines 218-219). 
 
18.     RESULTS (the first two paragraphs need some reordering to help with the flow) 
a.      Paragraphs in this section should follow THE order: a description of number of 
participants recruited and included in analysis; baseline characteristics; findings for the primary 
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outcome, secondary outcomes, adverse events, and finally any post-hoc or sensitivity analyses. 
No subheadings should be used in the Results or the Discussion sections. 
 
Results follow this order and no subheadings are used.  We have also reduced the word count 
of this section by removing text redundant to data available in the tables. 
 
b.      The first paragraph should state the exact dates (eg, Jan 1, 2013, to Dec 31, 2014) between 
which participants were recruited, and include with a trial profile the number of participants 
assessed for eligibility, the number ineligible, the number eligible, the number randomised to 
each group, the number of exclusions or dropouts at each stage, and the number assessed for the 
primary endpoint. Please provide also percentages along actual numbers 
 
These dates are included.  We’ve also added percentages for screening numbers (i.e. % 
ineligible, pg 10, lines 277-278).  We also moved the number randomised to each group from 
the second paragraph to the first (pg 10, line 282) and added a statement that all randomised 
were included in the analysis of the primary endpoint (pg 10, line 286). 
 
c.      Please add results of safety analysis (eg, data regarding the number of treatment-related 
deaths). Adverse events should be reported in a table, stratified by grade if appropriate (eg, 1-2, 
3, 4 and 5). For graded, adverse events, those of grade 1 or 2 occurring in ≥10% of patients 
should be reported; all grade 3, 4, and 5 events should be reported. 
 
We have added the number of treatment-related deaths to the text. In the ARUBA trial, adverse 
events were not graded and therefore we are unable to provide a breakdown of events by grade.  
The protocol provides definitions of pre-specified adverse events which are reported in table 3.  
 
19.     Discussion (needs to be thoroughly revised for flow and cohesion, it jumps between arguments, 
some statements are vague, and ): 
a.      Not sure why this has been added here – can we move to the appendix? “To address 
criticisms directed at the classical ‘as randomized’ result, the prior publication1 and post-
publication presentations had included ‘as treated’ analysis and one comparing outcomes based 
on analysis of the hazard ratios for outcome events for those ‘as treated” and among them those 
whose outcome had a value of mRS ≥2. For data including the follow-up, for those ‘as treated’ 
the disparity for outcome events had HR 0.22 (95% CI 0.12,0.41), for those mRS≥2  HR 0.13 
(95% CI 0.05,0.30). “ 
 
Deleted 
 
b.      The third paragraph seems random here and would be better suited (at least parts of it ) in 
the Research In Context panel 
c.      We try to avoid direct quotes – possible to rephrase? 
d.      Please make very explicit what the study limitations are 
e.      Discuss limitations and strengths of your study, noting sources of bias or imprecision. 
f.      Discuss any controversies raised by this study. 
g.      Consider possible underlying mechanisms for your findings. 
h.      Suggest future research directions. 
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i.      End with a general interpretation of data in light of all evidence available, noting the 
clinical significance and effects on patient care and policy, expanding on the summary provided 
in your Research in context panel. 
 
We have revised the discussion to meet the points above. 
 
 
20.     Figure 1: Please use the CONSORT trial profile as a template 
 
We have revised Figure 1 to match the CONSORT template 
 
21.     Figure 2: provide abbreviation legend; add figure title 
  
Done 
 
22.     Figure 3: provide abbreviation legend 
 
 Done 
 
23.     Figure 4: in text and appendix: please delete from the main text 
 
 Done 
 
24.     Tables: should be supplied in a separate Word file (not Excel or fdf/pdf). Each row of data 
should be in a separate line. Please ensure that rows and columns are not tabbed; data should be entered 
in cell form. 
 
 Done. 
 
25.     Table 1: please remove “ total cohort” column as this is not needed; add row for “male”; make 
clear for which group these baseline date were not available * Baseline score unavailable for 2 patients 
enrolled without angiography”; provide abbreviation legend 
 
Done. 
 
26.     Table 2: provide abbreviation legend 
 
Done. 
 
27.     APPENDIX: As mentioned previously, please submit as a separate pdf file with page numbers 
and refer to the appendix in the text as “appendix, p XX”. 
 
Done 
 
28.     Author signature form:  We are missing the signatures of all authors 
 
We will include these with our resubmission. 
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29.     ICMJE forms: we are still missing the ICMJE forms for all authors 
 
We will include these with our resubmission. 
 
30.     Any update on Dr Stapf? 
 
Dr Stapf has not responded to any emails inviting him to be a co-author, or acknowledged, in 
this manuscript, so we have removed him from our acknowledgement section per TLN 
requirement that we have his consent to be acknowledged in writing. 
 
31.     Author contribution: please streamline eg, XX, XZ, and RC wrote xxx. 
  
Done. 
 
32.     Declarations on interest: please streamline, eg, XX, XZ, and RC had nothing to declare. NOTE: 
The statement MUST match the information on the supplied ICMJE forms. If not, please revise. 
  
Done 
 
33.     Please add affiliation for NINDS Officers, DSMB Members, Adjudication Committee, an the 
Safety Officer 
 
Done 
 
34.     Research In Context panel (needs to be rewritten to comply with the required style): 
a.      Evidence before this study: This section should include a description of all the evidence 
that the authors considered before undertaking this study. Authors should state: the sources 
(databases, journal or book reference lists, etc) searched; the criteria used to include or exclude 
studies (including the exact start and end dates of the search), which should not be limited to 
English language publications; the search terms used; the quality (risk of bias) of that evidence; 
and the pooled estimate derived from meta-analysis of the evidence, if appropriate. A summary 
of what the existing evidence shows should also be included. 
b.      Added value of this study: Please describe here how your findings add value to the 
existing evidence (including an updated meta-analysis, if appropriate). IMPORTANT: Please 
do NOT reiterate the results or describe your study approach (this is already covered by the 
abstract), but rather explain how the findings extend knowledge in the field and/or address 
unanswered questions or controversies. 
c.      Implications of all the available evidence: Authors should state the implications for 
practice or policy and future research of their study combined with existing evidence. 
 
We have revised the research in context section accordingly. 
 
Reviewers' comments: 
 
Reviewer #1: The authors have improved the manuscript. 
 
Our thanks for this comment. 
 
11 
 
"As noted in the revision, we added text (Lines 238-244) to explain the paucity of information." Please 
clarify correct line numbers containing the added text. It is not clear how the authors addressed the 
reviewer's comment. 
 
We apologize for the confusion.  The correct line number in the updated clean version of the 
manuscript is pg 10, line 279 which reads “outcomes were not collected for eligible patients 
who were not randomized.” 
 
In lines 256-258, specific mention of which subgroups of venous drainage and AVM maximum nidus 
size are being described would assist in informing the reader. 
 
We thank the reviewer for pointing this out.  We’ve added the subgroups in parentheses after 
each (pg 12, lines 319-320). 
 
In lines 281-290, it would be helpful to the reader to include percentages of 116 patient corresponding 
to the number of patients treated with neurosurgery, radiosurgery or embolization. 
 
We agree that it will be helpful for readers to know the distribution of interventions received.  
We have added the percentage of patients who received each modality (either alone of as part 
of a combination) to the last paragraph of the results section. 
 
Reviewer #2: Overall Comments 
 
I get my head down in the minutiae of a review making point by point comments and I sometimes 
forget the big picture.  This study was a major achievement undertaking a novel adaptive design. 
 
The authors have addressed my comments and my comments below are advisory only 
 
Advisory comments for consideration 
 
[Original Comment]. Things have moved on from the original analysis.  There will soon be a 
CONSORT Guideline for adaptive designs. 
 
a.      No mention is made of bias adjustment to allow for the interim analysis within the study either in 
this paper or the original paper. 
[Additional Comment].  Due to the stopping rules (and no futility assessment) the bias would be 
minimal.  I personally would add a sentence, consistent with you feedback, that due to the descriptive 
nature of the study there is no bias adjustment due to the adaptive design 
 
Thank you for the feedback – we have added the sentence to the end of the statistical analysis 
section in the methods (pg 10, lines 262-263). 
 
[Original Comment]. I not mandate this but suggest this only.  There is a lot of literature on the bias in 
studies which stop early (different to the bias mentioned above).  This is a reporting bias not an actual 
bias.  Your first interim analysis is not biased (the second and planned for third are) but there is a 
reporting bias as studies such as yours do not report the first interim analysis.  Thus only those which 
do stop early at the first interim get reported.  It is difficult for you 6 years on and it is not a CONSORT 
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requirement now (but it will be) but if in supplemental you give the analysis of the first interim 
analysis. 
[Additional Comment].  Thank you for feeding back on the results.  This is only a nice to have and it 
would be good to include in the supplemental if you are able.  As I said papers erroneous report that 
trials which stop early are biased - see https://urldefense.proofpoint.com/v2/url?u=https-
3A__doi.org_10.1177_0962280211432211&d=DwIGaQ&c=G2MiLlal7SXE3PeSnG8W6_JBU6FcdVj
SsBSbw6gcR0U&r=ocMgXGLjsdweFgVd_pgarCirw2NyJtwGioPgIKR1sDI&m=fMcSM2HIOKCDsf
JBcqLMagPD3fQukDGoWVg8aKBZqts&s=DTVZlDCFSEKDh-SsZmNCTW6dQej0UVW2J2-
APt0aWVk&e=  - when they are not.  It is just that adaptive designs due not report all the steps 
 
We have included the graph in the supplement (supplemental figure 2), and reference it in the 
statistical analysis section of the manuscript (pg 10, lines 263-264). 
 
[Original Comment]. For the statistical analysis 
b.      Can you please clarify how the clustering effect of surgeon was accounted for in the IT arm.  
Although the study is individually randomised they are then clustered with surgeons the skill of which 
will impact on their outcomes. Either surgeon or centre for the IT arm should be entered as a cluster 
effect and the errors adjusted accordingly 
c.      Can the ICC for the clustering please be quoted 
[Additional Comment].  Thank you for the clarification.  Given you feedback I would have used centre 
myself as it was team medicine.  Personally I would in text only quote the result you provided as it had 
no effect.  A minimal ICC would confirm this. 
 
Thank you for your additional comments - we have added the site adjusted results to the results 
section (pg 11, lines 301-302) and describe the analytical approach in the methods (pg 9, lines 
241-242). 
 
[Original Comment]. The paper itself should be standalone.  It makes for a frustrating read to see "have 
been described previously" especially when this is in a paper behind a paywall.  There should be these 
details in the paper.  Can be complemented with supplemental material [Additional Comment].  Thank 
you for your feedback.  I did not realise paywall was a UK term! 
 
              Evidence of our ignorance in the Colonies 
 
[Original Comment]. Can all web references have date last accessed [Additional Comment].  This is 
just the data you last accessed.  Personally the last thing I do prior to a submission is click through all 
web links and put that date down 
 
We have added the last accessed date to the web address provided under the data sharing 
statement. 
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management alone for unruptured brain arteriovenous malformations (ARUBA): final 
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Supplemental Table 1. Randomizations by Region, Country and Clinical Centre 
Region Country Clinical Centre No. Enrolled 
ARUBA-Europe 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
France 
  
  
  
  
  
Hôpital Lariboisière 35 
Hôpital Roger Salengro, CHRU 24 
CHU Besançon 11 
Groupe Hospitalier Pellegrin 7 
Hôpital Saint Anne 1 
CHU Brest 1 
Germany 
  
  
  
  
  
  
Charite Campus Benjamin Franklin 12 
Neurologische Universitätsklinik, Dresden 12 
Klinikum der J.W.v.Goethe Universität 10 
BG-Kliniken Bergmannstrost 4 
Klinikum der Universität Mänchen-Grosshadern 2 
Universitätsklinikum Freiburg 2 
Universitätsklinikum Essen 1 
Netherlands 
  
Utrecht Medical Center 9 
UMC Groningen 3 
Switzerland Inselspital, University of Bern 1 
United Kingdom 
  
  
  
  
Western General Hospital 12 
Royal Hallamshire Hospital 8 
Walton Centre for Neurology & Neurosurgery 2 
Newcastle General Hospital 2 
Salford Royal NHS 1 
ARUBA-West 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Brazil Hospital de Clinicas de Porto Alegre 14 
Canada 
  
  
CHUM Notre Dame Hospital 6 
Hamilton Health Sciences 1 
University of Alberta 1 
South Korea Seoul National University Hospital 2 
United States 
  
  
  
  
  
  
  
  
  
  
  
  
Long Island Jewish Medical Center 7 
Columbia University Medical Center 6 
Winthrop University Hospital 4 
University of California at San Francisco 4 
Kaiser Permanente (LA) 4 
University of Alabama at Birmingham 3 
University of Miami 3 
Rush University 3 
Hartford Hospital 3 
Loyola University Stritch School of Medicine 2 
John P. Murtha Neuroscience and Pain Institute 1 
University of South Alabama 1 
Redwood City Kaiser 1 
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Supplemental Figure 1. Histogram of Patients Last Dates of Contact by Quarter 
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Supplemental Figure 2. Group Sequential Boundaries and Observed Z-Statistics at each Analysis 
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Supplemental Figure 3. Cumulative Enrolment Overtime 
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Supplemental Figure 4. Modified Rankin scale scores at 5 years post-randomisation*  
 
*Modified Rankin scale scores of 4 and 5 were not observed at 5 years post-randomisation and therefore 
are not represented in this plot 
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Supplemental Table 2. Treatment strategy and primary outcome in the 106 patients that initiated 
interventional therapy with an unruptured brain AVM * 
 
* Eight patients randomised to MM received IT prior to any stroke events. Among the 116 patients randomised to 
IT, n=15 never received therapy and n=3 suffered a stroke prior to the initiation of IT 
**  Documented AVM obliteration required cerebral angiography by study protocol. For n=16 (15%) patients, the 
AVM obliteration status was unknown due to missing imaging information, n=43 (41%) had a documented AVM 
remnant on last follow-up imaging. 
 
Type of interventional treatment 
Symptomatic stroke 
or death 
With documented 
AVM obliteration** 
n (row %) n (row %) 
Single modality of treatment   
Endovascular (n=28) 14 (50·0) 14 (50·0) 
Surgery (n=7) 2 (28·6) 7 (100·0) 
Stereotactic radiosurgery (n=33) 8 (24·2) 6 (18·2) 
Multiple modalities of treatment   
Endovascular and surgery (n=14) 6 (42·9) 14 (100·0) 
Endovascular and stereotactic radiosurgery (n=23) 12 (52·2) 6 (26·1) 
Endovascular, surgery and stereotactic radiosurgery (n=1) 1 (100·0) 0 (0) 
CONSORT 2010 checklist  Page 1 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2-3 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 3 
2b Specific objectives or hypotheses 3 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 4 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons 8-9 
Participants 4a Eligibility criteria for participants 6 
4b Settings and locations where the data were collected 6 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
7 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
8 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 8-9 
7b When applicable, explanation of any interim analyses and stopping guidelines 9 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 6 
8b Type of randomisation; details of any restriction (such as blocking and block size) 6 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
6 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
6 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 6-7 
Necessary Additional Data
CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 
11b If relevant, description of the similarity of interventions N/A 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 9-10 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 10 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
10 
13b For each group, losses and exclusions after randomisation, together with reasons 10, Figure 1 
Recruitment 14a Dates defining the periods of recruitment and follow-up 10-11 
14b Why the trial ended or was stopped 1, 7 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table 1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
11-12 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
11, 12 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended - 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
12 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 11 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 13 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 13-14 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 13-15 
Other information  
Registration 23 Registration number and name of trial registry 3, 10 
Protocol 24 Where the full trial protocol can be accessed, if available 6 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 4,10 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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Revision 
Number 
Date of 
Revision 
Text location 
(page) 
Description of Revision 
2 03/30/06 Created 
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PRÉCIS 
Study Title 
A Randomized Multicenter Clinical Trial of Unruptured Brain AVMs (ARUBA) 
Objectives 
Primary: To determine whether medical management improves long-term outcomes of 
patients with unruptured BAVMs compared to interventional therapy (with endovascular 
procedures, neurosurgery, or radiotherapy, alone or in combination).  The trial has been 
designed to test whether medical management or interventional therapy will reduce the 
risk of death or stroke (due to hemorrhage or infarction) by at least 46% (an absolute 
magnitude of about 9.5% over 5 years).  It will require 400 patients to detect the 
hypothesized 46% reduction in event rate, analyzed using the intention-to-treat principal.  
This sample size will support a test of non-inferiority if medical management is not 
superior to interventional therapy.  
 
Secondary: To compare the impact of medical management to interventional therapy with 
respect to adverse events, quality of life and cost. 
 
Design and Outcomes  
The study design is a prospective, multi-center, parallel design, randomized, controlled 
trial.  Treatment assignment will not be masked; however, clinical coordinating center 
personnel and outcome events committees will be blinded to treatment assignment. 
Interim study results will be kept confidential by the DCC. The primary outcome is the 
composite event of death from any cause or stroke (hemorrhage or infarction revealed by 
imaging).  Functional outcome status will be measured by the Rankin Scale, a widely-
used outcome measure for stroke.
  
The secondary measures of outcome include adverse 
events, quality of life and cost. 
 
Interventions and Duration 
The interventional therapy arm of the trial involves prophylactic efforts with a plan for 
eradication of the observed BAVM utilizing endovascular procedures, microsurgery, or 
radiosurgery, alone or in combination with pharmacological therapy for existing risk 
factors and coexisting medical conditions.  The medical management arm will involve 
pharmacological therapy as deemed appropriate for medical symptoms as determined by 
the treating investigator.  Should patients in the medical management arm develop 
hemorrhage or infarction related to their BAVM, they would then be candidates for any 
single or combination of interventional therapy using endovascular procedures, 
microsurgery and radiosurgery.  Patients will be followed for a minimum of 5 years and a 
maximum of 10 years (mean 7.5 years) from randomization. 
 
Sample Size and Population 
All patients with an unruptured BAVM diagnosed at a participating clinical center 
without prior interventional therapy to attempt eradication and with no contraindications 
to interventional therapy, will be candidates for this trial.  A total of 400 patients will be 
enrolled in the ARUBA trial.  Patients may be referred for enrollment by their clinical 
neurologist, neurosurgeon, or interventional radiologist.     
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1.  SPECIFIC AIMS 
 
Current interventional therapy for brain arteriovenous malformations (BAVMs) is varied and 
includes endovascular procedures, neurosurgery, and radiotherapy alone and in combination, 
largely dependent on the decisions of the local clinical team. All of these interventional therapies 
are administered on the assumption that they will decrease the risk of initial or subsequent  
hemorrhage and lead to better long-term outcomes. Despite these laudable goals, the literature 
contains almost no reference to the outcome for medical management before or after  
hemorrhage, or for intervention outcome for unruptured BAVMs. Published reports of 
interventional therapy outcome typically have blended the bled and non-bled cohorts together as 
if their risk for lesion-related morbidity and the response to intervention is expected to be the 
same.  
 
Although no clinical trial data exist on the effect of interventional therapy even after BAVM  
hemorrhage, the most contentious issue at present is whether interventional therapy should be  
considered for those increasingly being discovered incidentally by brain imaging, with lesions 
that have not bled.  Recent data from our institution on BAVM patients who presented without 
bleeding raises the possibility that interventional therapy may be detrimental compared with 
medical management. Among possible reasons may be that interventional therapy destabilizes 
the lesion  
toward hemorrhage.
   
Furthermore, there is disappointing evidence that contradicts prior  
assumptions that hemorrhage associated with BAVM treatment lie in functionally-inert tissues, 
and, therefore, are less disabling.  It appears that the disabilities associated with such events are 
equivalent to and possibly worse clinically than that seen with spontaneous BAVM hemorrhages, 
which still have a relatively low likelihood of occurring in the foreseeable future. 
 
1.1  Primary Aims 
 
The primary hypothesis of this randomized clinical trial is that medical management improves 
long-term outcomes of patients with unruptured BAVMs compared to interventional therapy 
(with endovascular procedures, neurosurgery, or radiotherapy, alone or in combination).  The 
primary outcome is the composite event of death from any cause or stroke (hemorrhage or 
infarction confirmed by imaging).  Functional outcome status will be measured by the Rankin 
Scale, a widely-used outcome measure for stroke.  There are three specific aims associated with 
the primary hypothesis: 
 
Specific Aim 1.1a To determine whether medical management is superior to interventional 
therapy for preventing the composite outcome of death from any cause or stroke (hemorrhage or  
infarction confirmed by imaging) in the treatment of unruptured BAVMs. 
 
Specific Aim 1.1b If medical management is not superior to interventional  therapy, to determine 
whether medical management is not inferior to interventional therapy for preventing the 
composite outcome of death from any cause or stroke (hemorrhage or infarction confirmed by 
imaging) in the treatment of unruptured BAVMs. 
 
Specific Aim 1.2 To determine whether treatment of unruptured BAVMs by medical 
management decreases the risk of death or clinical impairment (Rankin Score  2) at 5 years 
post-randomization compared to interventional therapy.  
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1.2  Secondary Aims 
 
A number of Secondary Aims are planned in support of the primary hypothesis to answer the  
following questions:  
1) Is there a difference in quality of life between interventional therapy and medical  
management? 
 
2) Is there a difference in mortality between interventional therapy and medical 
management? 
 
3) Is there a difference in quality-adjusted survival between medical management and  
interventional therapy? 
 
4) Is there a difference in the incidence of adverse events, such as cerebral hemorrhage and 
infarction, between interventional therapy and medical management? 
 
5) What are the costs associated with each treatment (medical management and 
interventional therapy); and if medical treatment is not superior, but also not inferior to 
interventional therapy what are the cost-effectiveness implication of choosing one 
therapy over another?  
 
6) Does any benefit of medical management or interventional therapy depend on BAVM 
size? 
 
7) Does any benefit of medical management or interventional therapy depend on BAVM 
 location? 
 
8) Does any benefit of medical management or interventional therapy depend on venous 
drainage pattern? 
 
9) Does any benefit of medical management or interventional therapy depend on age at  
randomization? 
 
10)  Does any benefit of medical management or interventional therapy depend upon the 
length of time the AVM was known? 
 
11) Is there a difference in the risk of the composite event of death from any cause or stroke  
between prophylactic treatment modalities (i.e. endovascular procedures, neurosurgery, 
and radiotherapy)? 
 
12) Among patients treated by interventional therapy, is there a relationship between the  
completeness of eradication of the BAVM and the composite event of death from any 
cause or stroke? 
13) Among patients treated by interventional therapy, is there a relationship between the 
Spetzler-Martin grading scale and the composite event of death from any cause or 
stroke? 
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The primary null hypothesis is that there is no difference between medical management and 
interventional therapy in the time to stroke or death from any cause. The null hypothesis will be 
tested against the alternative hypothesis that there is a difference between treatments with a two-
sided 0.05 level log-rank test. With a plan to enroll 400 patients, the test will have 80% power to 
detect a risk reduction of 46% (hazard ratio of 0.54) This hazard ratio corresponds to an absolute 
decrease in 5-year event rates of 9.5% for medical management, from an assumed 5-year event 
rate of 22% for interventional therapy. 
 
If the null hypothesis is not rejected, a test of non-inferiority of medical management compared 
to interventional therapy will be performed. The null hypothesis for the test of non-inferiority is 
that the hazard ratio for the composite event of death from any cause or stroke for interventional 
therapy compared to medical management is less than 0.87 (an 13% reduction in risk for 
interventional therapy). Thus, the null hypothesis that medical management is inferior will be 
rejected, and non-inferiority claimed, if the reduced risk of interventional therapy compared to 
medical management is less than the non-inferiority margin of 13% (hazard ratio  0.87) based 
on a one-tailed 0.05 level test. An 13% reduction in risk corresponds to an absolute difference in 
5-year event rates of 2.5%. 
 
 
The secondary hypothesis to be tested is that early intervention decreases the risk of death or 
clinical impairment at 5 years post-randomization. Death in this young, and otherwise healthy, 
population is a rare event.  The primary hypothesis has been constructed to be inclusive of all 
strokes that occur during the course of the trial (thereby averting judgment about severity), while 
the secondary hypothesis concentrates only on those events associated with impairment. 
 
2.  BACKGROUND 
 
2.1   Rationale 
 
With the emergence of new non-invasive imaging techniques, there has been a substantial 
increase in the incidental detection of non-ruptured BAVMs.  These BAVMs are being treated in 
a variety of ways, including medical management, endovascular procedures, neurosurgery, or 
radiotherapy.  The widespread diffusion of these various treatment approaches is partially driven 
by the existence of variations in the perception about the risks of rupture and how devastating 
such events would be.  The increased treatment rate of non-ruptured BAVMs consumes a 
considerable amount of health resources.  With an annual incidence in the US of nearly 3000 
cases, and treatment costs in the range of $50,000 to $100,000 per patient, widespread utilization 
of early intervention would amount to an expenditure of between $150 million and $300 million 
per year.  Thus, the choice between early interventional therapy and medical management 
involves making a critical trade-off between avoiding the upfront risks and cost of an early 
intervention and possibly mitigating the long-term risks and costs associated with medical 
management.  These trade-offs have not been adequately addressed in the clinical literature.  
 
 
2.2   Supporting Data 
 
There have not been any randomized trials comparing any of the forms of interventional therapy 
for BAVMs among themselves or with medical management.  This is the case despite the 
enormous resources committed to the treatment of patients with BAVMs.  Some data indicate 
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that interventional therapy is 
superior to medical management 
for BAVMs, but many of these 
studies do not distinguish between 
AVMs that have previously bled 
and those that have not.  Other data 
suggests that there is a spectrum of 
risk for medical management of 
BAVMs and those that are 
unruptured have a much lower risk 
for future hemorrhage than those 
that have previously bled. The 
currently available published data 
on both medical management and 
treatment-related morbidity and 
mortality do not separate outcomes 
by pre-treatment status (bled or 
unbled), and show little 
consistency for mode and number of treatments or for clinical severity. 
 
An important source of data that we have relied upon in planning this study is the Columbia 
AVM Databank project, which has prospectively enrolled 622 consecutive AVM patients 
clinically encountered at Columbia University Medical Center since 1989. The mean age of these 
patients is 34 years with a standard deviation of 15 years. Three hundred and twenty-two of the 
patients, or 53%, are female. Of the 622 study subjects, 282 (45%) presented with hemorrhage 
and 340 (55%) had unruptured AVMs. 
 
A recent analysis of these data favors early treatment intervention in patients who have bled, 
showing little additional clinical injury for the extirpation of the lesion, particularly in those 
harboring additional morphological risk factors. Of concern, however, is the low risk of 
spontaneous rupture in as yet unbled AVMs and the mild clinical syndrome from such rupture.  
As shown in the figure, interventional treatment was associated with an increased risk of 
hemorrhage (p < 0.0001; hazard ratio (HR) = 5.53, 95% CI 2.91 to 10.49). In this figure the 
value on the abscissa for the subgroup that underwent interventional treatment was defined as 
time-since- treatment-was-initiated in order to mimic the result that would be obtained in a 
clinical trial.  The actual analysis utilized time-dependent covariates that classify treatment status 
at each time point of follow-up on the basis of its relationship to the time at which treatment 
began. Interventional treatment was also associated with an increased risk of clinical impairment 
as assessed by a Rankin score > 2 (HR = 11.04, 95% CI 7.21 to 16.90, p < 0.0001). These 
observational data suggest that for AVM patients who have not yet bled, treatment may increase 
the risk of both hemorrhage and an acute, disabling persisting clinical syndrome.  
 
Comparing our own data to those taken from the literature (not stratified by AVM rupture status) 
offers two extreme cases for comparing the benefits of early interventional treatment versus 
watchful waiting.  Comparing the worst 5-year risk of stroke or death with medical management 
of 20%, and the best 5-year risk with early intervention of 5%, supports the strategy of early 
intervention, while the best 5-year natural history outcome of 5% and the worst 5-year early 
intervention outcome of 19% support medical management.   Thus, there is considerable 
uncertainty in the existing clinical literature, which does not provide conclusive evidence about 
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optimal treatment approaches for this vexing clinical problem. The Columbia database was 
collected prospectively, but like other clinical series, is not a randomized trial of treatment versus 
medical management, or of various modes of treatment. The findings in a randomized clinical 
trial could well be different from that in this one-center clinical cohort.  
 
3.  STUDY DESIGN 
 
The overall purpose of this multi-center RCT is to evaluate the effectiveness and safety (in terms 
of survival, clinical impairment, adverse events and quality of life), and costs of medical 
management compared to interventional therapy of patients with unruptured BAVMs.  While the 
nature of the treatments precludes blinding of patients and their treating clinicians, outcome 
evaluations should be done by an experienced person who is not directly involved in providing 
the interventional procedure.  Therefore a neurologist at each site who is certified to perform the 
Rankin assessment will do so for all outcome assessments at that center.  A parallel groups 
design with random assignment of patients to interventional therapy or medical management 
with equal probability will be performed. A total of 400 patients will be randomized.  Patients 
will be followed for a minimum of 5 years and a maximum of 9.5 years (mean 7.5 years) from 
randomization. 
 
4.  SELECTION AND ENROLLMENT OF SUBJECTS 
 
The patient population for this trial consists of patients with unruptured BAVMs. 
All patients who meet eligibility criteria may be included in the study regardless of gender, race, 
or ethnicity.  
 
4.1  Inclusion Criteria 
 
  1. Patient must have unruptured BAVM diagnosed by MRI/MRA, CTA and/or 
angiogram 
  2. Patient must be 18 years of age or older 
  3. Patient must have signed Informed Consent, Release of Medical Information, and 
Health Insurance Portability and Accountability Act (HIPAA/U.S. only) Forms 
 
4.2   Exclusion Criteria 
 
  1. Patient has BAVM presenting with evidence of recent or prior hemorrhage 
  2. Patient has received prior BAVM therapy (endovascular, surgical, radiotherapy) 
  3. Patient has BAVM deemed untreatable by local team, or has concomitant vascular or 
brain disease that interferes with/or contraindicates any interventional therapy type  
   (stenosis/occlusion of neck artery, prior brain surgery/radiation for other reasons) 
  4. Patient has baseline Rankin ≥2 
  5. Patient has concomitant disease reducing life expectancy to less than 10 years  
  6. Patient has thrombocytopenia (< 100,000/µL), 
  7. Patient has uncorrectable coagulopathy (INR>1.5) 
  8. Patient is pregnant or lactating 
  9. Patient has known allergy against iodine contrast agents 
  10. Patient has multiple-foci BAVMs  
11. Patient has any form of arteriovenous or spinal fistulas 
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Previous diagnosis of any of the following: 
  12. Patient has a diagnosed Vein of Galen type malformation  
  13. Patient has a diagnosed cavernous malformation 
  14. Patient has a diagnosed dural arteriovenous
 
fistula  
15. Patient has a diagnosed venous malformation 
 16. Patient has a diagnosed neurocutaneous syndrome such as cerebro-retinal  
  angiomatosis (von Hippel-Lindau), encephalo-trigeminal syndrome (Sturge-Weber), 
or Wyburn-Mason syndrome  
 17.  Patient has diagnosed BAVMs in context of moya-moya-type changes
 
 
18. Patient has diagnosed hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber)  
 
Pregnancy Risks: 
This study involves treatments or procedures which could be harmful to a fetus or breastfed 
baby. Women of childbearing age should be aware of the potential risks associated with the 
diagnostic and interventional treatments that are standard of care for the diagnosis and treatment 
of AVMs. This information must be discussed by the investigator at the time of enrollment. 
Women who are pregnant or nursing at the time of enrollment may not participate. Women of 
childbearing age who are randomized to interventional therapy are encouraged to use an 
effective form of birth control during the course of treatment. For women of childbearing age, a 
serum or urine HCG should be recorded as part of the source documentation. 
 
4.3 Study Recruitment and Enrollment Procedures 
 
There are 104 clinical sites in the U.S., Europe, South America, Asia, and Australia proposed as 
participating clinical centers in the ARUBA trial.  These centers have extensive clinical and 
research experience with the management of BAVMs.  Combined, these centers have an annual 
volume between 650 and 1000 patients, who would meet the eligibility criteria for the trial. 
 
Mailings will be sent out, with IRB approved flyers prepared for posting announcement of the 
study. Our recruitment efforts will target the front-line physicians, local neurosurgeons, and  
neuro-radiologists to make them aware of the trial, so that when they evaluate a patient with an 
unruptured BAVM, they have the option of referring them to the clinical investigators for 
consideration of enrollment in the trial.  We will conduct ARUBA seminars for the staff of the 
local neurology practices to inform them of the trial requirements. A set of Power Point ARUBA 
slides will be prepared by the DCC and made available to the site investigators so that they can 
meet and present the trial to physicians who practice in local communities. A pocket size 
laminated eligibility criteria list will be sent to all investigators to be distributed to all referring 
physicians.  The DCC will develop a template ARUBA informational packet directed at referring 
physicians, which can be adapted by the sites.  All such publicity materials targeted to patients 
will require IRB approval.  Through this method they will be able to identify potential 
candidates, and make appropriate referrals to the ARUBA team.   
 
All patients who are diagnosed with an unruptured BAVM are potential candidates for this trial.  
There are three main pathways that patients with unruptured BAVMs may be referred for 
evaluation for the ARUBA trial.  They may be referred by their clinical neurologist, 
neurosurgeon, or interventional radiologist.  If the examination and work-up confirms that a 
patient has met the eligibility criteria, the trial will be presented.  When a patient expresses 
interest, they can be referred to an ARUBA investigator who will evaluate the medical records 
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and initiate the consent process.  All referring physicians will be encouraged to present this trial 
to all their patients, including women and minority patients. 
 
An ARUBA web site has been developed to allow physicians to have access to up-to-date trial 
information.  Once the web site is approved by the IRB it will also be available to patients and 
their families.  The ARUBA web site will be linked to other medical and clinical trial sites, 
including the NIH, CDC, WebMD, and Center Watch sites.  Key words such as brain aneurysm 
and cerebral aneurysm will be included.  Lay terms will be used to make the information 
accessible to patients, their families and friends.  
4.3.1 Minority Recruitment 
Recruitment will not discriminate on the basis of age, gender, race, or socioeconomic status. The 
proposed clinical trials pose no scientific justification to exclude any gender or ethnic group.  
Given the international nature of this trial, a wide spectrum of ethnic backgrounds is expected.  A 
special effort will be made to ensure that no opportunity for recruitment of eligible women is 
overlooked and development of the recruitment database in cooperation with the clinical sites 
will place a special emphasis on effective recruitment of women from the general population.  
4.3.2 Informed Consent Procedures  
Only adults (those ≥ 18 years) with unruptured BAVMs will be considered for enrollment in the 
ARUBA trial.  The site clinical investigator will discuss the trial with the patient‘s primary care 
physician who will ascertain from the prospective enrollee whether or not they wish to be 
approached by the investigator.  The clinical investigator or a designated member of the 
investigative team will provide a thorough explanation of the objectives, patient responsibilities, 
risks and benefits of the study, and will fully address all the concerns raised by the patient and/or 
family.  After all issues have been adequately resolved, and the investigator confirms that the 
patient has fully consented to participate, the patient will be asked to sign the informed consent.  
All patients will be given a signed copy of the informed consent for future reference. Patients 
who decline to be in the trial will receive the same quality of care. 
 
4.3.3 Screening Log 
Patients who are screened for enrollment in ARUBA who are not enrolled should be recorded on 
the patient screening log. (see Appendix V). This document is located in the Electronic Data 
Capture system and should be completed each time a patient is screened.  This will include all 
AVMs seen at a participating institution.   
 
4.3.4.  Procedure for Enrollment.  
The site clinical investigator or clinical coordinator will log into the Electronic Data Center and 
complete the following data collection forms:   
 
A.  Demographics (AR01) which includes verification of signed Informed Consent, Release of 
Medical Information, and Health Insurance Portability and Accountability Act (HIPAA) Clinical 
Research Authorization (U.S. only) forms 
B.  Eligibility Evaluation form (AR02) 
C.  Imaging data (AR03) or (AR03A) 
D.  Presentation history (AR05) 
E.  AVM morphology (AR06) 
F.  Rankin Scale (AR07) 
G.  NIH stroke scale (AR08) 
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H.  Medical history (AR09) 
I.  Medications (AR10) 
J.  Quality of Life:  SF-36 (AR11) 
K. Quality of Life:  EuroQol (AR12).   
 
 
4.3.5 Procedure for Image Interpretation and Shipment 
Relevant image(s) chosen by the local investigator should not be older than one year.   
If an image study is older than one year, a waiver must be obtained from the CCC PI who will 
decide whether that image may be used for enrollment and randomization.  The decision will be 
based upon further conversation with the site clinical investigator.  The CCC PI will document 
reasons for acceptance/rejection of images.  On the EDC, a waiver request box will appear when 
the date of the images exceeds one year from enrollment date.   
 
Each clinical site will have a credentialed radiologist/neuroradiologist who will read the images 
and attest to the presence of an unruptured BAVM. In the US, the radiologist will be board 
certified and all non-US radiologists will have the appropriate clinical privileges at the academic 
institution affiliated with ARUBA.  After completing the Image Data form (AR03), the 
investigator or clinical coordinator can proceed with the randomization process.  A de-identified 
CD of the images will subsequently be sent to the DCC along with a copy of the 
radiologist/neuroradiologist‘s written report.   
 
In the event that a credentialed radiologist/neuroradiologist is not available at the local site, the 
images can be uploaded to the Imaging data form (AR03A) to be reviewed by the coordinating 
center radiologist within 24 hours.   
 
4.3.6. Randomization 
The randomization process will assign the patient to either medical management or 
interventional therapy.  When the site investigator or clinical coordinator has completed the data 
collection forms required for enrollment, a randomization button will appear in the top left hand 
corner of the EDC.  After clicking the button, the randomization form (AR04) will be 
automatically completed with the patient‘s randomization assignment. The coordinator or 
investigator will then sign the form electronically. 
 
 
5.  STUDY INTERVENTIONS 
 
5.1 Medical Management (Refer to Manual of Procedures) 
 
Patients participating in the trial will receive the best medical management possible for the 
disorder being tested in the trial and for any general medical illnesses they are demonstrated to 
have.  One important consideration in the medical management of patients in this trial is stroke 
risk factor reduction.   
 
An additional consideration for the medical management group is that an angiogram is not 
required for randomization for those unruptured BAVMs for whom the diagnosis can be made by 
non-invasive imaging alone.  The purpose of this planned limitation of data source is for patient 
safety. If a patient has a successful diagnosis of BAVM without conventional angiogram and is 
randomized to the non-intervention arm, there is no management reason for the risks, however 
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small, of a diagnostic angiogram. That risk (and whatever subsequent angiogram or procedure 
risk exists) will remain in the interventional therapy arm of the study.  If an angiogram exists, 
performed for reasons decided by the local center or its referring clinical team, the data is to be 
included with the screening data forms.  
 
 
5.2    Interventional Therapy (Refer to Manual of Procedures) 
A patient randomized to interventional therapy is expected to begin interventional therapy within 
3 months following randomization. Interventional therapy consists of endovascular attempts at 
occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, 
microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and 
timings. 
 
5.2.1. Endovascular treatment 
Endovascular treatment may include AVM embolization, coiling of aneurysms in the vascular 
territories feeding the BAVM (BAVM-related aneurysm), or coiling of aneurysms unrelated to 
the BAVM.  The embolization materials used for those who undergo embolization as part of the 
treatment plan will be limited to those agents approved by the FDA or by the approval agency 
applicable to the country in which the patient receives treatment at the time of the procedure. 
This plan allows for the introduction of new agents during the course of the study. The name of 
the agent, the amount, and the frequency of use during each treatment will be recorded on the 
Interventional Therapy form (AR13). 
 
5.2.2. Microsurgery  
Microsurgery may include AVM resection, aneurysm clipping related to AVM, and aneurysm 
clipping unrelated to AVM. 
 
 
5.2.3 Radiotherapy  
Radiotherapy involves the targeting of the BAVM nidus and adjacent vessels intended to induce 
a reduction, and possible obliteration, of the BAVM. Based on local patterns of practice, 
variations exist in the exact equipment used, the methods of measurement used to assess the 
location and size of the BAVM chosen for therapy, the individual doses and numbers of 
treatments, and whether radiosurgery is used before or after embolization or microsurgery.  The 
modality, energy, number of isocenters, collimator size, Gamma angle, prescription and duration 
of treatment will be recorded on the Interventional Therapy form (AR13). 
 
 
5.3 Completeness of Interventional Therapy  
The goal of randomization into the interventional therapy arm is to achieve eradication of the 
BAVM. The eradication plan may include any or a combination of endovascular, surgical, or 
radiotherapy treatments. Following interventional therapy, using a diagnostically relevant image 
study, treatment outcome will be documented as: technically complete AVM removal based on 
catheter angiography, technically complete AVM removal based on other than catheter 
angiography, technically incomplete AVM removal, technically complete aneurysm treatment, or 
technically incomplete aneurysm treatment 
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5.4 Handling of Study Interventions 
       
Not Applicable. 
 
5.5 Concomitant Interventions 
 
5.5.1 Required Interventions                                                                                           
The local Investigator will make these decisions for the extent of the treatment. 
 
5.5.2. Prohibited Interventions 
Medications and materials not approved by the U.S. FDA for American subjects or those not 
approved by the local country equivalent of the U.S. FDA are prohibited while the subject is on 
study. 
 
5.6 Adherence Assessment 
 
Compliance of the subjects with the study will be assessed by adherence to the follow-up visit 
schedule.  If a patient is unable to return for follow-up before the closure of a study visit window, 
the coordinator will make every attempt to contact the patient and complete the Patient  
Encounter form (AR14).  If unable to contact the patient, a Missed Visit form (AR18) will then 
be submitted. 
 
6.  ENDPOINTS    
 
6.1 Primary Endpoint 
The primary outcome is the composite event of death or stroke.  Stroke is defined as a 
symptomatic event (presenting with a new focal neurological deficit, seizure, or new onset 
headache) that is associated with brain imaging indicating hemorrhage (defined as fresh 
intracranial blood on head CT and/or MRI or in the cerebrospinal fluid, the primary bleeding 
location further classified as parenchymatous, subarachnoid, intraventricular, or any 
combination) or infarction, also defined as a clinically-related new CT (low density) or MRI 
(DWI, FLAIR, or T2) lesion.  The severity of the resulting clinical impairment from stroke will 
be analyzed. Clinical impairment will be determined by a score of 2 or greater on the Rankin 
Disability scale.  This scale will be measured at baseline, every 6 months to study completion, at 
every intervention, and at every neurological adverse event.   
 
For the purposes of adjudication, the Event Adjudication Committee will use the following 
guidelines:   
 
Diagnosis may be based on imaging features alone or with supporting clinical symptoms up to a 
year after the clinical event. In the absence of supporting clinical symptoms (neurological deficit, 
unusual headaches, epileptic seizure), diagnosis of stroke should not be coded as being 
―symptomatic‖.  In the absence of supporting images, diagnosis of stroke should not include a 
specification of type (ischemic versus hemorrhagic). 
 
 
6.2 Secondary Endpoints 
6.2.1 Quality of Life and Patient Preferences  
This clinical trial will employ a combined approach to assessing the health-related quality of life 
of participants by using two broad types of measurements: those that capture health status 
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through the description of functional capabilities, symptoms, and general health perceptions and 
those that generate global utility measures, which reflect both the health status and value placed 
on the health status by the individual.  Patient utility measures will be used as quality adjustment 
factors to derive quality adjusted life years for the cost-effectiveness study. 
 
The SF-36 is a 36 item generic self-report QoL instrument which provides measures on 8 
dimensions of quality of life: physical functioning, role limitations due to physical factors, 
mental health, general health, role limitations due to emotional factors, social functioning, bodily 
pain and vitality.  The analysis of quality of life as a secondary endpoint will include both the 
physical and mental composite scores of the SF-36.   
 
We will use the EuroQoL questionnaire to derive patient preferences.  This instrument examines 
five quality of life dimensions (mobility, self-care, usual activities (work, study, housework, 
family, or leisure), pain/discomfort and anxiety/depression).   In addition, respondents record 
their perception of their overall health on a visual analog scale (0, worst, 100, best).  The visual 
analog scale score directly reflects the respondents‘ view of their own health status.  A societal 
view of the health states can be derived from population-based valuations of the 243 unique 
states of health described by the 5 quality of life dimensions.   
 
6.2.2 Adverse Events 
The incidence of all protocol defined adverse events will be evaluated, regardless of whether 
they are anticipated.  Serious adverse events are defined as those that cause death or permanent 
disability, are life threatening or require a hospitalization, or prolong an existing hospitalization.   
  
Protocol-defined events will include: 
 
 
I.  Neurological Adverse Events: 
 
1. Stroke is defined as a clinically symptomatic event (revealed by a new focal neurological 
deficit, seizure, or new onset headache) when associated with brain imaging indicating 
hemorrhage (defined as fresh intracranial blood on head CT and/or MRI or in the 
cerebrospinal fluid, the primary bleeding location further classified as parenchymatous, 
subarachnoid, intraventricular, or any combination) or infarction, also defined as a clinically-
related new CT (low density) or MRI (DWI, FLAIR, or T2) lesion. 
 
Stroke presentation will be classified by the following subtypes: 
 
A.  Intracranial hemorrhage: Revealed by imaging showing subarachnoid, parenchyamtous or 
intraventricular fresh blood, or by spinal tap. 
 
B. Brain infarction: Signs of infarction on brain CT or MR imaging by DWI, T2, or FLAIR 
imaging. 
 
Stroke symptoms will be classified by: 
 
A.  New focal neurological deficit: A functional deficit on examination, stratified as to whether 
the deficit was persistent, progressive or reversible. 
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B.  New onset headache: Patient complaint of new onset headache. 
 
C.  New onset seizures:  Newly observed seizure activity. 
     
2.  Seizure (unrelated to stroke): Clinically suspected epileptic activity without signs of recent 
intracranial hemorrhage or cerebral infarction on brain imaging (CT and/or MRI). 
 
3.  Focal neurological deficit (unrelated to stroke): Focal neurological deficit on clinical exam 
without signs of recent intracranial hemorrhage or cerebral infarction on brain imaging (CT 
and/or MRI). 
 
4. Headache (unrelated to stroke): Patient complaint of new onset headache without signs of  
recent intracranial hemorrhage or cerebral infarction on brain imaging (CT and/ or MRI). 
 
5. Other Neurological Event: Any new, temporary or permanent, focal or global neurological 
deficit ascertained by standard neurological exam and appropriate diagnostic tests that is not a 
stroke, seizure, focal neurological deficit, or headache. 
  
II. Non-Neurological Adverse Events 
 
1. Acute renal failure:  An episode of acute renal failure requiring peritoneal dialysis,  
hemodialysis or hemofiltration (excluding hemofiltration for fluid management alone). 
 
2. Procedure related nephropathy —a rise in the plasma creatinine concentration of more than      
50 percent above baseline or of more than 1 mg/dL (88 µmol/L), whichever is smaller within 
7 days following a procedure. 
 
3. Contrast reaction:  Anaphylactic reaction in the context of intravenous or intra-arterial 
contrast dye injection. 
 
4. Infection related to BAVM invasive therapy:  Clinical or paraclinical signs of local or 
systemic infection related to invasive therapy. 
 
5. Peri-procedure bleeding (other than intracranial):  Bleeding that results in death or 
transfusion of packed red blood cells during the 24 hour period following an invasive therapy 
for an AVM. 
 
6. Systemic (non-brain) embolization:  Unintended dislocation of embolic material into non-
cerebral arteries or veins. 
 
7. Vascular injury related to BAVM invasive therapy:  Mechanical injury to any arterial or 
venous structures during the course of the intervention without stroke.  
 
8. Catheter adherence to embolization material:  Unintended adherence of a catheter delivering 
embolization material to the BAVM and the inability to remove the catheter without causing 
damage to the vessel and/or requiring a surgical procedure to correct it. 
 
9. Other non-neurological Adverse Event:  An event that causes clinically relevant changes in  
    the patient‘s health or any event that is life-threatening, results in a fatality, results in  
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    permanent disability, requires hospitalization, or prolongs an existing hospital stay. 
 
 
6.2.3. Cost Endpoints 
 
We will employ a health care perspective in this RCT and calculate the costs of all services 
associated with care, regardless of who bears the cost.  These costs will include the direct costs 
of medical care, the costs of non-medical care and indirect health care costs.  The Investigators 
will identify those costs that are related to the research protocol and are not part of usual care.  
We will conduct the economic analysis in the cohort of U.S. patients, with an expected sample 
size of 500 150 patients.   
 
 
 
6.2.3.1 Direct Costs of Medical and Non-Medical Care  
We will derive costs by using the clinical dataset to identify the resources that patients use during 
the course of the trial, and then assign payments/prices for each resource used.  There are a 
multitude of payers in the U.S. that reimburse for services at different rates. We propose to use 
the Medicare payments as representative rates.  For inpatient hospital days, we will use the 
Medicare reimbursement for the DRG codes assigned on the patient‘s discharge.  We will not 
include physician time in our costing, as it is a much smaller part of the overall costs and it 
requires substantial data collection efforts to capture.  For those patients who need nursing 
facilities or long-term institutional care, we will use the National Medicare average allowed daily 
rate to impute payments.  The use of services outside the study hospitals, such as emergency 
room visits, out of network hospitalizations, nursing home care, and rehabilitative facility care 
will be determined by a structured questionnaire administered by site coordinators to all enrolled 
patients.   
 
In seeking medical treatment, patients may also incur significant non-medical care costs.  These 
costs may include the value of unpaid care provided by family members and friends, the costs of 
uncompensated home health care and the ―costs‘ of time dedicated to care by the patient. We 
will focus on obtaining the value of unpaid care provided by family and friends with the 
following question administered at 6 month intervals by site coordinators on the Patient  
Encounter form (AR14): Has your illness required any members of your family or friends to 
restrict their work or social activities? If yes, about how many hours per week have friends or 
family spent in helping with your care?  Each hour of care will be valued at an average hourly 
total compensation rate for civilian workers as reported in the base year by the Bureau of Labor 
Statistics.  The value of home health care will be determined by asking patients directly if they 
had a home health aid or home nurse and the number of hours per week that they are employed.  
The hourly wage rate will be determined by the average Medicare reimbursement rate.  We will 
not collect data on travel costs or the amount of time patients must spend seeking treatment (i.e. 
the opportunity cost of lost leisure time as measured by the wage rate), because of the substantial 
burden involved in such data collection. 
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7.1 DATA COLLECTION SCHEDULE 
 
* collected following each BAVM interventional therapy, all neurological adverse events and hospitalization 
& collected following each BAVM interventional therapy 
^ window of -6 months for image study 
# if Rankin scale collected more than 6 months prior to randomization, assessment should be repeated 
Study Visit  
(months after randomization) 
(V)=Visit, (P)=Phone Call 
Screening / Baseline 
 
6 
(V) 
12 
(V) 
18 
(V) 
24 
(V) 
30 
(P) 
36  
(V) 
42 
(P) 
48 
(V) 
54 
(P) 
60 
Month 
Visit (V) 
66 
(P) 
72 
(V) 
78 
(P) 
84 
(V) 
End of Study 
(V or P) Event 
Driven 
 
(V) (P) 
Window (days) 0 ±30 ±30 ±30 ±30 ±30 ±30 ±30 ±30 ±30 ±30 ±30 ±30 ±30 ±30 -30  
Informed Consent x                 
Release of Medical Information  x                 
HIPAA Authorization (US only) x                 
Demographics   x                 
Eligibility Evaluation x                 
Randomization  x                 
Image Study x                 
Presentation History x                 
AVM Morphology x                 
Rankin Scale  x
# 
x x x x x x x x x x x x x x x x* 
NIH Stroke Scale x x x x x  x  x  x  x  x x  x* 
Medical History x          x       
Medications x x x x x x x x x x x x x x x x  
Quality of Life: SF-36 x x x x x  x  x  x  x  x x   
Quality of Life: Euroqol x x x x x x x x x x x x x x x x  
Interventional Therapy                 x 
Delayed Treatment                 x 
Patient Encounter  x x x x x x x x x x x x x x x x& 
Adverse Event                 x 
Hospitalization                 x 
Mortality                 x 
Missed Visit                 x 
Voluntary Withdrawal                  x 
60 Month Visit           x^       
End of Study                x  
Investigators Statement                 x  
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7.2  Timing of Evaluations 
 
Enrollment:  Screening and Baseline 
 
Consent: 
Prior to chart review, screening data and protocol defined procedures. 
 
Release of Medical Information Form (May be combined with consent): 
Prior to chart review, screening data and protocol defined procedures. 
 
Health Insurance Portability and Accountability Act (HIPAA) Clinical Research 
Authorization (US only) 
Prior to chart review, screening data and protocol defined procedures. 
 
Form AR01: Demographics  
At initiation of screening. 
 
Form AR02: Eligibility Evaluation 
At initiation of screening. 
 
Screening Log 
Documentation of patients screened by not enrolled in ARUBA.   
 
Form AR03 or Form AR03A: Image Study 
At initiation of screening. 
 
Form AR05: Presentation History 
At baseline, prior to randomization. 
 
Form AR06: AVM Morphology  
At baseline, prior to randomization. 
 
Form AR07: Rankin Scale 
At baseline, prior to randomization. If Rankin scale is collected more than 6 months prior to 
randomization, assessment should be repeated. 
 
Form AR08: NIH Stroke Scale  
At baseline, prior to randomization 
 
Form AR09: Medical History 
At baseline, prior to randomization. 
 
Form AR10: Medications 
At baseline, prior to randomization. 
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Form AR11: Quality of Life - SF-36 
At baseline, prior to randomization. 
 
Form AR12: Quality of Life - EuroQOL 
At baseline, prior to randomization. 
 
Randomization: 
 
Form AR04: Randomization 
 The investigator/coordinator who receives the randomization assignment from the DCC must 
electronically sign the form at which point they may proceed with the treatment assignment.   
 
On-Study Evaluations 
 
Form AR14: Patient Encounter  
Patients who meet the eligibility criteria and are randomized into the study will follow the same 
in person study visit and telephone communication schedule. Patient study visits will be 
scheduled at 6, 12, 18 and 24 months for the first two years with a 30 day window (+30 days). 
After two years, an in person annual visit (+30 days) for years 3, 4 and 5 will be scheduled with 
telephone communication scheduled at 6 month (+30 days) intervals  in between.  For patients 
who are randomized to interventional therapy, an interventional therapy visit which falls within 
the + 30 day window of a scheduled visit may be counted as a protocol defined scheduled visit.  
After 5 years (60 months) an annual in person visit (+30 days) will be scheduled with telephone 
communication at 6 month (+30 days) intervals in between until the end of the study.  
  
Form AR07: Rankin Scale 
At the time of all protocol defined scheduled visits. A Neurologist who has completed the ARUBA 
Rankin training must complete this scale.  
 
Form AR08: NIH Stroke Scale  
At the time of all protocol defined in person visits. A Neurologist or certified coordinator must 
complete this scale.   
 
Form AR09: Medical History 
At the 60 month point following randomization, this form must be completed 
 
Form AR10: Medications 
At the time of all protocol defined scheduled visits. 
 
Form AR11: Quality of Life - SF-36 
At the time of all protocol defined in person scheduled visits.  
 
Form AR12: Quality of Life – EuroQOL 
At the time of all protocol defined scheduled visits. 
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Form AR20: 60 Month Visit 
Once a patient reaches the 60 month point following randomization, this form must be completed 
 
 
Event Driven 
 
Form AR13: Interventional Therapy 
At time following each BAVM treatment. 
 
Form AR14: Patient Encounter  
At time following each BAVM treatment a Patient Encounter needs to be documented. 
 
Form AR07: Rankin Scale 
Within 48 hours of each BAVM treatment, following each neurological adverse event and 
hospitalization, a Rankin Scale needs to be documented. 
 
Form AR08: NIH Stroke Scale  
Within 48 hours of each BAVM treatment, following each neurological adverse event and 
hospitalization, an NIH Stroke Scale needs to be documented. 
 
Form AR15: Adverse Events 
Event driven. 
 
Form AR16: Hospitalization 
Event driven. 
 
Form AR17: Mortality 
Event Driven-within 24 hours of knowledge of event. 
 
FormAR18: Missed Visit 
Event Driven. 
 
Form AR19: Voluntary Withdrawal 
Event Driven. 
 
Form AR22: Adverse Events Adjudication 
Event Driven. 
 
Form AR23: Mortality Adjudication 
Event Driven. 
 
Form AR24: Delayed Treatment   
Event Driven. 
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Final Evaluations 
 
Form AR 25:  End of Study 
This form will be completed on all patients currently enrolled in the study 5 years (60 months) 
following the randomization of the last patient. 
 
Form AR21: Investigator Statement 
The investigator will sign this form electronically after all patient forms have been submitted at 
the completion of the trial. 
 
7.3 Special Instructions and Definitions of Evaluations 
 
Consent: 
The method of obtaining informed consent involves a discussion with the investigator, as a result 
of which, the patient accurately understands the study, the risks and benefits of participation, and 
has had all their questions answered about the study prior to making a decision whether or not to 
participate in the study (Refer to the protocol Appendix I. Informed Consent Template). 
 
Release of Medical Information Form: 
The patient must sign the Release of Medical Information form that authorizes release of medical 
records to the study investigators, monitors, NINDS, and the DCC. 
 
HIPAA Clinical Research Authorization 
The HIPAA Form approved by the IRB or Privacy Board allows site investigators to approach, 
screen, and enroll patients into the study (U.S. only). 
  
(Refer to the Manual of Procedures Appendix VI. for a copy of all Case Report Forms) 
 
Form AR01: Demographics  
A screened patient is an individual who was referred to, or identified at a clinical center for 
consideration in the study, and for whom some preliminary data (i.e. medical records) have been 
reviewed.  Demographic information including the patient‘s first, middle and last name initials, 
date of birth, gender, ethnic category, racial category, and  handedness. The electronic data 
capture system (EDC) will generate a sequential screening number to identify each patient. 
 
Form AR02: Eligibility Evaluation 
A complete checklist of inclusion and exclusion criteria will be documented. A waiver must be 
requested to enroll a patient who has a value outside of the protocol defined range. 
 
Form AR03: Image Study 
This form includes the date of the image study, the type(s) of the images, the presence of an 
unbled BAVM, the initials of the radiologist and the signature of the site investigator/clinical 
coordinator to confirm the information.  The form also documents that the de-identified CD of 
the images and the radiologist‘s final report were sent to the DCC.  In the event that an image is 
older than one year, a waiver must be obtained from the CCC PI who will document acceptance 
or rejection of the images.   
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Form AR03A: Image Study 
 This form is to be used by sites which do not have a credentialed radiologist available.  The 
form includes the date of the image study, the type(s) of the images, the uploaded images and the 
radiologist‘s review and approval, rejection or request for more images.    
 
Form AR04: Randomization 
The form includes the name of the clinical center, the date and time of randomization, the 
randomization assignment and the patient ID.  The form will be signed electronically by the 
clinical center by the clinical coordinator or the clinical investigator at the respective site. 
 
Form AR05: Presentation History 
This form documents the date of the diagnostic event, mode of presentation, incidental diagnosis, 
and clinical presentation. 
 
Form AR06: AVM Morphology  
This form documents the specific imaging source, location, and size of the AVM, arterial supply, 
presence of intranidial aneurysm(s) and the presence of unrelated aneurysm(s).  Questions 5-13 
can only be answered if an angiogram was performed. 
 
Form AR07: Rankin Scale 
This standardized scale includes 5 components to assess functional status. 
 
Form AR08: NIH Stroke Scale  
This standardized scale includes 14 components to assess for neurologic deficits.  
(See Appendix III. of the Manual of Operations for instructions on administration.)  
 
Form AR09: Medical History 
This form captures the information pertaining to the patient‘s baseline vital signs and medical 
history including vascular risk factors, and other concomitant diseases.   
 
Form AR10: Medications 
This form captures prescribed medications the patient has taken over the last seven days in the 
following categories:  antiepileptic medications, headache medications, antihypertensive 
medications, lipid lowering agents, anti-diabetic medications, anti-platelet agents and 
anticoagulants. 
 
Form AR11: Quality of Life - SF-36 
The Short Form 36 Health Questionnaire (SF-36) will be completed by the patient and used to 
assess quality of life. 
 
Form AR12: Quality of Life - EuroQOL 
The Euroqol is a 6 item questionnaire completed by the patient and is used to assess the patient‘s 
perception of their overall health status.  
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Form AR13: Interventional Therapy 
This form captures the details about the interventional therapy that enrolled patients receive, 
including the reason for interventional therapy, the type of interventional therapy, and the result 
of the BAVM therapy.  This form will be completed for all patients regardless of treatment arm 
when AVM eradication therapy is performed. 
 
Form AR14: Patient Encounter  
This form will capture any diagnostic procedures, interventional therapy, and/or clinical events 
the patient has experienced in between communication assessments and follow-up visits.  
 
Form AR15: Adverse Events 
Detailed information regarding adverse events will be recorded at the time an adverse event takes 
place.  Events will be sub-categorized as neurologic or non-neurologic.  Investigators will be 
asked to make a judgment as to the seriousness of the event.  The relationship of the event to the 
natural history of the index AVM or AVM-related interventional therapy will be ascertained.   
Interventions performed as a result of acute interventional therapy will be collected if an adverse 
event occurred. 
 
Form AR16: Hospitalization 
Information regarding all hospitalizations will be reported and include information regarding 
date of hospitalization, number of days in intensive care unit setting (i.e. Neuro ICU, MICU, 
CCU, SICU), length of stay, medical and surgical procedures performed, a clinical narrative, and 
disposition at time of discharge (home, skilled nursing facility, rehabilitation facility, death). 
 
Form AR17: Mortality 
The mortality form must include the primary cause of death and what the immediate cause of 
death was attributed to. A clinical narrative will be instrumental in the adjudication of mortality 
classification. Supporting source documentation should be collected, copied, and filed in the 
Case Report Binder.   
 
Form AR18: Missed Visit 
If a patient is unable to return for follow-up and unable to be contacted via telephone before the 
closure of a study visit window, a missed visit form must be completed.  
 
Form AR19: Voluntary Withdrawal 
The Voluntary Withdrawal form must be completed if the patient chooses to withdraw from this 
study.  The only anticipated withdrawal from this study is patient request. 
Form AR20: 60 Month Visit 
Once a patient reaches the 60 month point following randomization, the following data points 
must be obtained: 
a. A diagnostically relevant imaging study is suggested for all patients at the 60 month post-
randomization point.  The imaging study should be performed no earlier than 6 months prior to 
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the 60 month point.  If the image is performed before month 54, a waiver should be obtained 
from the CCC PI.  A de-identified CD and the radiologist‘s report will be sent to the DCC.    
b. A reminder that scheduled study visit forms for month 60 have to be completed.  These 
include: Rankin scale (AR07), NIH stroke scale (AR08), Medications (AR10), SF-36 (AR11), 
Euroqol (AR12), Patient encounter (AR14).  Adverse Events (AR15) and Hospitalization 
(AR16) must be submitted as applicable. 
 
Form AR21: Investigator Statement 
After a complete review of the electronic CRFs and patient summaries, the investigator will sign 
this form to attest to the accuracy and completeness of the data collected. 
 
Form AR22: Adverse Events Adjudication 
The adjudication committee will review all adverse events both neurological and non-
neurological and adjudicate the seriousness and relatedness of the event. 
 
Form AR23: Mortality Adjudication 
The adjudication committee will review all mortality adverse events and adjudicate the 
proximate and primary underlying cause of death. 
 
Form AR24: Delayed Treatment 
Any patient randomized to interventional therapy who does not begin interventional therapy 
within 3 months after randomization must have a reason documented.   
 
Form AR25: End of Study 
5 years (60 months) after the last patient is randomized, all patients currently enrolled will be 
seen either in person or contacted by phone.  A diagnostically relevant image study is suggested 
at this time.  If the imaging study is performed, a de-identified CD and the radiologist‘s report 
will be sent to the DCC.  The form contains a reminder that scheduled study visit forms for end 
of study have to be completed.  These include: Rankin scale (AR07), NIH stroke scale (AR08)(in 
person visit only), Medications (AR10), SF-36 (AR11) (in person visit only), Euroqol (AR12), 
Patient encounter (AR14).  Adverse Events (AR15) and Hospitalization (AR16) must be 
submitted as applicable. 
 
8.  MANAGEMENT OF ADVERSE EXPERIENCES 
 
It is anticipated that any complications suffered by the patient will be brought directly to the 
attention of the local PI. The information from the local investigator will separately document 
the accuracy of the initial classification and assess its severity. These will be classified into 
neurological and non-neurological events (as defined in section 6.2.2).  Adverse experiences will 
be sought and reported according to their relationship to index AVM and/or interventional 
therapy and seriousness. The investigators will be trained to identify and document these events 
in the EDC. Non-serious adverse events must be entered into the EDC within 72 hours. Serious 
adverse events must be reported to the DCC within 72 hours of knowledge of the event. 
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9.  CRITERIA FOR INTERVENTION DISCONTINUATION 
 
 
9.1 Brain Hemorrhage or Stroke Related to BAVM in Medical Management Group 
Any patient suffering hemorrhage in the course of the medical management arm is censored at 
that point and is eligible for intervention at the discretion of the patient and local center, but 
remains in the original randomization arm for the purposes of intent-to-treat analysis. The 
occurrence of hemorrhage will be documented in the Adverse Event form (AR15) , the 
coordinating center notified within 72 hours, the patient seen within 48 hours of the event by the 
neurologist blinded as to the nature of the event, and examined for the NIH Stroke Scale and 
Rankin Scale.  
 
 
9.2 Intervention-associated Hemorrhage 
Any occurrence of intervention-associated intracranial hemorrhage that occurs with evidence of 
the onset of new symptom(s) (new focal neurological deficit, seizure or new onset headache) is 
to be documented in the Intervention form (AR13) and applicable Adverse Event form (AR15) at 
the time of the event. The coordinating center must be notified within 72 hours, the patient seen 
within 48 hours of the event by the neurologist blinded as to the nature of the event, and 
examined for the NIH Stroke Scale and Rankin Scale. The decision(s) to continue with treatment 
and plan(s) for the types of treatment, are to be made by the treating team. 
 
 A serious adverse experience in the course of interventional therapy will be sufficient for 
discontinuation of interventional therapy.  The range of adverse events is noted in section 6.2.2. 
 
10.  STATISTICAL CONSIDERATIONS 
 
10.1   General Design Issues 
The study design is a prospective, multi-center, parallel design, randomized, controlled trial.   
Treatment assignment will not be masked; however, clinical coordinating center personnel and 
outcome events committees will be blinded to treatment assignment. The primary outcome is the 
composite event of death from any cause or stroke (hemorrhage or infarction revealed by 
imaging).  Clinical outcome status will be measured by the Rankin Scale, a widely-used outcome 
measure for stroke.
  
The secondary measures of outcome include adverse events, quality of life 
and cost. 
 
10.2 Sample Size and Accrual 
Sample size calculations are based upon both previously published studies and preliminary data 
obtained from our institution. Columbia data yielded Kaplan-Meier estimates of event rates at 5 
years of 4% for medical management and 19% for interventional therapy.  Published estimates of 
natural history risk range from 2-4% while quoted estimates of treatment risk vary but have been 
assumed to be 5% or lower for the purposes of cost-benefit analysis. 
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Our sample size calculations are based on the following assumptions: (1) time-to-event is  
exponentially distributed with a constant hazard, (2) the five-year event rate for patients assigned 
to interventional therapy is  22%  (3) patient accrual will occur uniformly for  60 months (5 
years), and follow-up will continue for an additional 60 months (5 years) after the last patient is 
randomized.  A total of  400 patients, randomized with equal allocation to medical management 
or to interventional therapy, assures 80% power to detect a 46% reduction (hazard ratio of 0.54) 
in the risk of death or stroke for the medical management arm compared to interventional 
therapy. Assuming that the 5-year event rate for patients treated with interventional therapy is  
22%, this corresponds to an absolute reduction of 9.5% the in 5-year event rate for treatment by 
medical management. 
 
With 400 randomized patients, the potential test of non-inferiority has 80% power to declare 
medical management non-inferior to intervention with a one-sided 0.05 level test, assuming: (1) 
a non-inferiority margin of 13% risk reduction (hazard ratio of 0.87) for interventional therapy 
compared to medical management (2) medical management reduces the risk of death or stroke by 
30% (hazard ratio of 0.70) compared to intervention. One hundred and five events are expected 
under these assumptions. The rationale for the test of non-inferiority is provided below 
 
Four hundred patients will also assure sufficient power to assess group differences in clinical 
impairment, the metric of interest for the third aim associated with the primary hypothesis (Aim 
1.1b).  Based on our preliminary data, the proportion of patients clinically impaired (Rankin 
Disability Score  2) at five years after discovery of their AVM is expected to be in the range of 
10-20% for those treated by medical management. If the proportion of impaired patients is as 
low as 10% in the medical management arm, then power is approximately 90% to detect a 
relative risk of impairment of 0.45 compared to the interventional therapy group (i.e., 10% 
impaired versus 22% impaired). If the proportion impaired is as high as 20% in the medical 
management group, then power is approximately 90% to detect a relative risk of 0.57 (i.e., 20% 
impaired versus 35% impaired).  These results are based on two-sided 0.05 level exact tests. For 
80% power, the detectable relative risks are 0.49 (10% versus 20.5%) and 0.61 (20% versus 
32.8%) respectively. 
 
The power of this trial is adequate to detect a fairly large, but we believe, reasonable effect. 
There is 80% power to detect a 46% relative reduction in risk (absolute 9.5% reduction in five-year 
events rates). We note that these effects are substantially smaller than the effects observed in our 
single center non-randomized series of 387 patients presenting with unruptured BAVMS 
between 6/87 and 7/03. Those data indicate a large benefit of medical management with an 
estimated hazard ratio of 0.18 (a relative reduction in risk of 82% for medical management) and 
95% confidence interval of (0.095, 0.34) (a relative reduction in risk between 66% and 90.5% for 
medical management).  
 
Ideally, the trial is powered to detect a smaller effect, in particular, the smallest effect that would 
likely change clinical practice.  However, we believe that 400 patients enrolled from 104 centers 
for a 10-year study conservatively represents the largest and longest practicable trial possible to 
assess this important question. To address this concern, we propose performing a non-inferiority 
test if the primary null hypothesis of no treatment difference is not rejected, to establish whether 
or not medical management is at least as good as interventional therapy.  
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Medical management would be at least as good as interventional therapy, if the relative benefit 
of interventional therapy could be clearly established to be less than 13% compared to medical 
management. This non-inferiority margin represents an absolute difference in five-year event 
rates of approximately 2.5%.  With 400 patients, there is 80% power to reject inferiority of 
medical management using this non-inferiority margin (13%), if the relative reduction in risk 
with medical management is at least 30%. 
10.3 Randomization Design and Procedure 
The ARUBA trial will use a 1:1 ratio in randomizing patients to the two treatment arms.  Pre-
stratification (stratification in the design) seeks to ensure that treatment groups are balanced with 
respect to factors that are likely to affect the outcome.  We will stratify by clinical center using a 
random permuted block design. 
Randomization will be implemented as described in section 4.3.5.  
 
10.4 Data Monitoring and Analysis  
10.4.1 Methods of Analysis 
The primary outcome of this RCT is the composite event of stroke or death.  The null hypothesis 
is that there is no difference in the time to occurrence of this outcome between patients 
randomized to receive medical management and those randomized to receive interventional 
therapy. The primary null hypothesis will be tested in an intent-to-treat analysis using the log-
rank statistic to test for differences between survival curves. The analysis will be based on a two-
tailed 0.05 level test.  Due to the large number of centers, the primary analysis will not be 
stratified by center even though the randomization is stratified by center.   
 
Failure to reject the primary null hypothesis will not necessarily imply that the two treatments 
are equivalent. To conclude equivalence or that one treatment is at least as good as another, a 
statistical test or confidence interval procedure must rule out clinical inferiority with a high 
probability.  If the primary null hypothesis is not rejected, we will test whether medical 
management is inferior to intervention with a one-sided 0.05 level test (taking account of two 
interim analyses for superiority). No inflation of Type I error is associated with performing a test 
of inferiority after a test of superiority has not rejected the null hypothesis, since this strategy 
represents a simple closed test procedure.  The test of non-inferiority will be based on a 
confidence interval approach. We will compute a 95% lower confidence bound for the hazard 
ratio for interventional therapy compared to medical management. If this lower bound is greater 
than 0.87 (i.e. the relative benefit of intervention compared to medical management is less than 
13%) the null hypothesis of inferiority will be rejected.  Details of the approach follow.  
 
Cox proportional hazards regression will be used to obtain an estimate of the (natural) log of the 
hazard ratio, log( θ̂ ), and its asymptotic standard error, se(log( θ̂ ). The hazard ratio  represents 
the relative risk of the composite event of death from any cause or stroke for interventional 
therapy compared to medical management. The lower bound to assess non-inferiority will be 
computed as exp{log( θ̂ )-1.695 se(log( )θ̂ }, where exp(x)=e
x
.  The Cox model will contain a 
single indicator for randomization group. The log hazard will be estimated as the maximum 
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partial likelihood estimator. The variance (squared standard error) of the estimate will be based 
on the inverse information matrix evaluated at the estimated log hazard ratio.  
 
We recognize that, in general, tests of non-inferiority are not conservative.  Flaws including 
violations in entry criteria, noncompliance, losses to follow-up, missing data, and protocol 
deviations tend to bias toward a conclusion of non-inferiority.  This trial‘s straightforward 
treatment protocol, gate keeping strategies, minimal cross-over between treatments and 
likelihood for minimal losses to follow-up (detailed below in sections on Missing Data and 
Crossovers) will tend to minimize this kind of bias. Nevertheless, we propose to test non-
inferiority using two analysis sets; the intention-to-treat set, considering all patients as 
randomized regardless of whether they received the randomized treatment, and the ―per 
protocol‖ analysis set. Criteria for determining the ―per protocol‖ group assignment would be 
established by the Steering Committee and approved by the DSMB before the trial begins. Given 
our expectation that very few patients will crossover or be lost to follow-up, these analyses 
should agree very closely. We propose declaring medical management non-inferior to 
interventional therapy, only if shown to be non-inferior using both the ―intention to treat‖ and 
―per protocol‖ analysis sets.  
 
The time to event experience of each randomization group will be described by survival curves 
estimated by the Kaplan-Meier method.  Of particular interest is the point estimate and 
associated 95% confidence interval of the five-year actuarial event rates in each randomization 
group. Cox proportional hazards regression will be used to estimate the hazard ratio and its 
associated 95% confidence interval.   
 
The primary analysis of the trial is the comparison of event-free survival between randomization 
groups described above. Several additional analyses will be performed to support the assessment 
of the trial‘s first specific aim. These analyses focus on the clinical impairment of patients. The 
principal measure of clinical impairment is the composite event of death or Rankin Score  2. 
 
The principal assessment of clinical impairment will be a comparison of the proportion of 
patients dead or clinically impaired (Rankin Score 2), at five years between randomization 
groups using an exact binomial test. Additionally, we will (1) compare the time to the first  
occurrence of death or clinical impairment (Rankin Score 2), between randomization groups 
using the log-rank test, (2) compare the rate with which the composite event of death or clinical 
impairment (Rankin score is  2) occurs over the course of the study between randomization 
groups using a Poisson regression model (the Poisson model will have the number of times the 
composite event occurs as the dependent variable and include the natural log of follow-up time 
as an offset), and (3) execute two longitudinal analyses of all available Rankin data for each  
patient (collected every 6 months) the first analysis will use  logistic regression  with  
parameter estimation via generalized estimating equations (GEE) to estimate the odds ratio of 
having a Rankin score  2 over the course of the study, and a second analysis using a linear 
mixed effects model considering the Rankin score as a continuous variable.  
10.4.2. Assessing the proportional hazards assumption 
The validity of the log-rank test of the equality of event-free survival depends on the 
appropriateness of the proportional hazards assumption. This assumption will be assessed both 
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graphically and by a formal statistical test. Graphical assessments will be based on two plots:  (1) 
a ―log-negative-log plot‖, i.e., a plot of log(-log(S(t)) versus log t for each treatment group and 
(2) a plot of the ―scaled Schoenfeld residuals‖ 
20
 versus log t for each treatment group (where by 
―log‖ we mean the natural logarithm and by ―t‖ we mean time in months). A formal test for the 
appropriateness of the proportional hazards assumption will also be performed if there is strong 
evidence of non-proportional hazards that could bias the result of the test of the null hypothesis 
(e.g., the survival curves cross).  Note that we are concerned about crossing hazards as might be 
expected if there were an early benefit to medical management and a later benefit to 
interventional therapy. We do not plan to deviate from the proposed log-rank analysis if the non-
proportionality stems from diverging hazards resulting from a monotonic accelerated benefit for 
one arm compared to the other. 
 
The formal test will assess the significance of the interaction between the indicator for treatment 
group and log(t) in a Cox proportional hazards regression model that also includes a main effect 
for the randomization group. Statistical significance of the interaction term (based on a two-
tailed 0.05 level test) would indicate a violation of the proportional hazards assumption. In that 
case, a comparison of five-year survival estimates based on a Kaplan-Meier analysis would be 
more appropriate.  Therefore, if the proportional hazards assumption is not valid due to crossing 
survival functions, the primary null hypothesis will be tested using a confidence interval 
approach based on the log-log survival function, as suggested by Kalbfleish and Prentice. 
10.4.3  Interim Analysis 
We will conduct formal interim analyses with respect to the primary endpoint to give us the  
option of stopping early should results strongly favor one arm or the other. As the decision to 
terminate early would likely occur after all patients were randomized, the principal benefit of 
early termination would be prompt dissemination of results and the possibility of cross-over from 
the medical arm, should interventional therapy prove to be superior.  A group sequential 
procedure allows for flexibility in the number and timing of interim analyses should the DSMB 
choose to modify the proposed plan. We will use the Lan-DeMets approach, implementing an 
O'Brien-Fleming-type spending function that allots most of the type I error to the final look. We 
plan for two formal interim looks.  Given the assumptions underlying sample size calculation, 
approximately 87events are expected to occur during the study. We propose to perform the two 
interim analyses at approximately equally spaced intervals with respect to the number of  
expected events, that is, after observing 29 and 58 events. The resulting critical values to be used 
for each analysis are 3.7103 at the first interim analysis, 2.5114 at the second interim  
analysis, and 1.9930 at the terminal analysis 
 
In addition to the ethical concern of continuing a trial that shows a clear benefit in favor of one 
treatment, there is usually a corresponding ethical concern of continuing a trial that has little 
chance of ever showing a benefit of one treatment compared to the other. However, since a major 
goal of this trial is to establish noninferiority of medical management to intervention if neither 
treatment is superior, we believe that an assessment of futility (i.e., the conditional probability of 
finding a statistically significant result if the trial were to continue to the planned maximum 
sample size) is not relevant.  We intend to perform the test of noninferiority at the final analysis 
only (not at any interim analysis).  
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We do not propose any a priori stopping criteria based on adverse events. The treatments in this 
trial are not experimental, and have well known adverse event profiles. Mortality is expected to 
be rare. Moreover, we believe that incident rates of adverse events and mortality must be  
interpreted along with information about the consistency of related measures, consistency across 
centers, data completeness, and any external factors including scientific developments that might 
impact patient safety. In addition to considering the data generated by this trial, the DSMB will 
consider all relevant background knowledge about the treatment of BAVMs. The DSMB would 
be capable, and uniquely suited, to determine decisions for convening outside the schedule of 
meetings, and to determine decisions to suspend or terminate the trial. These decisions should be 
at the discretion of the DSMB alone. We therefore recommend that the DSMB should be  
responsible for defining its deliberative processes, including event triggers that would call for an 
unscheduled review.  We propose that the DSMB meet every six months to review data prepared 
by the Coordinating Center. 
10.4.4. Assessment of Balance of the Randomization 
The success of the randomization procedure in balancing important covariates (e.g. age, AVM 
location, presence of aneurysms) between randomization groups will be assessed at each interim 
analysis and at the final analysis. Continuous measures such as age and AVM size will be 
compared using t-tests, while chi-squared tests will be used to compare categorical variables 
such as age and ethnicity.  As four hundred patients will be randomized, no substantial 
imbalances are expected.  However, should any covariate differ significantly between treatment 
groups at the 0.01 level, and be substantively large, we will adjust for those covariates in all 
analyses. For example, in the survival analyses described above, such covariates would be 
included as stratification variables. 
10.4.5  Analyses of Secondary Endpoints 
 
Aim 2.1 Quality of Life.  The SF-36 will be used to measure health-related quality of life (QoL).  
One approach to analyzing such data is to estimate longitudinal linear models, as in the Proc 
Mixed procedure in the SAS System.  Our models will predict outcome from treatment group 
and time. While we expect few drop-outs in this otherwise young and healthy group some  
missing QOL data are possible, if only from deaths. The mixed modeling approach requires an 
assumption that the dropout is ignorable in that the probability of dropping out at any time is  
related only to previously observed data items.  Of course, this assumption may not hold, and 
moreover it is impossible to test it robustly from the data at hand.  An alternative approach we 
will also use, not subject to this criticism, will be to separate the data into strata defined by the 
time of death or dropout.  We will then estimate a separate linear model, including a treatment 
effect, for the data in each stratum.  This method, known as pattern-mixture modeling is not  
sensitive to untestable assumptions about the dropout mechanism because it models the data  
directly in strata defined by dropout time.  The method of Wu and Bailey is an instance of 
pattern-mixture modeling.  
 
Aim 2.2 Mortality. Differences in time to death between randomization arms will be tested using 
a log-rank test in the same manner as the primary analysis of the composite event of death or 
stroke. 
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Aim 2.3 Quality-Adjusted Survival. To measure net health outcomes for the cost-effectiveness 
analysis, we will adjust survival for associated quality of life to derive quality-adjusted life years.  
This will allow us to capture the pertinent aspects of each of these individual measures of 
outcome in a single value and, thus, enhance our ability to make overall comparisons between 
the two treatment arms, as well as to facilitate exploring the trade-offs between quality of life,      
survival, and cost that are inherent in these therapeutic decisions.  QALYs are a general enough 
measure of outcome to support comparisons of disparate medical interventions, and, thus, will 
allow us to put our observations about the rates of health care resources expended in achieving 
quality survival with the management of brain AVMs into a more global health economic        
perspective. 
 
Aim 2.4 Adverse Events. Differences in the incidence of individual adverse events will be  
compared between randomization arms using Poisson regression. Exact 95% confidence  
intervals (based on the Poisson distribution) for the risk ratios for individual adverse events for 
medical management compared to interventional therapy will be computed. 
 
Aim 2.5 Costs and Cost-Effectiveness.   
Costs 
The differences in average costs will be compared between the two treatment approaches using a 
t-test.  The log transformation of costs will be utilized if distributions do not meet the assumption 
of normality.  Results will be expressed using 95% confidence intervals. 
 
Cost Effectiveness Analysis 
Cost-effectiveness is measured as the difference in the average costs of conservative medical 
management as compared to interventional therapy, relative to the difference in effectiveness of 
these two treatment approaches.  The difference in costs over the difference in effectiveness of 
medical management versus interventional therapy is known as the incremental cost-
effectiveness ratio, the economic parameter we will use in this trial.  We will also compute net 
health benefits (NHB) as an alternative way of looking at cost-effectiveness.   This parameter 
compares the incremental effectiveness of an intervention with the minimum health effect that 
society would demand in return for the investment, i.e., with the health produced by investing at 
the societal ceiling cost-effectiveness ratio (CR).  
 
Our main measure of effectiveness for economic analysis will be quality-adjusted life years 
(QALYs), or survival weighted by the QoL experienced by trial patients (as measured by the  
EuroQol).  Because we anticipate that few patients will die or be lost to follow-up, censoring 
should not be an issue here, and the data can be analyzed using straightforward statistical  
methods.  As with the QALY endpoint, we will measure health care costs (see above) incurred 
during the trial period.  Except for the few patients whom we will lose to follow-up, we expect to 
have complete cost data on all U.S. patients.  Consequently, our cost-effectiveness analysis 
should require relatively straightforward methods.  We will express uncertainty in the cost-
effectiveness ratio using the Bayesian methods (probability intervals) that we have  
pioneered.[26-28]   We anticipate that the distribution of costs will be skewed to the right.  If this 
violates the assumption of normality, we will modify the method using the nonparametric  
Bayesian bootstrap.[29]   We will employ traditional sensitivity analyses to garner insight into 
the effect of specific factors on the CE ratio, such as the location of care, the type of modality of 
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therapy used, and potential modifications in specific interventions over time.  We will use 
standard discount rates for both QALYs and costs.  
 
International Applicability of the Cost-Effectiveness Analysis 
When we publish the results of the cost-effectiveness analysis, we will document carefully the 
amount of resources used in both treatment arms.  We will also examine if there are any 
differences in patterns of hospitalization or other clinical resource use among the North 
American, European, and Australian centers due to potential differences in practice patterns.  By 
inserting country-specific payment rates and the specific resource use, the cost-effectiveness 
analysis can easily be tailored by our international collaborators for their specific national 
context. 
 
10.4.6  Additional Analyses of the Primary Endpoint 
We propose several secondary analyses of the primary objective, which address differences 
between prophylactic treatment modalities and differences in risk according to general patient 
characteristics and specific BAVM characteristics.   
 
Aim 2.6: This aim addresses whether BAVM size acts as an effect modifier for the relationship 
between treatment and the primary composite outcome of death or stroke. To test for effect 
modification, we will use a Cox model including an indicator for randomization group, BAVM 
size, and the interaction (product) of BAVM size and randomization group indicator as 
covariates. BAVM size will be considered as a continuous covariate to maximize power. The 
null hypothesis that the treatment effect does not depend on BAVM size will be rejected if the 
treatment-by-BAVM size coefficient is significant at the 0.05 level. Note that we will 
preliminarily assess the assumption that the effect of BAVM size on the hazard is linear by 
fitting a confirmatory model in each treatment arm separately in which BAVM is entered 
categorically in three levels defined by observed tertiles. The models would include two 
indicators for the three-level categorical version of BAVM size and the original linear BAVM 
size term. A formal test of linearity is obtained by calculating the difference between the partial 
log-likelihoods from the models with and without the BAVM size category indicators. If there is 
no significant departure from linearity at the 0.05 level, the analysis will be as described above. 
If there is a significant departure from linearity the Cox model used will include the two 
indicator variables for BAVM size and the two treatment-by-indicator interaction terms. The test 
of interaction would then be a two degree of freedom log partial likelihood test of the joint 
significance of the two treatment-by-BAVM category coefficients. 
 
Aim 2.7:  This aim addresses whether BAVM location (deep versus other) is an effect modifier 
for the relationship between treatment and the primary composite outcome of death or stroke. As 
for Aim 2.6, the test for effect modification will be based on a Cox model that contains 
indicators for randomization group, BAVM location (deep versus other) and a treatment-by –
BAVM location term. The null hypothesis that the treatment effect does not depend on BAVM 
location will be rejected if the treatment-by-BAVM location coefficient is significant at the 0.05 
level. 
 
 Aim 2.8: This aim will be addressed as is Aim 2.7 with appropriate substitution of venous 
drainage pattern (exclusively deep versus other) for BAVM location. 
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Aim 2.9: This aim will be addressed as is Aim 2.6 with appropriate substitution of age for 
BAVM size. 
 
Aim 2.10: We will estimate the time to the composite event of death or stroke via Kaplan-Meier 
survival functions for each prophylactic treatment modality, and test for differences between 
groups using a Cox model including two indicator variables to represent the three treatments. We 
will also estimate the proportion of patients dead or clinically impaired at 5 years after 
randomization, and the associated exact 95% confidence interval for each prophylactic treatment 
modality. Logistic regression will be used to test for treatment differences. These analyses will 
include only the sub-group of patients randomized to receive interventional therapy. 
 
Aim 2.11:  We will attempt to consider completeness of eradication of the AVM as a continuous 
variable and proceed analogously to the analysis of BAVM size described for Aim 2.6.  If this is 
not reasonable due to the distribution of values, we will treat completeness of eradication as 
categorical. The categories will be defined based on an examination of the distribution of values, 
but prior to analysis of the outcome. 
 
Aim 2.12: To estimate via a Cox proportional hazards regression model the hazard ratios and 
associated 95% confidence intervals comparing Speltzer-Martin grading scales (grades of 1-5 
with 5 being most severe) for death or  stroke among patients randomized to receive 
interventional therapy. The hazard ratios will reflect the risk of grades 2, 3, 4 and 5 compared to 
the reference grade of 1. A corresponding logistic regression model will estimate the odds ratios 
and associated 95% confidence intervals for relating these risk factors to the composite event of 
death or clinical impairment (Rankin Score 2) at five years after randomization.  These models 
will also be fit for each prophylactic treatment modality separately. 
 
10.4.7  Imputation Procedure for Missing Data 
While the analysis of the primary endpoint (death or stroke) will be based on a log-rank test and, 
therefore, not affected by patient withdrawals (as they will be censored) provided that dropping 
out is unrelated to prognosis; other outcomes, such as the Rankin Score at five years post-
randomization, could be missing for patients who withdraw from the trial. We will report reasons 
for withdrawal for each randomization group and compare the reasons qualitatively. Given the 
relatively young age and overall good health of this population, we believe the severity of  
potential events and associated anxiety will limit patient withdrawal from the study. The effect 
that any missing data might have on results will be assessed via sensitivity analysis of augmented 
data sets. Dropouts (essentially, participants who withdraw consent for continued follow-up) will 
be included in the analysis by modern imputation methods for missing data.  
 
The main feature of the approach is the creation of a set of clinically reasonable imputations for 
the respective outcome for each dropout.  This will be accomplished using a set of repeated 
imputations created by predictive models based on the majority of participants with complete 
data.  The imputation models will reflect uncertainty in the modeling process and inherent 
variability in patient outcomes, as reflected in the complete data. 
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After the imputations are completed, all of the data (complete and imputed) will be combined 
and the analysis performed for each imputed-and-completed dataset.  Rubin‘s method of multiple 
(i.e., repeated) imputation will be used to estimate treatment effect.  We propose to use 15 
datasets (an odd number to allow use of one of the datasets to represent the median analytic 
result).  
 
These methods are preferable to simple mean imputation, or simple ―best-worst‖ or ―worst-
worst‖ imputation, because the categorization of patients into clinically meaningful subgroups, 
and the imputation of their missing data by appropriately different models, accords well with 
best clinical judgment concerning the likely outcomes of the dropouts, and therefore will 
enhance the trial‘s results. 
10.5 Crossovers 
By design, crossovers (patients who after randomization switch from the allocated treatment to 
the non-allocated treatment) are expected to be few in this trial.  Patients randomized to 
interventional therapy who do not receive it during the trial can be considered crossovers.  In 
addition, patients who are randomized to medical therapy and subsequently receive 
interventional therapy are considered to have crossed over if the reason for intervention was 
other than AVM rupture.  Though we expect the rate of crossover to interventional therapy to be 
low, if medical management was actually superior, a crossover to interventional therapy would 
bias the study in favor of the null hypothesis.  
 
11. STUDY ORGANIZATION, DATA COLLECTION, SITE MONITORING, AND  
ADVERSE EXPERIENCE REPORTING 
11.1 Study Organization  
The trial has separate Clinical and Data Coordinating Centers.  The CCC and DCC jointly 
compose the operations committee.  This committee will direct the day-to-day operations of the 
trial and oversee the overall conduct throughout the course of the trial.  The Operations  
Committee will consist of the principal investigators and co-principal investigators of the CCC 
and DCC, the international coordinators and trial monitors.   
 
The CCC and DCC will conduct a series of annual meetings during the course of the trial.  These 
meetings will stimulate enthusiasm for the trial, enhance the synergy of the research team, and 
train the investigators and coordinators in specifics of the protocol design.  Moreover, they may 
result in updating the guidelines prepared by the sub-committees, protocol revisions, or 
investigator-generated sub-studies. 
 
The CCC will maintain regular contact with all the clinical sites, and address questions 
concerning the eligibility of patients, definitions of clinical factors, including endpoints, and on 
issues of managing patients in the ARUBA trial.  A contact log for all interactions will be kept 
for DSMB inspection to assure that all rules of the trial have been followed.  The CCC staff 
includes the trial‘s gatekeeper, who will be involved in the clearance of the randomization 
process.  The P.I. will provide overall scientific leadership to the trial, chair the Steering  
Committee, and ensure that all contacts of centers are directed to the appropriate sources of 
information, including the CCC co-investigators with expertise in clinical neurology, 
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endovascular procedures, microsurgical procedures, and radiosurgery.  The CCC will also 
communicate on a regular basis with the investigators to ensure that enrollment targets are being 
met, and will discuss any barriers to enrollment and opportunities to increase enrollment.  
 
The major committee of the DCC is the data committee.  This committee will meet every week 
during the first year of the trial, and subsequently on a bi-weekly basis.  This committee will 
oversee data flow, quality, and completeness.  In addition, the DCC (U.S. and Europe-based) will 
maintain open lines of communication with clinical center collaborators.  Query generation and 
site response will guarantee regular communication.  At least one member from the DCC will 
personally contact (by telephone or email) the clinical centers on a weekly basis to discuss 
enrollment and screening activity, resolve data entry issues, clarify protocol requirements, 
discuss adverse events, IRB status, other regulatory issues, and to troubleshoot when necessary.  
The Database Manager will be available for on-line support, report generation and technical 
help.  Two coordinators (1 U.S., 1 Europe-based) will be available by beeper on a 24-hour basis 
for troubleshooting.  
 
The underlying purpose of frequent and open communication is to ensure that the sites fully 
understand the protocol, and to provide support during the start-up phase.  After the first patient 
has been enrolled, issues surrounding data entry may arise requiring additional tutorials, or 
modification of the system. This communication model will ensure that this trial will remain in 
the forefront of our collaborators concerns, enhance enrollment, and ensure we capture the 
highest quality data.  
11.2 Training the Research Staff 
We will employ several methods for training the investigators.  Firstly, the trial‘s initial 
investigator meeting will be dedicated primarily to training.  In the plenary session, we will 
discuss the scientific rationale, hypotheses, specific aims, adverse events, and data collection 
schedule.  During the second part of the meeting, there will be breakout sessions for clinical sub-
committees: (1) neurosurgeons, (2) neuroradiologists, (3) neurologists and (4) coordinators.  The 
neurosurgical and neuroradiology sub-committees of the CCC will review guidelines for 
procedural techniques and post-procedural management, and the neurologists will do the same 
regarding short and long-term clinical care.  The coordinators will be trained to use the web-
based data entry system and to administer the quality of life instruments (refer to section 11.4 
Data Monitoring and Quality Assurance for more explicate detail).  
 
In addition, the DCC will conduct a site initiation for each clinical center, using a combination of 
conference call and web based demonstration, which we have successfully used in other trials.  
Prior to the site initiation, the DCC will send each clinical center an ARUBA binder that contains 
all the documents needed to conduct the study.  This binder will include the protocol, a detailed, 
comprehensive operations manual, and blank case report forms (CRFs).  A section of the 
ARUBA binder will be dedicated to regulatory documents. This section will include updated 
IRB approval letters and all other communications with the IRB, approved informed consent 
form, signature verification pages, responsibilities of the investigators, the monitoring visit log, 
the investigators‘ curriculum vitae, and the signed investigator agreement. There will be a 
communication section containing a telephone/email log on which all communication with the 
DCC will be recorded.  During the site visit, all aspects of the protocol, operations manual and 
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case report forms, including IRB requirements and regulations, will be reviewed with the 
complete clinical center staff.  In-person site initiations in Europe will be organized by the  
European Coordinating Center (Paris) 
 
 
11.3 Electronic Data Management 
11.3.1 The Data Center 
The InCHOIR Data Center will provide a centralized data storage and reporting facility and 
computing systems support for the trial.  The center will be responsible for the development and 
implementation of consistent standard operating procedures for the management of all trial data 
to ensure appropriate standards for software quality, data quality, access control, security, and 
physical protection of study data. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.3.2 Security 
The Data Center provides a strong network security infrastructure that treats the rest of the 
campus network as a potentially hostile environment.  The use of a private firewall to create a 
―network within a network,‖ a private email server with an aggressive email attachment filtering 
policy, and network monitoring hardware have all helped to create an exceptionally secure 
networking environment for clinical data management.  The Center has been has been  
completely unaffected by the large number of worldwide network security incidents over the past 
two years, including the most recent widely publicized Internet worm and email attacks. 
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The Center‘s firewall automatically blocks all Windows networking and database server traffic, 
which have been frequent sources of intrusions at other locations.  All web-based data 
management sessions will be encrypted with the 128-bit SSL standard.  All file transfers of 
project data use either secure FTP (SFTP) or WebDAV over SSL.  The Center maintains several 
Virtual Private Networking (VPN) connections that extend the secure networking environment to 
branch offices outside of our main location, and a network intrusion detection system monitors 
and logs all network traffic at the Center. 
 
11.3.3 Electronic Forms 
The primary data collection tool for forms-based data to be collected in the trial will be a web-
based forms management system that has been developed by the Center‘s system development 
team.  The system design is based on an industry-standard three-tier architecture consisting of 
the following components: 
 
 Tier 1: A client computer equipped with an ordinary web browser such as Netscape 
Navigator or MS Internet Explorer 
 Tier 2: An SSL-enabled application server consisting of the Apache web server and a 
Java servlet engine on the middle tier.  The servlet engine executes custom programs 
written in Java that process HTTP requests from the user‘s browser, access the relational 
database server (see below), and generate HTML response pages to be sent back to the 
user. 
 Tier 3: A relational database server (IBM DB2) on the back end.  The database can be 
queried directly by Data Center personnel using the SQL query language, and data can be 
automatically exported to a variety of machine-readable formats including SAS, ASCII, 
and Microsoft Access. 
 
The system has a number of features that facilitate the management of multi-center clinical trials- 
Rapid Application Development: The initial development and subsequent modification of the 
electronic form designs are both done using an in-house development system that enables the 
rapid development of low-cost web forms with a rich feature set for clinical data management.  
The system can generate database, validation and display components of the three-tier system, 
which can reduce both the overall development cost of the system and ensure a rapid 
implementation schedule. 
 
Form revision tracking: The electronic system can accommodate any number of modifications to 
the form designs, including additions, deletions and rewording of questions.  A form revision 
identifier is stored with each record so that data can be displayed with the version of the form 
with which it was captured.  If desired, different form versions can be automatically assigned to 
different centers.  Our implementation supports database queries that access either distinct 
revisions of a form or data that was collected using all versions.  
 
Pass-through authentication: The database system can securely pass a user‘s login to an existing 
institutional email or Kerberos server for authentication to avoid the need for a separate database 
account and local password storage.  Users need only remember their institutional login 
credentials. 
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Audit Trail and FDA 21 CFR Part 11 compliance: The database server stores each submitted set 
of changes to form data or a form design as a separate transaction in a log file, along with the 
identifier of the user who made the changes and the date and time of the edit session.  This 
design enables the database manager to identify the source and time of each change in the 
database, and the database can be ―rolled back‖ to recreate its state at any point in time.  All 
archived transactions are stored on-line so that they are accessible without the need to restore 
data from a backup tape. An interactive audit trail is available on-line that can enable a suitably 
authorized user to view, print, and restore any copy of a form as it was originally saved during an 
edit session. 
 
A reliable audit trail critically depends on an accurate system clock.  All servers at the DCC 
maintain synchronization with a stratum 2 time server at Mount Sinai Medical Center using the 
NTP protocol.   
11.3.4 Software Quality Assurance and Technical Support  
The electronic data systems development group at the DCC has an ongoing quality assurance 
program, which is based on their experience as developers of the FDA-regulated REMATCH 
Trial data collection software and their current work on the development of hospital medical 
error reporting systems.  
 
They have developed a software testing system that uses a clinical project‘s data dictionary to 
generate a series of automated tests for a web-based database to verify that every form variable 
in the system can be correctly entered, saved and restored over its expected range of values.  
Values outside the expected range are also programmed to validate the appropriate error 
responses.  The program generates scripts that simulate the actions of an end user by opening a 
web form in a browser window, entering data, saving, recalling the form, and comparing the 
results to a set of expected values.  The test runs are timed to ensure that the database provides 
acceptable response times under the anticipated user loads.  Additional scripts are generated to 
verify the system‘s access controls, ensuring that each simulated user can only access authorized 
functionality.   
 
In the event that a user experiences technical difficulty, direct 24-hour telephone access to the 
Center‘s development team is provided via cell phone.  Reported problems are logged and 
tracked on-line with the Center‘s web-based issue tracking system to ensure that any discovered 
system problems are recorded and addressed.  System change control is managed with a 
concurrent versioning system (CVS) server at the Center that enables the development team to 
document and retrieve all changes to system source code. 
11.3.5 Disaster Planning  
All servers at InCHOIR use battery-backed UPS‘s to ensure a controlled shutdown in the event 
of a power disruption.  All servers, UPS‘s and auxiliary networking equipment are housed in 
enclosures that are raised at least three inches from the floor, and they are protected from 
overhead leaks by a secondary waterproof covering between the enclosures and the ceiling.  Both 
on and off-site data backups will be maintained according to a schedule specified in the Data 
Center‘s operations manual.  All data entry locations will have blank hard copies of the forms, 
and manual alternatives will be provided for any automated functions such as patient 
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randomization or visit schedule display where a delay caused by a network disruption would 
adversely affect data collection activity. 
11.3.6 HIPAA Compliance 
No patient identifiers will be permanently stored in the study database.  During the course of the 
trial the study coordinator at each site will maintain a hard-copy list of participating patients, 
their contact information, and their study identifiers.  This list will be used by study coordinators 
to maintain patient follow-up and by trial monitors during monitoring visits to link actual 
patients to records in the study database in order to verify data entry with information from the 
patient chart.  This paper copy containing patient contact information will be destroyed at the end 
of the trial as part of the center closeout procedure. 
 
Some diagnostic images received at the DCC may have been routinely marked with patient 
identifies by the local hospital imaging system.  All images received at the DCC will be 
inspected for identifiers, and they will be manually removed with digital photo editing software 
(Adobe Photoshop) prior to inclusion in the study database. 
11.3.7 Data Access Control for Blinded Investigators 
During the course of the trial no investigators other than unblinded users who are designated as 
system managers will have direct access to the study database.  Other investigators who need 
access to trial data may log on to the web system to view a version of the database that is filtered 
according to the access control rules that apply to their roles in the study.  More complex 
database queries will be forwarded through the Operations Committee to the statistical group for 
manual processing, in which case the study statisticians will be responsible for ensuring that 
blinding and study confidentiality are maintained.  A data dictionary will be developed prior to 
the commencement of the trial.  This document will specify the metadata for all variables in the 
trial will define data access restrictions for each user role. 
 
11.3.8 Management of Digital Images 
Representative diagnostic images will be collected for each patient at baseline, at 5 years and/or 
at study completion, if not previously performed.  The baseline images will be interpreted by the 
site credentialed radiologist and a de-identified CD will be sent to the DCC along with a copy of 
the radiologist‘s report.  Images at 5 years and/or at study completion will be sent as a de-
identified CD and radiologist report to the DCC.   
 
In the event that a credentialed radiologist is not present during enrollment at the clinical site the 
following procedure will be followed: 
 
After logging in to the web database system, the local study coordinator will upload these images 
in digital form to the DCC via an SSL-encrypted connection.  The system will automatically 
catalog each image with a timestamp and patient study ID using software that we have 
previously developed for a separate X-ray data management project.   
 
To upload the images the coordinator at each site will log in to the DCC web site, open the 
patient screening form (or new procedure page for an existing patient) and click the ―upload‖ 
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button.  The browser will open a file selector window that will enable the user to select image 
files to be uploaded.  After selecting the files and clicking the ―OK‖ button the files will be 
automatically uploaded to the DCC server where the files will be cataloged.  The server will 
respond with a page that displays the images along with the patient identifier so that the user can 
verify that the correct images have been uploaded. 
 
In order to gather information about the technical capabilities and experience at each clinical 
center and to confirm the feasibility of using web-based image management at our anticipated set 
of centers we have developed an ARUBA clinical center registration site (see screenshot below).  
This web site gathers data about AVM experience and displays a set of 14 images for evaluation.  
We have also used a network diagnostic tool (tracert) to measure network latency across the 
Internet links to some of the more distant center locations from the DCC, and we have found 
average delays that would barely be noticeable to the user (92 milliseconds round trip to Paris, 
252 ms to Melbourne and 280 ms to Perth). 
11.3.9 Management of Faxed Source Data 
In order to reduce monitoring costs and to facilitate the rapid verification of screening data 
during patient enrollment, source documents will be faxed to a fax server at the DCC using the 
following procedure: 
 
At the clinical site the data coordinator affixes a printed patient identifier label to each page and 
faxes the stack of pages to the DCC fax server.  The server automatically converts the faxed 
pages to both html format for web viewing and PDF format.  The web pages are integrated to the 
ARUBA data management server so that the appropriate site monitor anywhere in the word can 
view the documents, move them into the appropriate patient folder and check them off on the 
patient‘s source document checklist.   
 
11.4 Data Monitoring and Quality Assurance 
Through the combination of our web-based, instantaneous electronic validation, the DCC‘s daily 
visual cross-validation of the data for complex errors, and regular on-site monitoring, the quality 
and completeness of the data will be reflective of the state of the art in clinical trials. 
 
Both the European and US  DCCs  will conduct monitoring of source documents via fax at all 
enrolling ARUBA sites and will conduct at least one onsite monitoring visit per year over the 
course of the study at 100% of clinical sites (with repeat visits to sites where performance is a 
concern). Monitoring of European study sites will be assured by the European Coordinating 
Center (Paris). The primary objectives of the DCC during the on-site visits are to educate, 
support and solve problems.  The monitors will discuss the protocol in detail and identify and 
clarify any areas of weakness.  At the start of the trial, the monitors will conduct a tutorial on the 
web-based data entry system.  The coordinators will practice entering data so that the monitors 
can confirm that the coordinators are proficient in all aspects of data entry, query response, and 
communication with the DCC.  They will audit the overall quality and completeness of the data, 
examine source documents, interview investigators and coordinators, and confirm that the 
clinical center has complied with the requirements of the protocol.  The monitors will verify that 
all adverse events were documented in the correct format, and are consistent with protocol 
definition.  
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The monitors will review the source documents as needed, to determine whether the data 
reported in the Web-based system are complete and accurate.  Source documents are defined as 
medical charts, associated reports and records including initial hospital admission report, 
operative procedure record, anesthesia record, discharge and re-admission reports, consult notes, 
diffusion-weighted MRI reports, radiology reports, lab reports, clinic records, and other study 
related notes.  Copies of all of these records must be kept in a binder with the patient‘s study 
code.   
 
The monitors will confirm that the regulatory binder is complete and that all associated 
documents are up to date.  The regulatory binder should include the protocol and informed 
consent (all revisions), IRB approvals for all of the above documents, IRB correspondence, case 
report forms, investigator‘s agreements, IRB roster, signature verification page, investigators‘, 
coordinator‘s and credentialed radiologist‘s curriculum vitaes, monitor site visit log, telephone 
contact log, and correspondence with the DCC. 
 
Scheduling monitoring visits will be a function of patient enrollment, site status and other 
commitments.  The DCC will notify the site in writing at least three weeks prior to a scheduled 
visit.  The investigators must be available to meet with the monitors.  Although notification of 
the visits will include the list of patients scheduled to be reviewed, the monitors reserve the right 
to review additional ARUBA patients. 
 
If a problem is identified during the visit (i.e., poor communication with the DCC, inadequate or 
insufficient staff to conduct the study, missing study documents) the monitor will assist the site 
in resolving the issues.  Some issues may require input from the Operations Committee, Steering 
Committee or one of the principal investigators. 
 
The focus of the visit/electronic monitoring will be on source document review and confirmation 
of adverse events.  The monitor will verify the following variables for all patients: initials, date 
of birth, sex, signed informed consent, eligibility criteria, date of randomization, treatment 
assignment, adverse events, and endpoints including mortality, stroke, and completeness of the 
functional health status tools and quality of life questionnaires.   
 
11.5 Adverse Experience Reporting 
 
11.5.1 Adverse Event 
The endpoints for safety will be reported as the frequencies of occurrence of each adverse event, 
and time to each event.  Safety data will be collected throughout this study and the incidence of 
each event will be computed along with associated 95% confidence intervals. 
 
An adverse event (AE) is defined as any undesirable clinical occurrence in a study patient.. Any 
condition that was recorded as pre-existing is not an AE unless there is a change in the nature, 
severity, or degree of the condition.   
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Detailed information regarding adverse events will be recorded at the time of their occurrence.  
Investigators will be asked to classify the seriousness of the event and if the event was related to 
the index AVM or interventional therapy.   
  
 
 
11.5.2 Serious Adverse Event  
A serious adverse event (by FDA regulation) is one that results in a fatality; is life-threatening; 
results in permanent disability; requires hospitalization or prolongs a hospital stay.  If an event is 
classified as ‗Other‘ it must meet the FDA definition of serious. 
 
11.5.3 Event Reporting 
Serious, protocol defined or interventional therapy related adverse events must be reported to the 
DCC and captured in the electronic data capture system within 72 hours of knowledge of the 
event.   
 
Any serious ‗Other‘ adverse events must be reported directly to the individual IRB within 10 
working days of knowledge of the event, or as dictated by the individual IRB.   
 
Non-serious events must be entered into the electronic data capture system within 72 hours.  
 
The cause of death, the categorization, and the severity of all adverse events will be determined 
by the site investigators, then monitored by the DCC, and finally adjudicated by an independent 
Morbidity and Mortality Committee.  The charge of this committee is to ensure that the 
categorization of adverse events and mortality meet the protocol definitions.  Published mortality 
and adverse event data will be based on the data adjudicated by the Morbidity and Mortality 
Committee. 
 
 
12.  HUMAN SUBJECTS 
12.1 Institutional Review Board (IRB) Review and Informed Consent 
The Human Subjects Committee/Institutional Review Board of each clinical center will approve 
the informed consent form.  A copy of the letter of approval from the IRB and a copy of the 
consent form will be filed with the Project Office and reviewed and approved by the NINDS 
before a clinical center will be allowed to initiate enrollment.  The informed consent will include 
the objectives of the study, a description of the screening process, the potential risks and benefits, 
the cost to the patient, alternatives to participation and liabilities of the particular participating 
center.  It will be made clear to patients that both treatment options are available, even if they 
decline to participate. The European CCC will ensure certified translation of informed consent 
forms and IRB-related materials as needed for participating sites in 8 different language zones. 
The signed informed consent will be faxed to the DCC prior to randomization. A copy of the 
consent form will be given to the patient (or legal guardian) and this fact will be documented in 
the subject‘s record.  
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12.2  Potential Risks 
Medical management and interventional therapy are both well-recognized clinical options, and 
are not considered to be experimental in nature.  Whether one approach offers a relative 
advantage over the other in terms of risk is not known, and is expected to emerge from this trial. 
12.3  Safety and Confidentiality 
Patients will undergo either medical management or interventional therapy.  All precautions to 
avoid untoward effects of interventional therapy will be taken, and defined in treatment 
guidelines.  Patients will undergo regular follow-up and receive care for any adverse events by 
their own physicians. 
  
We will follow rigorous procedures to protect patients‘ and clinicians‘ confidentiality.  Access to 
identifying information will be limited to those whose project roles demand it, and only for the 
period of time in which they need it.  Physical safeguards, such as locked file cabinets, will be 
used to protect the data and prevent unauthorized access.  We will use the following additional 
measures: identifying information will be physically separated from data collection instruments 
and only code numbers will identify individual participants or facilities; contact sheets with 
identifying information will be stored in locked cabinets; access to the database will be limited to 
project staff.  Patient contact information will only be accessible to the clinical site research 
nurse for a given site, the data monitor and the database system manager.   
 
12.4 Study Modification/Discontinuation 
12.4.1 Data and Safety Monitoring Board (DSMB) 
To meet the trial's ethical responsibility to its patients, an independent group will monitor the 
results during the trial.  This board will have no formal involvement with the patients or the 
investigators.  The clinical centers will have no contact with the DSMB.  The DSMB will act in a 
senior advisory capacity to the NIH on data matters throughout the duration of the study.  The 
DSMB will communicate directly only with the NIH.  In addition, it will periodically review 
study results by treatment group and evaluate the treatment for beneficial and adverse effects.  
NINDS will appoint members of the Data and Safety Monitoring Board.  The Board will ideally 
include neurologists, neurosurgeons, interventional radiologists, and statisticians.  Board 
meetings will be attended by senior representatives of the CCC, DCC and NIH, as well as by the 
Chair of the Steering Committee.  No voting member of the Board may participate in the study 
as an investigator. 
 
Specific functions of the DSMB are: (a) to review the protocol before it is implemented, and any 
subsequent changes; (b) to examine outcome and adverse experience data by treatment group; (c) 
to make recommendations to the NINDS on any proposed extension of the study or study arm 
because of beneficial or harmful effects; (d) to monitor the performance of the clinical centers 
and the DCC; (e) to advise the NINDS about policies related to confidentiality and conflict of 
interest.  The members of the DSMB will review the interim analyses of the primary endpoint, 
and adverse event data, as adjudicated by the Morbidity and Mortality Committee.  The DSMB 
will approve stopping guidelines developed by investigators, analyze the interim results and 
recommend an early termination because of safety issues or because of evidence of efficacy, and 
will also develop guidelines for recommending that the trial be extended if the assumptions that 
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went into the power calculations are found to be incorrect.  We anticipate 2 meetings of the 
DSMB annually (either by conference call or in person) to review interim analyses of the data, 
and one closing meeting to review the final results. 
12.4.2 Event Adjudication Committee  
The Event Adjudication Committee will classify the cause of mortality for all cases and review 
and classify all adverse events. The individuals who serve on the committee will not be 
investigators in the trial. 
 
12.4.3 Safety Monitor  
The safety monitor is an independent medical advisor to the Data and Safety Monitoring Board 
of the NIH concerned with the safety of patients enrolled in the ARUBA study.  The safety 
monitor will communicate directly with the DCC regarding patient outcomes and adverse events.  
The safety monitor will treat all study data as confidential and subscribe to the protocol defined 
confidentiality guidelines.   
The safety monitor will receive data on all serious and protocol defined adverse events and 
primary endpoint events on an occurrence basis.  Every two months the safety monitor will 
receive a summary report of all serious adverse events and primary endpoint events.  If 
necessary, the safety monitor may request more information from the DCC. After review of the 
data summary provided by the DCC, the safety monitor will provide the DSMB with an interim 
report and will contact the chair of the DSMB directly in the event of any safety concerns. 
 
13.  PUBLICATION OF RESEARCH FINDINGS 
Publication of the results of this trial will be governed by the policies and procedures developed 
by the Executive Committee.  Any presentation, abstract, or manuscript will be made available 
for review by the CCC, DCC, and the NINDS prior to submission. 
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